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ABSTRACT 
 
Type 1 diabetes (T1D) is characterised by pancreatic  cell autoimmunity and 
inflammation, resulting in  cell islet destruction and insulin deficiency. Prospective 
studies from different continents have shown that insulin resistance is independently 
associated with risk for the development of T1D. We wanted to investigate the role of 
adiponectin in mediating this link. Adiponectin is a circulating adipokine whose anti-
inflammatory and insulin sensitising actions appear to be mediated via two related 
receptors, AdipoR1 and AdipoR2. We began by characterising adiponectin receptor 
expression on PBMC by flow cytometry. We showed that monocytes express both 
receptors abundantly, that this expression correlates with insulin sensitivity in both 
health and diabetes. Furthermore, expression can be increased with lifestyle 
intervention. Adiponectin receptor expression on monocytes is reduced in T1D, and we 
demonstrate this leads to an apparent resistance in the ability of adiponectin to inhibit 
the stimulatory capacity of antigen presenting cells (APC). Specifically, we show that 
adiponectin inhibits the stimulatory capacity of APCs through down-regulation of CD86 
expression, and that this effect is decreased in T1D. In this way, the release from the 
regulatory effects of adiponectin is one potential mechanism by which immune 
tolerance is lost in T1D.   
 
(197 words) 
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For Elisha and Joshua, 
 
“I saw her. Your mother! 
Your mother is near! 
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1. INTRODUCTION 
 
1.1 The costs of T1D 
 
Type 1 diabetes (T1D) is a chronic disease of hyperglycaemia caused by insulin 
deficiency. Typical onset is in childhood and adolescence, at which point, the initiation 
of insulin replacement by injection is continued for life. The aims of insulin treatment 
are not only to prevent potentially fatal ketoacidosis and dehydration, but to also 
achieve near normal glycaemia. The clinical benefits were proven in the Diabetes 
Control and Complications Trial (DCCT). In this landmark multi-centre randomised 
controlled trial, intensive insulin treatment to maintain pre-meal glucose at 70-120 
mg/dl (3.9 – 6.7 mmol l-1) and <180mg/dl (10 mmol l-1) postprandially decreased 
microvascular complications by as much as 76% (The Diabetes Control and 
Complications Trial Research Group, 1993). This reduction, including those in 
cardiovascular disease, persisted in the 10 year post-trial observational period (The 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications Study Research,Group 2005).  
 
However, achieving tight glycaemic control is complex for patients. Precise insulin 
dosing for normoglycaemia needs to account for meals, lifestyle and pharmacokinetics 
of the different insulin preparations. Furthermore, tight glucose control is associated 
with risk of hypoglycaemia, some of which may be sufficiently serious to warrant third 
party assistance (The Diabetes Control and Complications Trial Research Group, 
1993). Fear of hypoglycaemia is common among patients and their carers, and the 
associated avoidance behaviour can hinder the optimisation of metabolic control (Wild, 
von Maltzahn et al. 2007).   
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T1D also impacts on our national health. The latest estimates suggest that it is 
associated with a 23 year reduction in life expectancy (Department of Health 2007), 
and mortality rates of up to 11 fold in certain populations (Soedamah-Muthu, Fuller et 
al. 2006). In addition, it is a major drain on healthcare costs to the NHS. The latest 
estimate stands at £2.5 billion, which accounts for 4% of its annual budget (Juvenile 
Diabetes Research Foundation. 2004). The costs of disease are projected to escalate 
further, as a direct consequence of the increasing incidence of T1D. In 2003, 
standardised incidence in the UK was 22-30 per 100 000, and the projected rise year-
on-year is 3-4% (Patterson, Dahlquist et al. 2009). These problems have added further 
impetus to understanding the natural history of T1D, in order to facilitate new 
approaches in preventing or ameliorating this disease. 
 
1.2 The pathogenesis of T1D 
 
Figure 1.1. Normal pancreatic islet. Insulin is labelled in green, glucagons in red and the 
nuclei in blue. Freely licensed media, courtesy of Süß C et al, University of Technology, 
Dresden, Germany.  
 
Insulin is produced by the  cells in the islet of Langerhans in the endocrine pancreas 
(figure 1.1). It is formed from post-translational cleavage of the prohormone proinsulin 
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(Sanger 1959), which is encoded by the INS gene at the position 11p15.5 (Genbank 
NM_000207). The destruction of  cells is the hallmark of T1D. In type 1B diabetes, the 
cause is idiopathic. A variant characterised by fuliminant onset and subacute 
pancreatitis has been described in Japanese patients (Imagawa, Hanafusa et al. 2000). 
In this thesis we will focus our discussion on type 1A diabetes. The immune mediated 
nature of type 1A diabetes is evidenced by its following characteristics, expanded 
further below:  
1) Association of immune genes with risk for T1D  
2) Chronic inflammation seen on islet histology in affected individuals      
3) Serum autoantibodies predate and predict disease 
4) Presence of auto-reactive T cells in affected individual 
5) Transference of disease by the transfer of diabetogenic immune cells in 
humans and in animal models. 
6) Preservation of  cell function by immunomodulatory therapies  
 
T1D is heritable, and susceptibility for disease is associated with genes encoding 
proteins with immunoregulatory functions. The largest contribution comes from MHC 
class II haplotypes HLA-DR and DQ (Concannon, Erlich et al. 2005). Recent studies 
have identified other immune genes in HLA class 1 and non-HLA regions conferring 
additional risk (figure 1.2). These include CTLA4, PTPN22 and IL2RA (Nejentsev, 
Howson et al. 2007, Concannon, Rich et al. 2009) (figure 1.2). This complex 
polygenicity indicates that multiple immune mechanisms lead to  cell destruction. 
 
Histologically, the pathognomonic lesion in T1D is insulitis (figure 1.3), which can be 
seen before clinical onset and consistently in established disease (In't Veld, Lievens et 
al. 2007, Foulis, Liddle et al. 1986) . The islets are infiltrated by immune cells, 
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Figure 1.2:  Putative functions of non-HLA genes that contribute to genetic risk of type 
1A diabetes. Adapted from Concannon et al (Concannon, Rich et al. 2009). In contrast the 
odds ratio for the HLA region 6p21 is 15. Reproduced with permission from the Massachusetts 
Medical Society. (ref PS-2011-0393).  
 
composing largely of CD8+ T cells and CD68+ macrophages, with a minority of CD4+ 
T cells and CD20+ B cells (Willcox, Richardson et al. 2009, Itoh, Hanafusa et al. 1993, 
Uno, Imagawa et al. 2007). Their cytotoxicity appears to be confined to  cells only 
(Rohane, Shimada et al. 1995), as neighbouring  and  cells are preserved (Foulis, 
Liddle et al. 1986, Hanafusa, Miyazaki et al. 1990). As disease progresses, insulin 
staining in the islets is replaced by an increasing infiltrate of of CD8+ T cells and 
CD20+ B cells (Rowe, Campbell-Thompson et al. 2010). Across the whole pancreas 
however, insulitis in patchy (Rowe, Campbell-Thompson et al. 2010). This 
hetereogeneity may be explained by pancreatic anatomy and differences in insulin 
content of the islets. Islets in the pancreatic head and body were more likely to be 
affected relative to the tail (Bottazzo, Dean et al. 1985), and this may relate to their 
more extensive lymphatic drainage(Donatini, Hidden et al. 1992). Also in support of -
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cell specificity, insulitis is seen much more frequently in islets rich in insulin content 
compared to relatively insulin-deficient ones (Foulis, Liddle et al. 1986).       
 
Further demonstration of the immune specificity is the presence of autoantibodies to  
cell proteins. Targeting the glutamic acid decarboxylase isoform of molecular weight 65 
kDa (GAD65) (Hagopian, Michelsen et al. 1993), tyrosine phosphatase (IA-2) 
(Lampasona, Bearzatto et al. 1996), proinsulin/insulin (Yu, Robles et al. 2000), these 
major autoantibodies are present in serum before and at the time of diagnosis (Bingley, 
Christie et al. 1994, Wenzlau, Juhl et al. 2007, Achenbach, Bonifacio et al. 2005). The 
assays for these autoantibodies are standardised in the Diabetes Antibody 
Standardisation Programme (DASP) (Torn, Mueller et al. 2008) and are used to stratify 
risk for T1D in genetically susceptible individuals (Sherry, Tsai et al. 2005). Other  cell 
autoantibodies can also be detected (Lieberman, DiLorenzo 2003), including the 
recently identified zinc transporter ZnT8 (Slc30A8) (Wenzlau, Juhl et al. 2007), which 
appears to further improve risk estimation.  
 
 
Figure 1.3 Insulitis. The normal distribution of  cells (insulin in red) is lost and replaced by an 
infiltrate of T cells (green). Courtesy of Anne Cooke, University of Cambridge. Reproduced 
from,(Narendran, Estella et al. 2005) with permission of the author.   
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Circulating T lymphocytes reactive to the autoantigens GAD65, IA-2, insulin, as well as 
to islet-specific glucose-6-phosphatase catalytic subunit related protein (IGRP), can be 
detected in patients with human T1D (Roep, Arden et al. 1990, Atkinson, Kaufman et 
al. 1992, Honeyman, Stone et al. 1997, Harrison, Chu et al. 1992, Hawkes, Schloot et 
al. 2000, Yang, Danke et al. 2006). Whilst each clone may have limited pathogenicity 
on its own (Burton, Vincent et al. 2008), collectively, these autoreactive cells are 
thought to be responsible for transferring diabetes in animal models (Wicker, Miller et 
al. 1986, Hanafusa, Sugihara et al. 1988, Bendelac, Carnaud et al. 1987). Analogously 
in humans, there are case reports of T1D transmission by bone marrow allograft 
(Lampeter, Homberg et al. 1993, Lampeter, McCann et al. 1998). The recipients, who 
were negative for islet autoantibodies,  developed T1D two to four years following the 
transplant from HLA-matched donors with T1D.  The duration is in keeping with the 
insidious course of islet autoimmunity, and there was no clinical evidence for 
generalised graft versus host disease. A contention is that the recipients could have 
developed T1D because of exposure to an environmental trigger, given that they 
possessed high risk HLA haplotypes.   
 
Lastly, the immunomodulatory therapies can counter the natural decline in  cell 
function. Treatments tried include immunosuppressants, stem cell transplant, biological 
immunomodulators and vaccines against islet autoantigens. Cyclosporine, a 
calcineurin inhibitor, has been shown in two multicentre RCT to induce remission in 
newly diagnosed T1D (Assan, Feutren et al. 1990, The Canadian-European 
Randomized Control Trial Group 1988). The treatment was associated with 
nephrotoxicity, although the increase in serum creatinine was reversible upon lowering 
of dosage and did not result in participant withdrawal. Encouragingly, there was a 
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24.1% complete remission rate in the treatment group at nine months, compared with 
5.8% in the placebo group. However, insulin independence rarely lasted beyond 12 
months (Bougneres, Landais et al. 1990). Azathioprine, the pro-drug of 5-
mercaptopurine which inhibits DNA synthesis, has also been tested in newly diagnosed 
patients in RCT setting. In adults, azathioprine at a dose of 2mg kg-1 d-1 was associated 
with increased insulin-free remission after 12 months of treatment (azathioprine: 7 out 
of 13 subjects, versus 1 of 11 placebo), but 5 subjects in the active arm withdrew and 
two because of side effects (Harrison, Colman et al. 1985). Bone marrow suppression, 
a recognised severe adverse event, was not seen. However, the remission was not 
sustained in the post-treatment follow-up period. In contrast, azathioprine in children 
had no significant impact on complete remission rates, metabolic control or  cell 
function (Cook, Hudson et al. 1989) , although adjuvant prednisolone in the early phase 
may be of benefit, with 3 out of 20 treated patients achieving insulin independence 
versus none in the control group (Silverstein, Maclaren et al. 1988).   
 
Remission of up to 58 months has been reported with autologous non-myeloablative 
haemopoietic stem cell transplant (Voltarelli, Couri et al. 2007, Couri, Oliveira et al. 
2009). 20 out 23 study patients became insulin free and 12 of these maintained 
remission for a mean of 31 months. Eight patients relapsed but maintained 
endogenous  cell function at 48 months. However this required high dose 
immunosuppression which carried serious risks of infection (two developed bilateral 
nosocomial pneumonia) and endocrine gland dysfunction (9 patients developed 
oligospermia).   
 
More recent clinical trials have employed interventions with much fewer adverse 
effects. A short treatment course of humanised anti-CD3 monoclonal antibody, 
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modified to prevent Fc receptor binding, preserved   cell function and reduce insulin 
dosage in newly diagnosed patients, for up to 18 months (Keymeulen, 
Vandemeulebroucke et al. 2005, Herold, Hagopian et al. 2002). During treatment, 75% 
of patients experienced a transient infectious mononucleosis-like syndrome and 
increased parameters of Epstein-Barr virus immunity, as well as a reduction of 
circulating lymphocytes. Complete recovery was seen two weeks after the last infusion. 
Pre-clinical studies suggest the mechanism of the anti-CD3 treatment relates to a shift 
in pathogenic Th1 responses (interferon-  and IL-2) in favour of Th2 (IL-10) (Smith, 
Tang et al. 1998). However, in the larger clinical trial, the temporary changes in 
cytokine levels and lymphocyte counts did not predict primary outcome (Keymeulen, 
Vandemeulebroucke et al. 2005). Additionally, the rise in titres for anti-idiotype 
antibodies during treatment phase may counteract its efficacy.      
 
Rituximab is an anti-CD20 monoclonal antibody. It cross links cell surface CD20 and 
selectively depletes B lymphocytes through antibody-mediated and complement-
dependent cytotoxicity (Bour-Jordan, Bluestone 2007).  A four-dose course of the 
antibody in patients within 3 months of diagnosis ameliorated the decline in  cell 
function at 1 year (Pescovitz, Greenbaum et al. 2009). The intervention group had 
lower levels of HbA1C and required less insulin. The depletion of B cells persisted at 
12 months (69% of baseline) but was not associated with increased infections. These 
results confirm the relevance of B cells in T1D, which can modify local production of 
cytokines at sites of autoimmunity and function as specialised antigen presenting cells 
for T lymphocyte action. Their roles are further discussed in Section 1.4.1.    
 
Treatments discussed so far are not antigen specific, and thus can result in 
immunocompromise with a potential for opportunistic infections and neoplasia. 
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Vaccination using autoantigens is a realistic alternative for inducing specific 
immunologic tolerance. The effects of 65 kDa isoform of glutamic acid decarboxylase 
(GAD), a recognised autoantigen in T1D, have been reported in a phase 2 study 
(Ludvigsson, Faresjö et al. 2008). Combined with the adjvuvant alum, GAD vaccination 
in children within 18 months of diagnosis resulted in a slower decline in   cell function 
against placebo, for up to 30 months. There were no differences in frequency of 
adverse events between the two groups. Active treatment was associated with higher 
GAD antibodies, GAD-induced cytokines (interferon- , TNF , interleukins 5, 10, 13 17) 
and expression of FoxP3 and TGF-  in whole PBMC. Larger confirmatory trials are in 
progress (NCT00723411 & NCT00751842).    
 
1.3 Natural history of T1D 
 
Follow-up studies of at-risk subjects show the loss of  cell function is insidious (figure 
1.4). Family history and HLA class II genes determine genetic risk (Ziegler, Nepom 
2010). Children with an affected first degree relative will have a 10 times increased risk 
compared to those without family history (Table 1.1). HLA class II genes have a 
comparable impact. The genotypes HLA DRB1*03, *04 and DQB1*0302 confer the 
highest risk (odds ratio for T1D = 17). In contrast, HLA-DQB alleles are protective. For 
example, the HLA-DQB1*0602 haplotype reduces lifetime risk in those with first degree 
family history from 5-8% to ~1% (Baisch, Weeks et al. 1990).  
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Table 1.1 Type 1 Diabetes Risk Stratification by T1D Family History and HLA 
Genotyping  
Population Type 1 Diabetes Risk (%) 
Low Risk 
No affected FDR plus HLA protective genes 0.01 
No affected FDR 0.4 
Affected FDR plus HLA protective genes 0.3 
Intermediate Risk 
No affected FDR plus HLA risk genes 4 
One affected FDR 5 
 Mother with T1D 3 
 Father with T1D 5 
 Sibling with T1D 8 
High Risk 
One affected FDR plus HLA high risk genes 10–20 
Multiple affected FDRs 20–25 
Very High Risk 
Identical twin affected 30–70 
Multiple affected FDRs plus HLA risk genes 50 
Sibling affected plus HLA risk genes, identical by descent 30–70 
FDR, first-degree relative; HLA risk genes, HLA DRB1
*
03,
*
04;DQB1
*
0302; HLA protective 
genes, HLA DQB1
*
0602. Type 1 diabetes risk (%) refers to lifetime risk of develop disease. 
Table reproduced from (Ziegler, Nepom 2010) with permission from the publisher (Elsevier 
License number 2550221424517). 
 
 
The development of autoantibodies compounds the baseline genetic risk. Rarely 
present before the age of 6 months, their detection signals initiation of islet 
autoimmunity (Bingley, Christie et al. 1994, Achenbach, Warncke et al. 2006). 
Autoantibodies used for risk prediction are insulin/proinsulin, GAD65/GAD67, IA-2 and 
the recently identified ZnT8 (Wenzlau, Juhl et al. 2007). Incremental risk is seen with 
multiple positive antibodies, as well as the presence of higher titre and greater affinity 
antibodies.   
 
Thus, genetic and immunological factors can stratify an individual‟s risk for T1D. This 
strategy has been successfully used to identify high risk cohorts, with a predicted 
incidence of >25% in 5 years, for prevention studies (Diabetes Prevention Trial–Type 1 
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Diabetes Study Group 2002, Gale 2004). In these subjects with pre-clinical T1D, the 
rate of decline in  cell function in the pre-T1D period can be tracked by glucose 
challenge and mixed meal tolerance tests. The loss of first phase insulin secretion 
(FPIR) and impaired glucose tolerance identify subjects with accelerated progression to 
diabetes (Barker, McFann et al. 2007). Approximately 10-20% residual  cell function 
remains at diagnosis (Komulainen, Knip et al. 1997). In a proportion of patients, there is 
partial or complete clinical remission, resulting in insulin independence. This period, 
called a „honeymoon‟ period, can last a number of years. However, all patients will 
inevitably relapse to requiring insulin therapy as the continuing autoimmune process 
proceeds to destroy surviving  cells. Therefore, after a number of years of diabetes 
there is minimal amount of  cell function, and this has traditionally been estimated 
using the technique of C-peptide measurement following a hyperglycaemic stimulus 
(Sherry, Tsai et al. 2005). Analysis of the DCCT shows that even at the time of 
presentation with diabetes, the small amounts of endogenous insulin secretion reduces 
the risk of vascular complications and severe hypoglycaemia (Steffes, Sibley et al. 
2003). Hence, measures that dampen islet autoimmunity and sustain  cell function will 
be of clinical benefit to patients at the time of, as well as before, diagnosis with T1D.  
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Figure 1.4: Natural history of type 1 diabetes. After birth,  cell mass may still increase with 
linear growth and increased metabolic demand from obesity or pregnancy (Sherry, Tsai et al. 
2005). In pre-T1D (a),  cell mass declines because of autoimmune attrition. Glucose 
intolerance can be identified on dynamic testing. Symptomatic presentation (b) of T1D occurs 
when  cell mass falls below a threshold for required glucose homeostasis (dotted line). 
Honeymoon remission (c), characterised by a period of insulin independence, may occur in 
some patients following initial insulin treatment. However, in all patients this does not last and  
cell mass declines and again falls below the threshold (d). Nevertheless, functional  cells can 
be isolated in patients with longstanding T1D (>10 years) (Walker, Johnson et al. 2010).  cell 
function is measured by a C-peptide response to a hyperglycaemic stimulus such as a mixed 
meal challenge.    
 
a 
b 
c 
d 
Beta cell 
function 
time 
 13  
1.4 Overview of current concepts in the immunopathogenesis of T1D   
1.4.1 The non-obese diabetic (NOD) mouse 
 
Understanding the immune dysregulation in human T1D is limited by the availability of 
tissue, and the slow progression of disease. Much of our knowledge is attributed to the 
non-obese diabetic (NOD) mouse model, an inbred strain that exhibits spontaneous 
autoimmune diabetes, usually within 12-16 weeks of birth (Adorini, Gregori et al. 2002, 
Anderson, Bluestone 2005). It mimics some features of human T1D. The genetic 
susceptibility for disease in NOD mice is largely determined by the single functionally 
homologous MHC class II allele H2g7. A similar panel of autoantigens, GAD, 
proinsulin, IA-2 and IGRP is targeted in both. NOD diabetes is preceded by a short 
prodrome of increasing glucose intolerance with parallel insulitis. The major advantage 
of the NOD mouse is that it allows the controlled interrogation of an immune 
mechanism. Techniques such as adoptive transfer, where cells from diseased mouse 
are injected into a healthy coisogenic and immunodeficient host, allow apportion of 
each cellular component in the autoimmune response. Genetic manipulations through 
transgenes and selective gene targeting can dissect the relevance of specific molecular 
pathways. 
 
CD4+ and CD8+ T cells are obligate effectors in the aetiology of T1D (Wicker, Miller et 
al. 1986, Hanafusa, Sugihara et al. 1988, Bendelac, Carnaud et al. 1987, Miller, Appel 
et al. 1988, Christianson, Shultz et al. 1993). Their individual MHC-class restricted 
clones, generated from leucocytic infiltrates of insulitic lesions, transfer disease (Wong, 
Visintin et al. 1996, Graser, DiLorenzo et al. 2000, Haskins, Wegmann 1996). In 
addition, anti-CD3, CD4, and CD8 monoclonal antibodies confer protection and can 
induce disease remission (Chatenoud, Thervet et al. 1994, Koike, Itoh et al. 1987, 
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Herold, Montag et al. 1987, Makhlouf, Grey et al. 2004, Shizuru, Taylor-Edwards et al. 
1988, Herold, Bluestone et al. 1992, Wang, Gonzalez et al. 1996, Parish, Cooke 2005). 
For activation, naive autoreactive T cells require the presentation of a processed 
cognate antigenic peptide complexed to the MHC class II molecule by an antigen-
presenting cell (APC) (Itano, Jenkins 2003, Hoglund, Mintern et al. 1999, Gagnerault, 
Luan et al. 2002). This process initially takes place at the pancreatic lymph node 
(Gagnerault, Luan et al. 2002). Dendritic cells (DC) are a group of diverse and 
specialised APC found in tissues, blood and secondary lymphoid organs (Banchereau, 
Briere et al. 2000). They can be expanded ex vivo from myeloid or lymphoid 
progenitors, in peripheral blood and bone marrow. They are classified according to 
their maturation, phenotype and secretory profile (Penna, Vulcano et al. 2002). DC and 
also macrophages and monocytes, can perform the antigen presentation role and their 
introduction to the diabetes-prone NOD mouse can initiate disease (Saxena, Ondr et 
al. 2007, Jun, Yoon et al. 1999, Serreze, Fleming et al. 1998).  
 
The B lymphocyte can also function as APC. Autoreactive B cells have constitutive 
HLA class II expression and surface-bound autoantibodies efficiently capture self-
antigens (Falcone, Lee et al. 1998). In the NOD mouse, B cell deficiency ameliorated 
spontaneous diabetes and adoptive transfer of B cells from diabetic mice restored islet 
autoimmunity (Serreze, Fleming et al. 1998, Hämäläinen, Savola et al. 2001).  
 
The pathogenicity of the B lymphocytes was not dependent on their antibody secretory 
capacity, as seen in an IgM transgene model which retained antibodies on the cell 
surface (Wong FS, Wen et al. 2004). Rather it is their antigen presenting function that 
is crucial, as selective inhibition of HLA expression on B cells prevented diabetes 
(Noorchashm, Lieu et al. 1999). There is also evidence to suggest B lymphocytes can 
modify autoimmunity in the NOD mouse in a paracrine fashion. B lymphocytes 
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activated by anti-IgM F(ab')2 antibodies could skew cytokine expression in T cells 
towards Th2 phenotype, attenuate insulitis and delay diabetes (Hussain, Delovitch 
2007), and this regulatory effect was fully dependent upon IL-10 expression. In 
contrast, islet autoantibodies are not believed to be pathogenic, as they do not bind to 
the cell surface or matrix antigens, or form immune complexes (Wong, Wen 2005). 
Furthermore, their transplacental transfer in humans did not initiate  cell autoimmunity 
(Serreze, Fleming et al. 1998, Hämäläinen, Savola et al. 2001). 
 
In humans, B lymphocytes are present in human insulitic lesions and their numbers 
increase with progression (Willcox, Richardson et al. 2009). Their depletion by the anti-
CD20 monoclonal antibody rituximab resulted in preservation of  cell function in 
clinical trials (Pescovitz, Greenbaum et al. 2009), This positive result confirms the 
importance of B lymphocytes in human T1D, although their role is not absolutely 
critical, as disease can occur in X-linked agammaglobulinemia, where tyrosine kinase 
mutation results in B cell deficiency (Martin, Wolf-Eichbaum et al. 2001).    
 
NK lymphocytes are another cell type that can influence disease course. They are 
cytotoxic to  cells in co-cultures, and are a rich source of the pro-inflammatory 
cytokine IFN-  (Nakamura, Woda et al. 1990). In corroboration they promote insulitis 
and diabetes in transgenic models (Poirot, Benoist et al. 2004, Alba, Planas et al. 
2008). However, the picture in human T1D is less clear cut. NK cell counts are reduced 
at the time of disease onset and their induced IFN-  expression does not correlate with 
more aggressive disease (Rodacki, Svoren et al. 2007).    
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1.4.2 The MHC and cytokines 
 
Direct cytotoxicity by autoreactive CD8+ T cells is an important cause of  cell loss in 
T1D (Mathis, Vence et al. 2001). MHC-class 1 expression on the  cell target is critical, 
as molecular knockout prevents diabetes in NOD mouse (Serreze, Chapman et al. 
1997). CD8+ T cells, recognising antigen-MHC class 1 complex, kill  cells via perforin, 
granzyme B and Fas ligand mechanisms (Mathis, Vence et al. 2001). This process 
may be enhanced by elevated glucose, which can increase proinsulin presentation 
(Skowera, Ellis et al. 2009). Inflammatory cytokines such as IL-1  and IFN- , secreted 
by immune cells, act in synergism in effecting  cell death (Cnop, Welsh et al. 2005). 
However, no single cytokine is an absolute requirement for autoimmune diabetes, as 
sole knockout strains remain susceptible to disease, albeit with delayed onset 
(Hultgren, Huang et al. 1996, Kagi, Ho et al. 1999, Thomas, Irawaty et al. 2004). This 
may simply highlight the redundancy common in cytokine networks. Collectively they 
switch on pathways that lead to increased presentation of antigens ( MHC class 1 and 
proteasome components), chemokine expression (IL-15, IP-10, MCP-1 and ICAM-1) 
and apoptosis, which perpetuate immune process and  cell loss (Zhang, O'Brien et al. 
2002). 
 
1.4.3 Central and peripheral tolerance 
 
Important questions in understanding T1D pathogenesis therefore include how islet 
reactive T cells develop and are later primed to action. Self-reactive T cells are thought 
to undergo negative selection during thymic development because of their strong 
affinity to self antigens (Hogquist, Baldwin et al. 2005), a process called central 
tolerance. Again the NOD mouse provides clues on how this process can be 
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compromised (Lesage, Hartley et al. 2002). Firstly, differences in the expression of 
MHC-class 2 molecules are important (Kanagawa, Martin et al. 1998). Attempts to alter 
MHC class II expression by transgenes are successful in preventing insulitis 
(Nishimoto, Kikutani et al. 1987, Lund, O'Reilly et al. 1990). It has been suggested that 
the single NOD I-Ag7 has an unstable tertiary structure, resulting in poor peptide 
binding (Kanagawa, Martin et al. 1998). However, this may be oversimplified, as the 
clonal deletion of diabetogenic thymocytes in transgenic class-II NOD mice appears to 
be autoantigen independent (Bohme, Schuhbaur et al. 1990, Schmidt, Amrani et al. 
1999). Secondly, the ectopic expression of self-antigens may also account for disease 
susceptibility. The importance of this is shown by defects in the Aire gene (Liston, 
Lesage et al. 2003). Aire controls the expression of a number of self proteins in thymic 
medullary epithelial cells and its silencing creates the clinical syndrome APECED 
(autoimmune polyendocrinopathy, candidiasis and ectodermal dysplasia) characterised 
by spontaneous endocrine autommune diseases, including T1D. Whilst the Aire gene 
is not defective in NOD mice, measures that alter autoantigen expression in the 
thymus, such as proinsulin and GAD65, can modify disease (Tisch, Yang et al. 1993, 
Thébault-Baumont, Dubois-Laforgue et al. 2003). In corroboration, decreased thymic  
expression of insulin in humans, associated with alleles in the VNTR element of the 
insulin gene promoter, negatively correlates with T1D risk (Pugliese, Zeller et al. 1997).  
Lastly, diabetogenic thymocytes in the NOD mouse may be more resistant to apoptotic 
elimination, possibly through the upregulation of anti-apoptotic proteins (Lamhamedi-
Cherradi, Luan et al. 1998, O'Brien, Geng et al. 2006).     
 
The process of central tolerance is incomplete and circulating autoreactive T cells are 
detectable in health. Peripheral tolerogenic mchanisms keep these cells in check 
(Lohmann, Leslie et al. 1996, Semana, Gausling et al. 1999, Arif, Tree et al. 2004, 
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Mannering, Morris et al. 2004). The best characterised of these center on DC and 
regulatory T cells (Tregs).  
 
1.4.4 Dendritic cells and regulatory T cells  
 
Myeloid DC, defined by CD11c expression, are some of the first cells to infiltrate islets 
in the autoimmune diabetes in the NOD mouse, and are involved in the priming of 
autoreactive T cells (Rosmalen, Leenen et al. 1997, Turley, Poirot et al. 2003, Jansen, 
Homo-Delarche et al. 1994). In addition, they secrete abundant levels of IL-12 which 
skew effector T cells towards a Th1 phenotype (Trembleau, Penna et al. 1995, 
Weaver, Poligone et al. 2001, Trembleau, Penna et al. 2003). This response appears 
to be critical in the development of insulitis in the NOD mouse (Nitta, Kawamoto et al. 
2001). Th1 type cytokines include IFN- , IL-2, and IL-21, promote inflammatory 
responses of effector cells (Hultgren, Huang et al. 1996, Allison, McClive et al. 1994, 
Sutherland, Van Belle et al. 2009). In particular, IL-21 may be especially potent, as the 
transgenic overexpression of IL-21 in islets can trigger diabetes in a normally diabetes 
resistant strain (Sutherland, Van Belle et al. 2009). This preferential expression of Th1 
cytokines by T cells on encountering autoantigens appears to also apply in human T1D 
(Arif, Tree et al. 2004). In contrast, immature DCs are adept in antigen presentation 
and have reduced allo-stimulatory capacity (Lutz, Schuler 2002). They are identified by 
their low expression levels of MHC Class 2 and co-stimulatory molecules. Propagated 
from bone marrow cells and pulsed with autoantigenic peptides, these cells can delay 
disease onset in the NOD mouse (Feili-Hariri, Dong et al. 1999, Clare-Salzler, Brooks 
et al. 1992), and are the subject of current immunotherapy trials in human T1D (Lo, 
Clare-Salzler 2006). 
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Naïve T cells require a second signal in addition to the TCR-MHC-Class II-antigen 
complex for activation. This is provided by the binding of CD80 or CD86 on APC to 
CD28 on T cells (Sperling, Auger et al. 1996). In addition, CTLA-4 on the surface of T 
cells is an alternative ligand for CD80/86 (Walunas, Lenschow et al. 1994). This 
engagement produces an opposing inhibitory signal. Interventions on this pathway 
have complex effects on diabetes incidence on the NOD mouse. In keeping with its 
priming role, anti-CD86 antibodies can prevent diabetes onset only if administered 
before 10 weeks of age (Lenschow, Ho et al. 1995). However, antagonism of CD80/86 
with a soluble CTLA-4 antibody, as well as gene knockouts of CD28, CD80 and CD86, 
all produced paradoxical acceleration of diabetes (Anderson, Bluestone 2005). This 
finding may potentially be explained by the finding that these models have significantly 
reduced population of cells called Treg. CD80/86 – CD28 stimulation is required for the 
maintenance of Treg (Salomon, Lenschow et al. 2000, Tang, Henriksen et al. 2003).  
 
Treg police diabetogenic T cell responses in the NOD mouse by cell-contact and TGF-
 dependent mechanisms (Bluestone, Tang et al. 2008).  They possess CD62L, CTLA-
4, GITR on their surface, and can be also be identified also by its low CD127 
expression (Hartigan-O'Connor, Poon et al. 2007). Crucial to Treg function are 
transcription of the nuclear factor FoxP3 (Fontenot, Gavin et al. 2003), expression of 
CTLA-4 (Schmidt, Wang et al. 2009), and the cytokines IL-2 and TGF  (Setoguchi, 
Hori et al. 2005, Peng, Laouar et al. 2004) . Their numbers are reduced in NOD mice, 
and inversely correlate with rate of  cell destruction (Salomon, Lenschow et al. 2000, 
Chen, Herman et al. 2005). Whilst anergic to antigenic and polyclonal stimulation 
(Setoguchi, Hori et al. 2005, Gavin, Clarke et al. 2002), Treg numbers can be 
expanded in vitro with anti-CD3, anti-CD28 and IL-2 (Tang, Henriksen et al. 2004)  or 
using DC exposed to IL-10 and TGF-  (Rutella, Danese et al. 2006). Their subsequent 
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transfer to NOD mouse can curtail insulitis and reverse disease (Tang, Henriksen et al. 
2004, Lepault, Gagnerault 2000, Stephens, Mason 2000, Bresson, Togher et al. 2006).  
 
Whether defects in tolerance described in the NOD mouse are relevant to human T1D 
is open to debate (Bresson, von Herrath 2009, Atkinson, Leiter 1999). For example, a 
meta-analysis of Treg in human T1D found variable reports of functional impairments 
(Tree, Roep et al. 2006), and this is partly attributable to differences in stimulatory  
conditions. In positive studies, Tregs were tested against the stimulatory effects of anti-
CD3 (Brusko, Wasserfall et al. 2005, Lindley, Dayan et al. 2005). Adaptive Tregs are a 
subset of antigen-specific Treg that had developed from mature T cells under certain 
conditions of antigen stimulation (Bluestone, Abbas 2003). Using an in vitro culture 
system with APC and peptides, GAD- and IGRP- specific Treg in T1D were found to 
have similar function compared to other adaptive Treg in the same subject (Long, 
Walker et al. 2009). 
 
Moreover, DC from T1D patients and those at risk do not have an inflammatory 
phenotype (Takahashi, Honeyman et al. 1998, Zacher, Knerr et al. 2002, Angelini, 
Duca et al. 2005, Summers, Marleau et al. 2006). Adding complexity to the issue is that 
diabetogenic T cells may in fact be resistant to Treg suppression (D'Alise, Auyeung et 
al. 2008, Schneider, Rieck et al. 2008). This may be attributable to cytokines such as 
IL-21 and activation signals from the Toll-like receptor and the TNF receptor families 
(Walker 2009).        
 
A working model of the immunopathogenesis of T1D is presented in figure 1.5.  
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Figure 1.5: Working model of T1D autoimmunity. Antigen presenting cells (APC), in this case 
CD11c+ dendritic cells, process and traffick  cell antigens in the pancreatic lymph node. They 
activate naïve diabetogenic CD4+ T cells via MHC Class 2-antigen-T cell receptor synapse. 
Important co-stimulatory signals come from CD80/86-CD28 pathway and IL-12 secreted by DC. 
The CD4 T cells secrete predominantly Th1 type cytokines (IFN , IL-2 and IL21) in their 
recruitment of islet reactive CD8+ cytotoxic T cells and local macrophages. These cells effect  
cell killing through Fas ligand, TNF, IL-1  and reactive oxygen species (ROS). Treg, defined by 
the phenotype markers CD4+CD25+FoxP3+, is able to suppress diabetogenic T cells via cell 
contact and TGF-  dependent mechanisms. 
 
1.5 Insulin resistance is a propellant of T1D autoimmunity in susceptible 
individuals 
 
The discordance for disease in monozygotic twins has previously been cited as 
evidence for the environment in the pathogenesis of T1D (Redondo, Yu et al. 2001). 
Studies showing the negative impact in genetic risk in causing the worldwide increase 
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in T1D incidence (Gillespie, Bain et al., Fourlanos, Varney et al. 2008) have drawn 
further interest into the area.   
 
Insulin resistance (IR) refers to a fall in the biological activity of insulin at a given dose 
(Pang, Narendran 2008a). It manifests clinically as the metabolic syndrome (Reaven 
1988). Its prevalence is rising because of our obesity pandemic (Ford, Giles et al. 
2002, Mattsson, Ronnemaa et al. 2007). The gold standard in measurement of IR is 
the euglycaemic hyperinsulinaemic clamp (DeFronzo, Tobin et al. 1979). However this 
is time consuming and not suited to large scale clinical studies. Alternative validated 
measures include the HOMA-IR index (Wallace, Levy et al. 2004), which utilises paired 
fasting glucose and insulin, and the minimal model, based on insulin response at the 
IVGTT (Saad, Anderson et al. 1994).  
 
In the accelerator hypothesis, Wilkin proposed diabetes is the result of three processes 
contributing to  cell apoptosis (Wilkin 2001). These are constitution (genetic factors), 
autoimmunity and IR. Based on the increasing obesity rate, IR has been proposed as a 
likely environmental factor in driving the increasing incidence of T1D. If this is true, then 
a cohort of recent new cases would have a higher pre-morbid body mass index 
compared to an older group. Also adjusting for other known risk factors, the more 
aggressive islet autoimmunity would lead to an earlier age of diagnosis. Several groups 
have now reported these associations (Betts, Mulligan et al. 2005, Kibirige, Metcalf et 
al. 2003, Knerr, Wolf et al. 2005, Libman, Pietropaolo et al. 2003), but there are 
disagreements (Porter, Barrett 2004, Dabelea, B. et al. 2006). Others have attempted 
to examine the relationship between weight gain and positivity for autoantibodies, but 
again there is conflicting data (Couper, Beresford et al. 2009, Cambuli, Incani et al. 
2010). Despite this, stronger evidence can be found from prospective studies of 
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subjects with high-risk pre-T1D (Table 1) (Greenbaum, Sears et al. 1999, Fourlanos, 
Narendran et al. 2004, Mrena, Virtanen et al. 2006, Xu, Cuthbertson et al. 2007, 
Bingley, Mahon et al. 2008).  
 
The Melbourne Prediabetes Study first reported on the deleterious effect of insulin 
resistance on the development of T1D (Fourlanos, Narendran et al. 2004). The authors 
had employed an earlier version of HOMA-IR, standardised against FPIR, a surrogate 
of insulin secretary function. This adjustment compensates for the systematic 
underestimate by the natural decline in  cell function. Adjusting for known 
immunogenetic risk factors, HOMA-IR:FPIR at baseline was a powerful and 
independent predictor of diabetes (hazard ratio (HR) 2.14, 95% CI 1.39 – 3.29). 
Conversely, subjects who were relatively insulin sensitive were protected from disease. 
These findings were consistent with later studies conducted on different continents 
(Mrena, Virtanen et al. 2006, Xu, Cuthbertson et al. 2007, Bingley, Mahon et al. 2008). 
In particular, investigators for the DPT-1 found this relationship to apply to high and 
intermediate risk groups (Xu, Cuthbertson et al. 2007). Additionally they reported 
further increases of IR relative to baseline 6-12 months before diabetes onset. In 
contrast, two other studies recorded neutral effects (Greenbaum, Sears et al. 1999, 
Bingley, Mahon et al. 2008). However, posthoc analysis of ENDIT suggested the effect 
is dependent on baseline  cell reserve. The strong predictive power of IR remains in 
those with low FPIR and thus at high risk of progression (HR for low FPIR 3.67, p<0.05 
versus 1.27 ns for preserved insulin secretion) (Bingley, Mahon et al. 2008). Thus, the 
negative findings from the earlier Seattle Family Study could be explained by its lower 
risk study population (Greenbaum, Sears et al. 1999). Overall, the main effect of IR on 
diabetes onset is on those at high genetic risk (constitution) and those already with low 
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insulin reserve, because of autoimmunity. This is in keeping with its proposed role as 
an environmental modifier of disease risk in the accelerator hypothesis.       
 
Confirming the environmental origin of the IR, genome wide scan studies of T1D have 
not shown any loci known to modify insulin sensitivity to be associated with disease 
(Barrett, Clayton et al. 2009). Further supporting evidence comes from the British 
Diabetic Twins Study, which prospectively followed non-diabetic identical twins whose 
co-twin has T1D (Hawa, Bonfanti et al. 2005). Despite sharing the same genetic risk, 
twins who later developed diabetes were more insulin resistant than their control twins 
who maintained normal glucose tolerance.  
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Table 1.2: Prospective studies evaluating the effect of IR in development of T1D  
(in order of the year of publication) 
Study  N Median 
duration 
of follow-
up (years) 
 
Progression 
to clinical 
diabetes   
(%) 
Measure of IR Adjusted 
hazard ratio 
(95% CI) 
Seattle Family 
Study (1999) 
(Greenbaum, Sears 
et al. 1999) 
85 2.8 11.8 Minimal model 
of glucose 
kinetics from 
IVGTT 
1.0 (NS)  
Melbourne Pre-
Diabetes Family 
Study (2004) 
(Fourlanos, 
Narendran et al. 
2004) 
 
104 4.0 41.3 HOMA1-
IR:FPIR 
2.14  
(1.39 – 
3.29) 
Childhood Diabetes 
in Finland study 
(2006) (Mrena, 
Virtanen et al. 2006) 
 
77 15.0 40.3 HOMA1-
IR:FRIR 
2.4  
(1.2 – 5.0) 
Diabetes Prevention 
Trial- Type 1 
(moderate risk 
group) (2007) (Xu, 
Cuthbertson et al. 
2007) 
 
186 4.3 28.5 HOMA1-IR  2.70  
(1.45 – 
5.06) 
Diabetes Prevention 
Trial- Type 1 (high 
risk group) (2007) 
(Xu, Cuthbertson et 
al. 2007) 
 
170 3.7 41.2 HOMA1-IR 1.83  
(1.19 -2.82) 
European 
Nicotinamide 
Diabetes Intervetion 
Trial (2008) 
(Bingley, Mahon et 
al. 2008) 
 
213 4.2 49.3 HOMA2-IR 1.43  
(0.99 – 
2.06) 
DPT-1 Moderate risk group – 25-50% 5 year risk of developing T1D 
DPT-1 High Risk group - ≥ 50% 5 year risk of developing T1D 
HOMA1-IR – measure of IR at steady state based on the formula: fasting insulin (mU/L) × fasting glucose 
(mmol/l) / 22.5 
HOMA2-IR – refined model of HOMA1-IR, taking into account steady state changes in glucose and insulin 
at higher levels of fasting glucose and interference of insulin assays by proinsulin 
FPIR – sum of serum insulin concentration at 1 and 3 minutes after glucose injection in the IVGTT 
 - calculation based on insulin sensitivity index (× 10
-5
 min
-1
/[pmol/l]) from frequently sampled IVGTT 
between progressors (4.47 ± 0.584) and non-progressors (4.48 ± 0.443) 
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1.6 Adipose tissue and immunity  
 
How can we explain the association between IR and the accelerated development of 
T1D? Diabetes may be revealed earlier as the higher IR overloads the compromised  
cell (Dahlquist 2006). But data exists to suggest IR may also directly modulate islet 
autoimmunity. In the Melbourne Prediabetes Study, the effect of increasing IR on 
diabetes incidence was analysed in a post hoc Kaplan Meier analysis (figure 1.6). 
Subjects, controlled for family history, HLA haplotype and autoantibody profile, were 
divided into four quartiles based on their IR on entry. Of interest is the divergence in the 
Kaplan Meier curves and the relative protection from disease in subjects who were 
insulin sensitive. If IR is to only have an overload effect, then the pattern seen would be 
that of a divergent-convergent curve, ie disease onset is delayed in the insulin sensitive 
quartile but eventually all four groups will develop disease because of the same rate in 
 cell mass loss. This analysis suggests IR is a modifier of  cell autoimmunity, and 
there is evidence to support such a link is biologically plausible. 
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Figure 1.6 Kaplan-Meier analysis of increasing quartiles of IR on incidence of diabetes in 
the Melbourne Prediabetes Study (Fourlanos, Narendran et al. 2004). Reproduced with 
permission (Springer licence number: 2551431389203). HOMA-R denotes HOMA IR. Subjects 
controlled for known risk factors of T1D were stratified into quartiles according to their HOMA-
IR, standardised to FPIR, on entry. The divergence in Kaplan-Meier curves and low diabetes 
incidence in the insulin sensitive quartiles (0-25
th
 and 26
th
-50
th
 percentiles) indicate IR is a 
modifier in the pathophysiology of T1D.  
 
In animal models,  cells triggered to apoptose because of gluco- and lipotoxicity 
display increased autoantigens (Bjork, Kampe et al. 1992), and this in turn can activate 
DC and CD8+ T cells (Bjork, Kampe et al. 1992, Trudeau, Dutz et al. 2000). 
Alternatively, the association may be attributed to effects of adipose tissue (AT). AT 
decreases on whole body insulin sensitivity (Kahn, Hull et al. 2006), and recent studies 
show that it has the capability to direct T cell immunity. 
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Fat accretion shifts the balance of resident T cells in AT (Nishimura, Manabe et al. 
2009, Winer, Chan et al. 2009, Feuerer, Herrero et al. 2009). Wild type mice on high 
chow diet had an overall higher number of T cells in their visceral adipose tissue. T cell 
numbers in cutaneous fat, which has a much lower proportion of white adipose tissue 
implicated in the metabolic syndrome, were unchanged (Winer, Chan et al. 2009). The 
infiltrate was largely CD8+ (Nishimura, Manabe et al. 2009) and IFN-  expressing 
(Winer, Chan et al. 2009), with diminished numbers of CD4+FoxP3+ cells (Feuerer, 
Herrero et al. 2009). The mechanism for T cell influx is not clear, although intriguingly, 
analysis of TCR rearrangements of these shows the T cells were of limited repertoire, 
suggesting antigenic stimulation plays a role (Winer, Chan et al. 2009, Feuerer, 
Herrero et al. 2009, Feuerer, Herrero et al. 2009). Similar changes in the balance in 
favour of pro-inflammatory effector T cells over FoxP3+ cells are seen in ob/ob mice 
(Feuerer, Herrero et al. 2009), a model of genetic IR and also in obese human subjects 
(Winer, Chan et al. 2009, Feuerer, Herrero et al. 2009). These T cells appear to be 
important in modulating AT inflammation and IR. In mice fed with high fat diet, 
expanding FoxP3 numbers using recombinant IL-2 and a particular–IL-2–specific 
monoclonal antibody (Feuerer, Herrero et al. 2009), or mitogenic CD3 antibody (Winer, 
Zern et al. 2006) ameliorated IR. The selective removal of CD8+ T cells using 
neutralising CD8 antibodies mitigated the recruitment of macrophage into AT and 
downregulated IL-6 and TNF  expression in AT.  
 
Moreover, the immunomodulatory potential of perinodal fat is recognised (Knight 2008) 
where adipocytes are in close proximity to DC. Here, crosstalk is likely to involve 
adipokines. Discovered by gene expression profiling of adipocytes, adipokines have 
paracrine and endocrine functions in energy metabolism and inflammation (Zhang, 
Proenca et al. 1994, Maeda, Okubo et al. 1996). Examples of adipokines include the 
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archetypal leptin, resistin, TNF , as well as the adipokine that is the subject of this 
thesis, adiponectin. It is by far the highest expressed adipokine and has attracted the 
most research interest as a putative modulator of obesity-associated disease. 
  
1.7 Adiponectin biology 
1.7.1 The adiponectin gene (ADIPOQ) and protein structure 
 
Adiponectin is encoded by the ADIPOQ gene on chromosome 3q21 (Kissebah, 
Sonnenberg et al. 2000, Takahashi, Arita et al. 2000), which spans 17kb. It consists of 
three exons and two introns (figure 1.7A). Its mRNA transcripts were previously 
believed to be restricted to AT and in mature adipocytes (Maeda, Okubo et al. 1996, 
Scherer, Williams et al. 1995, Maeda, Okubo et al. 1996). In the 3T3-L1 cell line, a 
widely used model in studies of adipocyte biology, ADIPOQ transcripts were absent in 
pre-adipocyte cultures, but is induced 100-fold upon maturation (Scherer, Williams et 
al. 1995). Recent studies have found ADIPOQ expression in extra-adipose tissues can 
be induced in inflammatory states, in exocrine glands (Katsiougiannis, Kapsogeorgou 
et al. 2006), heart muscle (Guo, Xia et al. 2007) and respiratory epithelium (Miller, Cho 
et al. 2009).  
 
It is a 30 kDa monomeric protein, consisting of 244 amino acid residues (figure 1.7B). It 
has a N-terminal signal sequence, a domain containing 22 Gly-X-Pro repeats which 
forms the straight collagen stalk, and a globular domain at the carboxyl terminal that 
has sequence homology to the complement factor C1q (Scherer, Williams et al. 1995). 
The tertiary structure of the protein is similar to TNF  (Kadowaki, Yamauchi 2005).  
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1  MLLLGAVLLL LALPGHDQET TTQGPGVLLP LPKGACTGWM 
41  AGIPGHPGHN GAPGRDGRDG TPGEKGEKGD PGLIGPKGDI 
81  GETGVPGAEG PRGFPGIQGR KGEPGEGAYV YRSAFSVGLE      
121  TYVTIPNMPI RFTKIFYNQQ NHYDGSTGKF HCNIPGLYYF 
161 AYHI  TVYMKD VKVSLFKKDK  AMLFTYDQYQ ENNVDQASGS 
201    VLLHLEVGDQ VWLQVYGEGE RNGLYADNDN DSTFTGFLLY      
241 HDTN
a
b
c
Figure 1.7 ADIPOQ gene (A) and primary protein structure of adiponectin (B) 
A. Obesity decreases expression of adiponectin RNA. Increased TNF , ER stress 
and associated increase in CREB levels act in concert to alter balance of promoter 
(PPAR and FoxO1) and repressor (ATF3 and NCAT) activity on ADIPOQ 
transcription. B. Primary structure of adiponectin (244 aa). Box a indicates the signal 
sequence. Box b is a region containing short collagen like motif Gly-X-Y triplets. Box 
c shows sequence homology to C1q.
Promoter        exon1             exon2              exon3
PPAR
FoxO1 ATF3
NCAT
+ _
CREB
PKC
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JNK
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Through non-covalent associations between the collagenous domains, adiponectin can 
form dimers and trimers. These can further polymerise via disulphide bonds and other 
post-translational modifications to form low and high molecular weight species in 
circulation (Waki, Yamauchi et al. 2003, Tsao, Tomas et al. 2003, Richards, Stephens 
et al. 2006). The ability to form multimeric adiponectin appears to be confined to 
mammalian cells and is dependent on the glycosylation of lysine residues in the 
collagenous domain (Richards, Stephens et al. 2006). Together, adiponectin multimers 
circulate at concentrations of 10 ug ml-1 in plasma. Globular adiponectin (gAd), a 
fragment of full length adiponectin following cleavage of the collagenous tail by 
leucocyte elastase (Waki, Yamauchi et al. 2005), is present in small amounts but has 
recognised biological functions (Fruebis, Tsao et al. 2001).     
 
1.7.2 The adiponectin Receptors AdipoR1 and AdipoR2 
 
Using expression cloning, where binding of recombinant adiponectin was screened 
against proteins made from a human skeletal muscle cDNA library, Yamauchi et al 
were the first to describe specific surface receptors for adiponectin, termed AdipoR1 
and AdipoR2 (Yamauchi, Kamon et al. 2003). The receptors belong to the G-protein 
related receptor superfamily and have an inverted topology, such that the C-terminus is 
on the external surface. They have similarities on crystallography to the TNF  receptor 
(Yamauchi, Kamon et al. 2003, Kupchak, Garitaonandia et al. 2009). Whereas 
AdipoR1 is exclusively expressed on mice skeletal muscle, both receptors are 
ubiquitously expressed in human tissues (Kadowaki, Yamauchi 2005). 
 
Despite sharing 67% protein sequence homology, the two isoforms are distinguished 
by their genetic origin, affinity profile for adiponectin multimers and signal transduction. 
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The AdipoR1 gene lies on chromosome 1 (Genbank NM_015999) and the AdipoR2 
gene is on chromosome 12 (Genbank NM_024551). AdipoR1 is a high affinity receptor 
for gAD and a low affinity receptor for full length adiponectin, whereas AdipoR2 exhibits 
intermediate avidity for all forms.  
 
Although the full signal transduction pathway following agonist-receptor binding is 
unknown, both receptors activate PPAR  and ERK 1/2, key intermediaries in lipid 
metabolism and cell growth respectively (Yamauchi, Nio et al. 2007, Lee, Klein et al. 
2008). However there are also key differences (fig 1.8). In the liver, selective 
manipulation of each receptor subtype resulted in a different phenotype (Yamauchi, Nio 
et al. 2007). Upregulation of AdipoR1 by adenovirus vector activated AMP kinase and 
reduced endogenous glucose production. The converse was seen with AdipoR1 
knockout, but these changes were not seen with genetic manipulation of AdipoR2 
expression. In contrast, AdipoR2 expression was found to have exclusive effects on 
PPAR  targeted genes and glucose uptake by the liver. In human synovial fibroblasts 
which also express both receptors, it is the selective siRNA knockdown of AdipoR1, not 
AdipoR2, that resulted in the dissociation of AMP kinase, p38 MAPK and NF B 
signalling with adiponectin (Tang, Chiu et al. 2007). In support of these downstream 
differences, upstream events critical to AdipoR1 signalling, such as clarthrin- and Rab 
5- dependent endocytosis of agonist receptor complex, and interaction with signalling 
adaptor proteins APPL1 and ERp46, have not been shown to be of functional 
relevance for AdipoR2 (Charlton, Webster et al. 2010, Mao, Kikani et al. 2006, Ding, 
Wang et al. 2009). Thus, although both AdipoR1 and AdipoR2 can bind full length 
adiponectin, the differences in signalling argue against redundancy commonly seen in 
cytokine pathways. Hence, deficiency of one receptor isotype would not be 
compensated by the other. However, in combination, AdipoR1 & AdipoR2 signalling 
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accounted for the metabolic actions of adiponectin. Double receptor knockdown 
recapitulated the metabolic phenotype of the adiponectin-deficient mice (Yamauchi, Nio 
et al. 2007, Yamauchi, Kamon et al. 2001). When fed on a high fat diet, these animals 
develop diabetes with marked insulin resistance. Changes at the tissue level include 
increased triglyceride content and expression markers of inflammation and oxidative 
stress.    
 
Mammalian high molecular weight adiponectin has also been reported to bind T-
cadherin in vitro, a glycosylphosphatidylinositol-anchored extracellular protein 
expressed on endothelial and smooth muscle cells (Hug, Wang et al. 2004). The 
biological significance of this had been questioned, as T-cadherin lacks a cytoplasmic 
domain for intracellular signal transduction (Takeuchi, Adachi et al. 2007). However, 
recent studies have demonstrated co-localisation of adiponectin and T-cadherin in 
tissue and via the T-cadherin deficient model, the interaction is important in mediating 
adaptive changes of cardiac muscle to insult (Denzel, Scimia et al. 2010). 
 
Interactions of adiponectin with LPS (Peake, Shen et al. 2006), C1q (Peake, Shen et 
al. 2008), C1q receptor (Yokota, Oritani et al. 2000), chemokines such as monocyte 
chemoattractant protein-1 and macrophage-inflammatory-protein 1  (Masaie, Oritani et 
al. 2007), and calreticulin receptor (Takemura, Ouchi et al. 2007) have also been 
described in vitro. However, criticisms against these studies, which include use of non-
mammalian sourced adiponectin (Peake, Shen et al. 2006, Peake, Shen et al. 2008), 
pharmacological concentration of reagents (Yokota, Oritani et al. 2000, Takemura, 
Ouchi et al. 2007) and lack of supporting functional data (Peake, Shen et al. 2006, 
Masaie, Oritani et al. 2007), cast doubt on their physiological relevance. 
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AdipoR1 AdipoR2
Figure 1.8 Adiponectin and its receptors AdipoR1 & AdipoR2. Monomeric adiponectin has a 
globular head and a collagenous tail. Circulating adiponectin is multimeric. Low molecular weight 
(LMW) and HMW adiponectin are formed through non-covalent bonds and disulphide linkage 
between the tails. The collagenous tail is cleaved in globular adiponectin (gAd). AdipoR1 binds gAd
preferentially and has low affinity to LMW and HMW adiponectin (dotted arrow), whilst AdipoR2 
binds all species equally. AdipoR1-agonist complex is endocytosed via a clathrin- and Rab5-
dependent mechanism, and interacts with the chaperone protein ERp46 and the signal transducer 
APPL1 (adaptor protein containing pleckstrin homology domain, phosphotyrosine binding (PTB) 
domain and leucine zipper motif) {{692 Mao,Xuming 2006}}. Various downstream intracellular 
kinases and nuclear transcription factors are activated () or inhibited   (         )  
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1.7.3. Regulation of adiponectin production 
1.7.3.1 Negative regulators 
 
Serum and mRNA adiponectin levels are reduced in obesity (Kern, Di Gregorio et al. 
2003, Weyer, Funahashi et al. 2001, Lihn, Bruun et al. 2004, Hu, Liang et al. 1996). 
With weight gain, the hypoxic microenvironment and increased production pro-
inflammatory cytokines are thought to be the main factors that drive the suppression of 
adiponectin expression (Ye 2009, Hotamisligil 2006, Bruun, Lihn et al. 2003, Hosogai, 
Fukuhara et al. 2007). Obesity leads to ER stress (Gregor, Hotamisligil 2007) and 
consequent activation of JNK (c-Jun-N-terminal kinase) and ATF3 (activating 
transcription factor 3), two repressors of ADIPOQ transcription (Koh, Park et al. 2007). 
Other repressor proteins induced in obesity include CREB and NFAT (nuclear factor of 
activated T-cells) (Liu, Liu 2009). Fat accretion also results in the increased production 
of TNF  from adipocytes (Kern, Ranganathan et al. 2001) and also the influx of 
activated lymphocytes and macrophages (Nishimura, Manabe et al. 2009, Winer, Chan 
et al. 2009). One mechanism by which TNF  suppresses adiponectin expression is 
through PPAR . TNF  inhibits PPAR  expression on adipocytes by a protein kinase C 
dependent mechanism (Lim, Kim et al. 2008). The promoter activity of PPAR  on 
ADIPOQ transcription (Yu, Javorschi et al. 2002, Kanatani, Usui et al. 2007) is lost 
upon phosphorylation (Zhang, Berger et al. 1996). In addition, synthesis of ER 
chaperones involved in secretion of multimeric adiponectin, namely DsbA-L (disulfide-
bond A oxidoreductase-like protein) and Ero1 (ER membrane-associated 
oxidoreductase)-L  (Wang, Schraw et al. 2007, Liu, Zhou et al. 2008), is reduced by 
the inactivation of PPAR  by TNF  (Liu, Liu 2009). 
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1.7.3.2 Positive regulators  
 
As discussed, PPAR  is a known inducer of adiponectin expression and secretion.  The 
promoter region of ADIPOQ was also found to contain response elements to FoxO1, a 
member of the forkhead box O transcription factor family involved in cell differentiation. 
Changes in adiponectin production following FoxO1 over-expression and knockdown 
are consistent with FoxO1 being a positive transcriptional regulator (Nakae, Cao et al. 
2008). FoxO1 mRNA can be increased in human inflammatory states (Valenti, Rametta 
et al. 2008). Also, post-translational modifications of FoxO1 can also influence its 
cellular localisation and activity. Sirt1, a NAD-dependent deacetylase promotes its 
nuclear translocation (Qiao, Shao 2006), and Sirt1 protein levels are increased with 
caloric restriction . This may be a mechanism for accounting the rise in serum 
adiponectin following lifestyle intervention (Mather, Funahashi et al. 2008, Cambuli, 
Musiu et al. 2008, Esposito, Pontillo et al. 2003, Monzillo, Hamdy et al. 2003).  
 
Increased adiponectin expression is seen in some inflammatory conditions (Šenolt, 
Pavelka et al. 2006, Rovin, Song et al. 2005, Yamamoto, Kiyohara et al. 2005, Leth, 
Andersen et al. 2008); (Tsatsanis, Zacharioudaki et al. 2005, Ehling, Schaffler et al. 
2006, Ehling, Schaffler et al. 2006, Haugen, Drevon 2007). This could relate to the 
induction of adiponectin in extra-adipose tissue (Katsiougiannis, Kapsogeorgou et al. 
2006, Guo, Xia et al. 2007, Miller, Cho et al. 2009), and include skeletal muscle 
(Krause, Liu et al. 2008). Injection of LPS and TNF  increased expression of 
adiponectin in skeletal muscle by 10-fold (Delaigle, Jonas et al. 2004). The combination 
of TNF  and interferon-  was also effective in inducing skeletal muscle adiponectin 
RNA and protein in vitro, in a dose dependent manner. This was dependent on 
stimulated nitric oxide production, as expression of inducibe nitric oxide (NO) synthase 
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preceded the rise in adiponectin mRNA, and that inhibitors of NO synthesis, L-NNMA, 
suppressed the inducive effect. The mechanism of how NO affect ADIPOQ 
transcription is not clear. 
 
1.7.4 Physiological functions of adiponectin 
1.7.4.1 Glucose and lipid metabolism 
 
The functional relevance of adiponectin in energy metabolism is best demonstrated in 
the ADIPOQ knockout mice. These mice had normal features on normal caloric intake. 
However, when place on a high fat diet, the animals developed marked insulin 
resistance, despite comparable weight gain in wild type controls  (Maeda, Shimomura 
et al. 2002, Kubota, Terauchi et al. 2002). Clamp studies showed increased hepatic 
glucose output and reduced peripheral glucose uptake. Tracer studies demonstrated 
impaired  oxidation, and in keeping with this, increased tissue triglyceride and 
appearance of ectopic intramyocellular fat. Moreover, insulin receptor substrate-1 
activity was reduced and TNF  levels were markedly increased. Adiponectin 
replacement reversed this phenotype, through increased activation of AMP kinase, 
PPAR  and p38 MAPK. This was followed by increased phosphorylation of acetyl 
coenzyme A carboxylase and  oxidation at both the liver and skeletal muscle. At the 
liver, there was also decreased expression of enzymes involved in gluconeogenesis, 
namely glucose-6-phosphatase and phosphoenolpyruvate carboxylkinase, with 
resultant decrease in hepatic glucose output. In skeletal muscle, increased glucose 
uptake was facilitated by increased expression of glucose transporter GLUT4. Plasma 
TNF  was reduced. Adiponectin treatment of the ob/ob mice, whose genetic leptin 
deficiency was associated with hyperphagia and exaggerated weight gain, was 
effective in ameliorating IR (Berg, Combs et al. 2001). In vitro testing showed 
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adiponectin allowed suppression of glucose output by hepatocytes at sub-physiological 
doses. These activities were dependent on AdipoR1 and AdipoR2 signalling 
(Yamauchi, Nio et al. 2007), through which AMP kinase and PPAR /  are activated.  
 
In agreement with a role in human physiology, polymorphisms in ADIPOQ (Gong, Long 
et al. 2010.Hivert, Sullivan et al. 2008, Menzaghi, Trischitta et al. 2007), as well as 
reduced serum adiponectin levels (Li, Shin et al. 2009) are independent predictors of 
glucose intolerance and type 2 diabetes (Table . The genomic region in which ADIPOQ 
lies was found to be strongly associated with insulin resistance (Kissebah, Sonnenberg 
et al. 2000). The effect of two single nucleotide polymorphisms in the ADIPOQ 
promoter region (rs17360539 & rs266729) has been evaluated in case-control studies 
across the world. In a fixed effects modelling meta-analysis of these studies, G at 
position 11391 in place of A was associated with an odds ratio (OR) of 1.09 (p = 0.046) 
for T2D (Gong, Long et al. 2010). G in place of C at the 11377 position was associated 
with an OR of 1.08 (p = 0.03). There was some heterogeneity in the studies, and the 
authors cited ethnicity of the study group as a contributor. Neither SNP were found to 
be associated with T2D in a pooled analysis of studies of East Asians. The significance 
in the overall analysis was largely attributed to the estimates from studies of Caucasian 
subjects. In contrast, meta-analysis of the effect of adiponectin on T2D risk in 
prospective observational trial found a consistent protective effect of adiponectin, 
regardless of sex, age, BMI and ethnicity. A one log ug ml-1 increase was associated 
with an OR of 0.72 (95% CI 0.67-0.78), ie a 28% reduction in disease incidence (Li, 
Shin et al. 2009).   
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 No of studies OR for T2D (95% CI) 
ADIPOQ rs17360539 6 1.09 (1.00 – 1.19) 
ADIPOQ rs266729 
       Caucasian 
       East Asians 
13 
6 
7 
1.08 (1.01 – 1.15) 
1.06 (1.00-1.12) 
1.09 (0.95 – 1.24)  
   
Log serum adiponectin 
increase (overall) 
14 0.72 (0.67 – 0.78) 
       Caucasian 6 0.71 (0.65 – 0.78) 
       East Asians 3 0.70 (0.61 – 0.80) 
       Asian Indians 1 0.74 (0.59 – 0.93) 
       Age < 50 3 0.51 (0.28 – 0.94) 
       Age > 60 6 0.77 (0.70 – 0.84) 
       BMI < 25 3 0.70 (0.61 – 0.80) 
       BMI  > 25 11 0.74 (0.67 – 0.81) 
 
Table 1.3 Effects of polymorphisms of ADIPOQ and serum adiponectin levels on T2D 
risk, from meta-analysis (Gong, Long et al. 2010, Li, Shin et al. 2009). OR derived from fixed 
effects modelling, which assumes the effect of the dependent variable is the same across 
studies. As a result, the weighting for each study in the pooled analysis is based on sample size 
and the SD of the estimate. A large study with a small SD of the point estimate will thus have a 
greater weighting. 
 
Consistent with findings in the ADIPOQ knockout mice, normoglycaemic subjects with 
ADIPOQ polymorphisms associated with decreased adiponectin expression were of 
normal BMI (Kondo, Shimomura et al. 2002). This suggests that adiponectin does not 
determine constitutional fat mass, but rather it is an adaptive mechanism of restoring 
insulin sensitivity in an otherwise insulin resistant state. In support, adiponectin 
expression is upregulated in animals made insulin resistant by silencing insulin 
receptor expression (Lin, Kim et al. 2007).  
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1.7.4.2 Inflammation 
 
Adiponectin has been widely reported to be anti-inflammatory. Population studies show 
an inverse correlation of serum adiponectin against TNF  (Hivert, Sullivan et al. 2008, 
Krakoff, Funahashi et al. 2003), IL-6 (Engeli, Feldpausch et al. 2003, Hung, McQuillan 
et al. 2008) and CRP (Winer, Zern et al. 2006, Monzillo, Hamdy et al. 2003, Ouchi, 
Kihara et al. 2003, Mantzoros, Li et al. 2005, Schulze, Rimm et al. 2004). Consistent 
with a causative association is the reduction of these inflammatory cytokines in insulin 
resistant animals with adiponectin treatment (Maeda, Shimomura et al. 2002, Uji, 
Yamamoto et al. 2009, Xu, Wang et al. 2003). In support, adiponectin has the ability to 
suppress expression of NF- B, an essential transcription factor for inflammation-related 
proteins (Haugen, Drevon 2007, Maeda, Shimomura et al. 2002, Ouchi, Kihara et al. 
2000, Ajuwon, Spurlock 2005). Recent studies suggest this inhibitory effect is specific 
to AdipoR1 signalling, and is cyclic AMP dependent (Tang, Chiu et al. 2007, Ouchi, 
Kihara et al. 2000). 
 
At the cellular level, adiponectin has been shown to have anti-inflammatory effects on 
monocyte-macrophages, NK lymphocytes and neutrophils (Yokota, Oritani et al. 2000, 
Tsatsanis, Zacharioudaki et al. 2005, Chinetti, Zawadski et al. 2004, Wolf, Wolf et al. 
2004, Wulster-Radcliffe, Ajuwon et al. 2004, Saijo, Nagata et al. 2005, Kim, Kim et al. 
2006, Magalang, Rajappan et al. 2006, Neumeier, Weigert et al. 2006, Okamoto, Folco 
et al. 2008, Weigert, Neumeier et al. 2008, Turner, Smolinska et al. 2009, Kumada, 
Kihara et al. 2004, Wulster-Radcliffe, Ajuwon et al. 2004) (Table 1.2). Yokota et al were 
the first to describe anti-inflammatory effects of adiponectin on myeloid macrophages, 
grown ex vivo from primary monocytes in RPMI supplemented with 10% human type 
AB serum. The addition of recombinant adiponectin (10 ug ml-1) at the beginning of 
 41  
culture did not impair viability and differentiation of the monocytes. The macrophages 
were re-fed adiponectin for 24 hours before functional assays. Adiponectin treated 
macrophages had reduced phagocytic activity when incubated with fluorescent 
microspheres. Following brief LPS stimulation, these cells also had reduced TNF  
mRNA and protein in the supernatant, compared human serum albumin control. A 
limitation of the paper is the bacterial source of recombinant adiponectin used. 
Recombinant adiponectin from non-mammalian sources are purely monomeric, as they 
lack post-translational modifications required for oligomerisation (Turner, Smolinska et 
al. 2009). Thus their action here may not be representative of human physiology.  Wolf 
et al used a similar protocol to generate macrophages, but 10% FCS and a higher dose 
of adiponectin (20ug ml-1) from a non-specified source were used instead. They found 
adiponectin treated macrophages expressed increased levels of IL-10 and IL-1RA in 
the culture supernatant, compared to a solvent control treatment. When stimulated with 
LPS, these cells secreted significantly less interferon- . The authors also demonstrated 
the adiponectin treated macrophages had reduced stimulatory capacity when tested 
with [3H] thymidine labelled allogeneic T cells. They ascribed this to reduced phagocytic 
activity using a FiTC-dextran assay, although the raw data for this was not presented in 
the paper. No changes in costimulatory molecules on adiponectin treated macrophages 
were detected by flow cytometry. A strength of the paper is the investigation into the 
mechanism for anti-inflammatory cytokine production. The authors tested a range of 
kinase inhibitors against the effect of adiponectin stimulated IL-10 release. They found 
a selective inhibitor of PI3-kinase abrogated the effect. PI3 kinase is known to be 
modulated by APPL-1 dependent AMP kinase activity (Chandrasekar, Boylston et al. 
2008) , which in turn, is an important downstream transducer of AdipoR1 (Mao, Kikani 
et al. 2006). AdipoR1 RNA expression has been described on macrophages (Chinetti, 
Zawadski et al. 2004), thus we speculate that macrophage functions are mediated by 
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the adiponectin receptors. Testing this requires the application of specific receptor 
agonist/antagonist, or means of genetic knockout, of the adiponectin receptor on the 
functional assay.     
 
Adiponectin appears to inhibit leucocyte migration. In the atheroma model, adiponectin 
treatment inhibits inflammatory infiltrates of vascular plaques. The decreased 
recruitment of immune cells from the circulation is thought to be due to reduced 
expression of integrins on endothelial cells (Ouchi, Kihara et al. 1999), and attenuated 
function of chemokines (Masaie, Oritani et al. 2007, Okamoto, Folco et al. 2008). At 
sites of inflammation, cells undergoing apoptosis can be pro-inflammatory and trigger 
autoimmunity (Savill, Dransfield et al. 2002). Here adiponectin is thought to facilitate 
the phagocytosis of early apoptotic bodies (Takemura, Ouchi et al. 2007). Takemura et 
al found  marked persistence of apoptotic bodies in thymi of adiponectin knockout 
mice, upon challenge with dexamethasone. Treatment with adiponectin reversed this 
phenotype. As further confirmation, the authors found adiponectin pre-incubation 
coated the surface of  apoptotic Jurkat T cells and this facilitated their uptake by 
macrophages. This effect was thought to occur independently of the adiponectin 
receptors AdipoR1, AdipoR2 and T-cadherin, as their siRNA knockdown on 
macrophages did not affect phagocytosis. Instead the effect was attributed to the 
calreticulin receptor, as its knockdown and neutralisation by specific antibody (anti 
CD91), abrogated the enhanced phagocytosis.  The case for the calreticulin receptor 
could be further strengthened if the effect of the anti-CD91 is studied in the in vivo 
model.  
 
Furthermore, cytotoxicity of neutrophils and NK lymphocytes is inhibited (Kim, Kim et 
al. 2006, Magalang, Rajappan et al. 2006). Kim et al found adiponectin to inhibit IL-2 
mediated activation of NF- B and consequent cytotoxicity, tested in vitro using the 
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51Chromium release assay with labelled YAC-1 lymphoma cells. The supra-
physiological dose (30ug ml-1) and source of NK cells (mouse primary) are limitations to 
the data‟s applicability to human subjects. Adiponectin also appears to be a potent 
inhibitor of hydrogen peroxide generation by neutrophils (Magalang, Rajappan et al. 
2006). However this effect did not apply across all pharmacological stimuli and the 
paper did not append any mechanistic data to explain the discrepancy. 
 
Collectively, these functions are protective in inflammatory diseases associated with 
insulin resistance, such as atherosclerosis and steatohepatitis (Shimada, Miyazaki et 
al. 2004, Schaffler, Scholmerich et al. 2005). Thus, it has been proposed that the 
reduced synthesis of adiponectin with weight gain has a permissive effect on 
inflammation in obesity (Fantuzzi 2008).  
 
However, the paradigm that adiponectin is anti-inflammatory has come under scrutiny. 
Controlling for body mass index, raised local and serum levels of adiponectin has been 
reported in chronic inflammatory and autoimmune diseases, including SLE, rheumatoid 
arthritis, Crohns disease and type 1 diabetes (Šenolt, Pavelka et al. 2006, Rovin, Song 
et al. 2005, Yamamoto, Kiyohara et al. 2005, Leth, Andersen et al. 2008). In support, 
adiponectin can be pro-inflammatory  (Tsatsanis, Zacharioudaki et al. 2005, Ehling, 
Schaffler et al. 2006, Ehling, Schaffler et al. 2006, Haugen, Drevon 2007) (Table 1.4), 
and activate classical complement cascade (Peake, Shen et al. 2008) (Table 1.3). 
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Table 1.4 immune effects of adiponectin  
Function Source of 
adiponectin 
tested 
 
Culture system Reference 
Anti-inflammatory    
(-) TNF  Full length, 
bacterial 
 
Not stated 
LPS-stimulated, primary 
macrophage 
 
LPS-stimulated porcine 
macrophage 
(Wulster-Radcliffe, 
Ajuwon et al. 2004) 
 
(Neumeier, Weigert 
et al. 2006) 
 
(-) IL-6 LMW, insect 
 
Not stated 
Monocytic cell line THP-1 
 
LPS-stimulated porcine 
macrophage 
(Wulster-Radcliffe, 
Ajuwon et al. 2004) 
 
 
(Saijo, Nagata et al. 
2005) 
(-) IL-8 
 
HMW, plasma 
derived 
Primary macrophage (Wolf, Wolf et al. 
2004) 
(-) IFN  
 
Not stated LPS-activated primary 
macrophage 
(Wolf, Wolf et al. 
2004) 
 
(+) IL-10 Not stated 
 
 
Full length, 
bacterial 
 
 
Not stated 
LPS-activated human 
monocytes 
 
Primary macrophage 
 
 
 
LPS-stimulated porcine 
macrophage 
(Kumada, Kihara et 
al. 2004) 
 
(Wulster-Radcliffe, 
Ajuwon et al. 2004) 
 
(Wolf, Wolf et al. 
2004) 
 
(+) IL-1RA 
 
Not stated LPS-activated human 
monocytes 
(Yokota, Oritani et 
al. 2000, Chinetti, 
Zawadski et al. 
2004) 
 
(-) phagocytosis by 
macrophage 
Full length, 
bacterial 
 
Full length, 
bacterial 
 
Not stated 
 
HMW adiponectin 
plasma derived 
Primary macrophage 
 
 
Primary macrophage 
 
 
Primary macrophage 
 
Primary macrophage 
 
(Wolf, Wolf et al. 
2004) 
 
(Saijo, Nagata et al. 
2005) 
 
(Wolf, Wolf et al. 
2004) 
(-) T cell stimulatory 
capacity of 
macrophage 
 
Not stated Primary macrophage  (Okamoto, Folco et 
al. 2008) 
(-) CXCR3 on 
macrophage & T cell 
chemotaxis 
 
 
 
Full length, insect 
cell 
Primary macrophage (Kim, Kim et al. 
2006) 
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(-) NK cell 
cytotoxicity 
Full length, 
bacterial  
Mice C57BL/6 NK cells (Magalang, 
Rajappan et al. 
2006) 
(-) neutrophil 
superoxide 
generation  
 
Full length, 
bacterial 
Primary neutrophils (Peake, Shen et al. 
2008) 
Pro-inflammatory    
Complement 
activation 
Classical pathway 
 
Full length, 
bacterial 
 
Human serum (Peake, Shen et al.) 
(+) TNF   gAd, bacterial 
 
Macrophages derived from 
THP-1 monocytic cell line 
(Tsatsanis, 
Zacharioudaki et al. 
2005) 
 
(+) IL-6 gAd, bacterial 
 
HMW, mouse 
 
Full length, 
mammalian 
 
Full length, 
bacterial 
Macrophages derived from 
THP-1 monocytic cell line 
Primary monocytes 
 
Primary monocytes 
 
 
Primary synovial 
fibroblasts 
(Neumeier, Weigert 
et al. 2006) 
(Weigert, Neumeier 
et al. 2008) 
(Ehling, Schaffler et 
al. 2006) 
(Weigert, Neumeier 
et al. 2008) 
(+) IL-8 Full length, 
mammalian 
Primary monocytes (Haugen, Drevon 
2007) 
(+) NF- kB 
   
Full length, 
mammalian 
Monocytic cells lines THP-
1 and U937 
{{397 Haugen,Fred 
2007}} 
 
Notwithstanding, I believe adiponectin to be chiefly anti-inflammatory. The 
heterogeneity from the in vitro studies (Table 1.3) can be explained by differences in 
experimental conditions. How the cells were prepared is an important variable. 
Adiponectin added to macrophages differentiated in its absence induced IL-6 and 
TNF  in a dose dependent manner (Tsao, Tomas et al. 2003, Haugen, Drevon 2007, 
Neumeier, Weigert et al. 2006, Palmer, Hampartzoumian et al. 2008). However, after 
24 hours of adiponectin exposure, pro-inflammatory cytokine output following LPS or 
further adiponectin dosage did not increase further, compared to placebo control. Also, 
pre-treatment of macrophages with LPS can affect the readout. Adiponectin treated 
macrophages nascent to LPS had reduced IL-8 expression and phagocytic ability 
(Saijo, Nagata et al. 2005), but the converse was seen when the macrophages were 
exposed to LPS before adiponectin treatment. 
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The source used may also be relevant, as there appears to be functional differences 
between multimers. The most direct demonstration of this comes from the paper by 
Neumeier et al (Neumeier, Weigert et al. 2006), where the actions of LMW and HMW 
adipnectin were compared in the same culture system with primary monocytes. The 
authors had used the same cDNA sequence and vector, but two different host cell lines  
to express recombinant adiponectin. But adiponectin from the insect cell source were 
of LMW multimers, as non-mammalians cells are not capable of the post-translational 
modifications required for HMW adiponectin formation (Richards, Stephens et al. 
2006). HMW adiponectin, but not LMW species, induced IL-6 release from primary 
monocytes and the THP-1 cell line. In contrast LMW adiponectin selectively 
suppressed LPS-induced IL-6 production, and enhanced IL-10 release. In support of 
this, there were differences in intracellular signalling between the multimers. LMW 
adiponectin reduced, whereas HMW adiponectin increased nuclear NF- B protein 
levels. This difference has been confirmed independently by another group, using 
monocytic cell lines and NF- B activity was measured by a luciferase reporter system 
(Haugen, Drevon 2007). 
 
Further confounding may be attributed to LPS contamination in commercially available 
adiponectin (Aprahamian, Bonegio et al. 2009). Adiponectin was used in doses of at 
least 10ug ml-1 in cell culture systems. The minimum amount of LPS contamination was 
reported to be 1-5%, and hence this translated to a potential exposure of 0.1-0.5ug ml-1 
of LPS to macrophages rich in Toll-like receptor 4 expression. Only one study 
(Tsatsanis, Zacharioudaki et al. 2005) reporting had attempted to counteract this 
potential source of confounder by the use of polymyxin B, a LPS antagonist .  
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On the other hand, evidence from in vivo studies is overwhelmingly supportive of the 
anti-inflammatory role for adiponectin. Using gene silencing and then induced gene 
upregulation, adiponectin expression was shown to ameliorate pathology in a disease 
model of lupoid glomerulonephritis (Aprahamian, Bonegio et al. 2009). Similarly, 
overexpression of adiponectin by gene transfer can attenuate autoimmune arthritis in 
another in vivo model (Ebina, Oshima et al. 2009). Also, the increase in extra-adipose 
adiponectin expression following inflammatory stress is potentially protective (Jortay, 
Senou et al. 2010). LPS injection into skeletal muscle of the adiponectin knockout mice 
caused exaggerated inflammatory response, with marked NF B and TNF  
expression. This effect was attenuated with electrotransfer of the ADIPOQ gene to the 
study muscle. It is plausible therefore that increased levels of adiponectin seen in 
autoimmune diseases reflect an attempt by the body to mitigate the inflammatory 
response. The mechanism of this may involve NO, FoxO1 and PPAR   (Section 1.7.4). 
The increased adiponectin may also be a consequence of more advanced disease. In 
T1D, glycaemia, residual  cell function, microangiopathy and renal reserve are 
determinants of serum adiponectin levels (Maahs, Ogden et al. 2007). The 
mechanisms of how these factors drive up adiponectin levels and in turn, how the 
raised adiponectin influence disease course, are not clear. 
 
1.8 Adiponectin in pre-T1D and autoimmunity 
 
Evidence supporting a pathogenic role for adiponectin in T1D can be found in the 
Belgian Diabetes Registry (Truyen, De Grijse et al. 2007). Relatives of patients with 
T1D were followed up for a median duration of 81 months. The overall T1D risk for the 
antibody positive cohort is low at 18%, compared to the other studies of pre-T1D and 
insulin resistance. But in those subjects who developed T1D, serum adiponectin levels 
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for each subject fell significantly in the two years prior to onset, compared to matched 
controls whose levels at -1 and -2 years were similar to the last sample drawn at the 
close of follow-up (fig 1.9). Possibly because of the wide confidence interval (5-25 ug), 
there were no significant differences in adiponectin levels between the groups at each 
timepoint. In keeping with epidemiological studies, adiponectin had a significant inverse 
correlation with adiposity, and in a smaller group, with HOMA-IR. Overall, this study 
suggests in the later stages of pre-T1D, falling adiponectin levels in an individual is a 
risk factor for T1D onset.  
  
The immunomodulatory potential of adiponectin has not been tested in the NOD 
mouse, although there are encouraging results from another murine model of 
autoimmunity. The lpr mouse has a single gene defect in Fas, resulting in impaired 
clearance of cell debris. This gives rise to development of multiple autoantibodies and 
lymphoproliferation, and leads to a clinical phenotype similar to human systemic lupus 
erythematosis. With the additional knockout of ADIPOQ, these mice displayed more 
pronounced autoimmunity, along with marked joint inflammation and glomerulonephritis 
(Takemura, Ouchi et al. 2007). These features were ameliorated upon genetic 
overexpression of ADIPOQ. The authors attributed this to the facilitation of apoptotic 
body clearance by adiponectin. 
 
 49  
 
Figure 1.9. Adiponectin levels in pre-type 1 diabetes. (a) Serum levels in subjects (n=28) 
who developed diabetes (overall p<0.001; *p=0.029 vs onset –1 year; ‡p=0.028 and †p<0.001 
vs clinical onset), (b) age and sex-matched subjects (n=28) at high risk (autoantibody positive) 
but remained non-diabetic in the follow-up period (overall p=0.113). Each box shows the median 
(solid black line) and IQR (box length) of adiponectin levels at a given time-point; the whiskers 
indicate extreme values within 1.5 box lengths from the upper and lower edge of the box. 
Adiponectin levels at onset of disease (a) were not significantly different from the last sampling 
drawn in high risk subjects who remained non-diabetic (b).Adapted from (Truyen, De Grijse et 
al. 2007) electronic supplementary material, with permission from Springer (license 
2482151204744) 
 
1.9  Summary 
 
T1D is a costly disease with complex management issues. The destruction of the 
insulin producing  cell is the culmination of multiple breaches in immune tolerance. 
Immunogenetic factors contribute to risk. From prospective studies, IR is an additional 
predictor for progression in the most susceptible pre-T1D subjects. Obesity is the 
commonest cause of IR and its increased prevalence may explain the current rise in 
T1D incidence worldwide. The biological basis for this contention may lie with adipose 
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tissue, and in particular the adipokines it secretes. Adiponectin is an anti-inflammatory 
and insulin-sensitising adipokine whose functions are mediated by the specific 
receptors AdipoR1 and AdipoR2. Its levels appear to be reduced before development 
of T1D. This may be of significance in the maintenance of tolerance, as adiponectin 
appears to have the capability to downregulate autoimmunity in other disease models.   
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2. HYPOTHESIS AND AIMS 
 
Given that adiponectin has anti-inflammatory and insulin-sensitising actions, we 
hypothesise that changes in the adiponectin signalling explains the association 
between insulin resistance and progression to T1D. If proven, there are clear benefits 
in augmenting adiponectin action in delaying onset of this disease.   
 
Our aims are: 
 
1) To characterise adiponectin and its receptor expression on PBMC.  
2) To investigate effects of insulin resistance and T1D on adiponectin signalling to 
PBMC.  
3) To investigate effects of modifying insulin resistance through exercise on adiponecin 
receptor expression.  
4) To demonstrate effects of adiponectin on antigen-driven T cell responses 
 
This experimental approach was chosen to explicitly test predictions based on our 
hypothesis. The adiponectin receptor should be expressed on immune cells for 
adiponectin to have immunomodulatory functions. Secondly, the adiponectin signalling 
to immune cells should respond to changes in insulin sensitivity, so to account for the 
accelerated disease onset with increasing insulin resistance. Crucially, adiponectin 
should have the capacity to direct antigen-driven T cell responses, as they are central 
to the immunopathogenesis of T1D.   
 52  
3.MATERIALS AND METHODS  
 
 
3.1 Subjects 
3.1.1 Cross sectional clinical study 
 
Male Caucasian subjects with T1D and T2D were recruited from diabetic outpatient 
clinics following informed consent. Patients with T1D had been diagnosed on clinical 
grounds that indicate -cell destruction, as per 1999 World Health Organisation 
classification. These include presentation with osmotic symptoms, weight loss, ketosis 
and requirement for insulin within 3 months of diagnosis, or by the presence of the 
above with positive islet antibodies. Diabetic subjects were assumed to have T2D if 
they did not have the above features, together with the absence of a family history of 
maturity onset diabetes of the young (MODY), or a diagnosis of diabetes before the 
age of 30. All T2D subjects were insulin treated. Islet autoantibodies were not 
measured in this cohort for the definitive exclusion of LADA (Fourlanos, Dotta et al. 
2005). Nevertheless, we believed this was unlikely, given the absence of associated 
clinical features in our study patients. They were diagnosed at an older age (>40 
years), and did not have autoimmune diseases in their past medical history (Fourlanos, 
Dotta et al. 2005). Furthermore, insulin treatment was not initiated within six years of 
diagnosis (Turner, Stratton et al. 1997).    
 
Exclusion criteria were:  
1) acute illness and infection  
2) poorly controlled diabetes (HbA1C >10)  
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3) presence of cardiac (NYHA grade 3 or above), liver (raised liver enzymes > 3 
times of upper normal limit) or renal disease (estimated GFR from MDRD 
formula < 30 ml/min (Levey, Bosch et al. 1999))  
4) use of thiazolidinediones or fibrates, whose PPAR /  agonistic activity is known 
to increase AdipoR1 & AdipoR2 expression on monocytes (Chinetti, Zawadski 
et al. 2004) 
5) use of exenatide or gliptins, as their effect on AdipoR1 and AdipoR2 expression 
on tissues is unknown.      
 
Body mass index (BMI), blood pressure and point of care testing HbA1C were taken 
from clinic records on the day of recruitment. Waist circumference was taken as the 
transverse diameter at the level of the midpoint between costal cartiliage and iliac 
crest, after maximal exhalation. The hip circumference is the maximal transverse 
diameter across the buttocks. These measurements were done either by myself, or Dr 
Ed Goble, academic FY1 medical house officer. For T1D subjects, the estimated 
glucose disposal rate (eGDR), in mg kg-1 min-1, was calculated using the formula: 
24.31- (12.22  WHR) – (3.29  HT) – (0.57  HbA1C) (Williams, Erbey et al. 2000). HT 
is a binary variable and refers to the hypertension status (140/90 mm Hg or on anti-
hypertensives). eGDR was derived from linear regression using components of the 
metabolic syndrome, with the glucose disposal rate from the last 30 minutes of the 
euglycaemic clamp, as the dependent variable. It remains the only clinical estimate of 
IR to be validated against the gold standard of the euglycaemic clamp in T1D, and is 
an accepted surrogate measure in epidemiological studies (Chillaron, Goday et al. 
2009, Kilpatrick, Rigby et al. 2007, Pambianco, Costacou et al. 2007, Orchard, Olson et 
al. 2003, Olson, Erbey et al. 2002). However, limitations of eGDR include the relatively 
 54  
small validation set (n=24) used in the original study from which the model was derived 
(Williams, Erbey et al. 2000), and the lack of external replication.  
 
Healthy volunteers were age and BMI matched to the T1D cohort. Their normal 
glucose tolerance was confirmed by random capillary glucose values < 6.0 mmol l-1.  
Full ethical approval was obtained for this study (University Hospitals Birmingham NHS 
Foundation Trust research ethics committee, reference number 06/Q2703/47).   
 
3.1.2   Lifestyle Intervention studies  
3.1.2.1 Early ACTID –in collaboration with University of Bristol 
 
Sixty-six consecutive participants enrolled in the Early ACTID trial 
(www.bristol.ac.uk/earlyactid) were studied. Subjects recruited into Early ACTID had 
been diagnosed with T2D within 6 months of entry. They were subsequently 
randomised to lifestyle interventions consisting of diet and exercise advice through 
monthly appointments with diabetic specialist nurses and dieticians, or to standard 
care. Venous blood samples in EDTA, taken at entry and at 6 months were stored at -
80°C. Samples were transported on dry ice to the laboratories of the University of 
Birmingham, and RNA extracted for study. The recovery of RNA in frozen blood stored 
in EDTA has been previously described, although lower yields were to be expected 
because of degradation during storage (Theophilus 1998, Rainen, Oelmueller et al. 
2002). We verified the quality the RNA using the Nanodrop spectrophotometer (Section 
3.9) before rt-qPCR. In addition, we analysed the correlation between the date of 
sampling and gene expression values as a means of uncovering the potential 
confounding of frozen storage (fig 6.3). All samples were fully analysed, by intention-to-
treat, before unblinding of trial data. We also examined nine subjects in the exercise 
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arm of the trial who had latent autoimmune diabetes of adulthood (LADA), a subtype of 
diabetes characterised by insidious progression to insulin dependency and the 
presence of antibodies to GAD65 at levels >14 WHO IU/ml (Tuomi, Groop et al. 1993). 
The DASP-validated radioimmunoassay for GAD65 was performed by Mr AJK Williams 
at the Medical School Unit, Southmead Hospitial, Bristol. Clinical parameters including 
estimated VO2 max based on six-minute walk, and measurements of fasting insulin, 
glucose values, and HbA1C were kindly provided by Dr R Andrews, Principal 
Investigator of the Early ACTID trial, University of Bristol. Basal insulin resistance was 
estimated by HOMA-IR modeling (Wallace, Levy et al. 2004). 
 
3.1.2.2  Exercise intensity study – in collaboration with University of Bath 
 
Study participants were 45-64 years old, non-smokers, had a BMI of 25-35 kg m-2, and 
not on medication. Female subjects were all post-menopausal. Prior to the study, they 
performed no regular structured exercise, defined as 30 minutes of activity for more 
than 5 days a week. All subjects followed a hypocaloric diet (5000 kCal/week) and had 
five supervised treadmill sessions per week for three weeks. The two arms were 
differentiated by exercise intensity, whilst the amount of energy expended per session 
(600kCa) was controlled. In the moderate intensity group (MOD), subjects were asked 
to perform at 50% VO2 max, estimated based on target heart rate. In the vigorous 
intensity arm (VIG), prescribed exercise was executed at 70% VO2 max. Expressed in 
terms of time for exercise completion, subjects in the MOD cohort would stop after 75 
minutes versus 45 minutes in the VIG group. Subjects were allocated to one of the two 
groups using a sealed envelope. The envelopes were numbered with the sequence 
generated and known only by a third party. 
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The treadmill studies were supervised by Miss N Dixon, at the University of Bath. 
 
Venous peripheral blood samples were collected with full informed consent, in the 
fasting state, on the morning of day 1 (start) and day 22 (completion). They were 
posted for over-night delivery to the laboratories of the University of Birmingham. The 
samples were processed on the day of arrival – no more than 24 hours after 
venesection.  Thus, possible effects of diurnal variation, fed/fast state and transit on 
PBMC counts and distribution, as well as adiponectin receptor expression were 
controlled.  
 
This study was conducted in collaboration with Dr D Thompson, Health and Science 
School for Health, University of Bath. 
 
3.1.2.3 Exercise and overfeeding study – in collaboration with University of Bath 
 
Lean (BMI < 25) male recruits of age 21-37 years were randomised to 1 of 2 arms. In 
the control arm (SED), subjects were asked to remain sedentary and increase caloric 
intake by 50%. In the interventional group (EXE), subjects consumed the equivalent 
hypercaloric diet in addition to supervised running sessions at 70% VO2 max for 45 
minutes everyday for 1 week. Again, randomisation was done using sealed envelopes 
and venous blood drawn in the fasting state on the morning of day 1 and day 8 of the 
study. The running sessions were supervised by Mr JP Wahlin, at the University of 
Bath. 
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In both studies, anthropometric data and laboratory values regarding serum 
adiponectin, fasting insulin and glucose were kindly provided by Miss N Dixon and Mr 
JP Wahlin, research fellows to Dr D Thompson.   
 
3.2 Materials 
3.2.1 Culture reagents, antigens and mitogens 
 
Human recombinant adiponectin (Cat #: ALX-522-063-C050) was purchased from 
Alexis Biochemicals (Exeter, UK). It is produced from the human embryonic kidney 293 
cell line. The manufacturer reports endotoxin content of < 0.1EU/ug of the purified 
protein by the LAL test. In addition the product data sheet states that the reconstituted 
preparation contains multimeric adiponectin. It mimics activation of AMP activated 
protein kinase in skeletal muscle (Suzuki, Okamoto et al. 2007) and stimulates islet 
insulin secretion (Okamoto, Ohara-Imaizumi et al. 2008).  
 
Cellgro SCGM (product no: 2001) and Cellgro DC (product no: 2005) were obtained 
from Cellgenix (Freiburg, Germany), who discloses plasma derived human albumin, 
recombinant human insulin and transferrin as the only protein content in the media. 
They confirm specifically the absence of adiponectin in the media. GM-CSF (Cat # 300-
03) and IL-4 (Cat # 200-04) were from Peprotech (Hamburg, Germany). Tetanus toxoid 
(Cat # 582231) was purchased from Calbiochem (San Diego, USA).  
 
PHA (Cat # L8902), LPS (Cat # L2654) and PWM (Cat # L8777) were from Sigma 
(Dorset, UK). Dynabeads CD3/CD28 for T cell activation (Cat # 111-31D) were from 
Invitrogen (Paisley, UK). The stimulatory monoclonal OKT3 antibody was a kind gift 
from Dr David Sansom, University of Birmingham. 
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3.2.2 Antibodies 
 
The details of primary anti-adiponectin, AdipoR1 and AdipoR2 and their secondary 
antibodies are presented in Table 3.1. Antibodies used in flow cytometry are listed in 
3.2. Blocking goat and rabbit sera were from Sigma, and Fc receptor blocker 
purchased from Miltenyi (Church Lane Bisley, UK).  
 
Antibody Source Supplier Cat # Use 
Anti-human adiponectin 
IgG 
Mouse 
monoclonal 19F1 
Abcam ab22554 WB 
HRP-conjugated anti-
mouse IgG 
Rabbit polyclonal Dako P 0161 WB 
Anti-human adiponectin 
IgG 
Rabbit polyclonal Abcam ab18839 IP 
Anti-AdipoR1 IgG Rabbit polyclonal Phoenix Peptides G-001-044 FACS, 
sorting 
Anti-AdipoR2 IgG Rabbit polyclonal Phoenix Peptides G-001-023 FACS, 
sorting 
AdipoR1 immunising 
peptide (357-375) 
Chemical 
synthesis 
Phoenix Peptides 001-044 Blocking 
AdipoR2 immunising 
peptide (374-386) 
Chemical 
synthesis 
Phoenix Peptides 001-023 Blocking 
Anti-rabbit IgG (H + L), 
conjugated to Alexa Fluor 
488 
Goat polyclonal Invitrogen A11034 FACS 
Table 3.1 Anti-Adiponectin and anti-AdipoR1/AdipoR2 antibodies.  
WB – Western blotting; IP – immunoprecipitation; FACS- flow cytometry 
Abcam (Cambridge, UK); Phoenix Peptides (Karlsruhe, Germany); Dako (Ely, UK); Invitrogen (Paisley, UK) 
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Antigen – 
fluorochrome 
conjugate 
   Clone Isotype Supplier Cat.No. Optimised 
volume /10
6
 
cells (ul) 
CD1a-PE HI149 IgG1 eBiosciences 12-0019 5 
CD3-APC UCHT1 IgG1 eBiosciences 17-0038 2.5 
CD4-FITC OKT-4 IgG2b eBiosciences 11-0048 4 
CD4-PE RPA-T4 IgG1 BD Pharmingen 555347 3 
CD4-APC OKT-4 IgG2b eBiosciences 17-0048 4 
CD4-PerCP SK3 IgG1 BD Pharmingen 345770 4 
CD11c-PE B-ly6 IgG1 BD Pharmingen 555392 5 
CD11c-APC B-ly6 IgG1 BD Pharmingen 559877 8 
CD14-PE 61D3 IgG1 eBiosciences 12-0149 2.5 
CD14-APC 61D3 IgG1 eBiosciences 17-0149 2.5 
CD19-PE HIB19 IgG1 BD Pharmingen 555413 5 
CD25-PE 4E3 IgG2b Miltenyi 130-091-
024 
5 
CD25-APC M-A251 IgG1 BD Pharmingen 555434 5 
CD56-PE B159 IgG1 BD Pharmingen 555516 5 
CD80-FitC L307.4 IgG1 BD Pharmingen 557226 3 
CD86-PE FUN-1 IgG1 BD Pharmingen 555657 3 
CD86-PE/ 
CD209-PERCP-
Cy5.5/CD83-APC 
FUN-1/ 
DCN46/ 
HB15e 
IgG1/IgG
2b 
BD Pharmingen 334098 6 
HLA-DR FitC L243 IgG2a BD Pharmingen 555811 3 
FoxP3-APC 
 
3G3 IgG1 Miltenyi 130-093-
013 
20 
IFN -PE 26723.11 IgG2b BD Biosciences 554707 3 
IL10-APC JES3-
19F1 
IgG2a BD Pharmingen 340452 5 
Isotype 
 
Mouse IgG1-FITC MOPC-
21 
IgG1 BD Pharmingen 555748 3 
Mouse IgG1-PE  IgG1 eBiosciences 12-4714 2 
Mouse IgG1-APC  IgG1 eBiosciences 17-4714 3 
Mouse IgG2a-PE  IgG2a eBiosciences 12-4724 3 
Mouse IgG2b-PE 27-35 IgG2b BD Pharmingen 555743 3 
Table 3.2: Antibodies used in flow cytometry. 
3.3 Buffers, gels, and media 
 
All chemicals were obtained from Sigma unless otherwise stated. The ingredients of 
buffers and gels used in the experiments are listed in alphabetical order. All buffers and 
media were stored at 4 C. 
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Agarose gel 2%: 1g of agarose (Bioline) was dissolved in 50ml of heated Bionic buffer 
1 . Ethidium bromide 5ul was then added to the cooled solution in a fume cupboard.  
 
Complete culture media: RPMI supplemented with 10% foetal calf serum, 2mM 
glutamine, penicillin 100 units/ml and streptomycin 100ug/ml.  
 
HNET lysis buffer: HEPES 25mM, Sodium Chloride 150mM, EDTA 5mM, Triton X 1% 
pH 8.0, with ice cold protease inhibitor cocktail 1  (Sigma, Cat No: P8340) added 
immediately before use. 
 
MACS buffer: PBS, 0.5% BSA and 2mM EDTA 
 
PBS Tween (0.1%): 5 PBS tablets and 1ml of Tween 20% were mixed with 1L of 
deionised water using a magnetic stirrer 
 
Reagent A (2L): under magnetic stirrer, 275g sucrose, 2.5ml 1.0M Tris HCl pH8.0, 
2.55ml 4.9M MgCl, 25ml Triton X added to 2L distilled water.  
 
RIPA wash buffer (50ml): Sodium deoxycholate 0.25g, NP40 0.5ml, SDS 10% 0.5ml, 
Sodium chloride 5M 1.5ml, Tris HCl 1M pH8.0 2.5ml, deionised water 45ml.  
 
Serum free culture media: Cellgro SCGM supplemented with 2mM glutamine, penicillin 
100 units/ml and streptomycin 100ug/ml.  
 
SDS-PAGE resolving gel 12%: Protogel (30:0.8) 2.4ml, Tris Hcl 1.5M pH 8.8, 
Deionised water 2.0ml, SDS 10% 60ul, APS 10% 21ul, TEMED 9ul  
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Stacking gel 6%: Protogel (30:0.8) 0.4ml, Tris HCl 0.5M pH 6.8 0.75ml, deionised water 
1.85ml, SDS 10% 30ul, APS 10% 15ul. 
 
3.4 Extraction of peripheral blood mononuclear cells (PBMC) 
 
Venous blood collected in EDTA was diluted 1:1 with RPMI at room temperature. Up to 
25ml of the diluted blood was layered on 15ml Lympholyte-H (Cederlane, Burlington, 
NC, USA, Cat # CL-5016) at room temperature. After centrifugation at 800G for 25 
minutes (brake off) PBMC were removed from the interface using pastettes and 
transferred into a new 50ml Falcon tube. The cell pellet was washed twice in RPMI, 
and then centrifuged at 800G for 10 minutes. A similar procedure was used for 
processing buffy coats but this was diluted 1:2 with RPMI, and the PBMC were washed 
in at least four 600G cycles to remove platelets. The cell pellets were then suspended 
in 10ml of RPMI and counted by light microscopy. 
 
Cryopreserved blood samples from the Early ACTID trial were thawed on ice, 
transferred into a 50ml falcon tube, into which Reagent A (recipe in 3.3) was added to 
achieve a total volume of 20ml. The tube was shaken manually for 15 seconds and 
then on an orbital shaker for 5 minutes at maximum speed. The pellet containing 
leucocytes, acquired after a 15 minute 1500g centrifuge, was washed two more times 
with 10ml of reagent A before RNA extraction. 
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3.5 Magnetic cell sorting       
 
PBMC were passed over a 30um nylon mesh to remove clumps. All washing steps 
were done in MACS buffer followed by centrifugation at 600G for 10 minutes.  
 
PBMC subsets for AdipoR1 and AdipoR2 mRNA expression were obtained by positive 
selection. 107 PBMC were incubated in 100ul of MACS buffer with 10ul PE-conjugated 
anti-CD3, CD14, CD19 or CD56 antibodies (BD Biosciences) for 15 minutes in the dark 
at 4°C. After washing, the cells were resuspended in 80ul per 107 cells and incubated 
for 15 minutes at 4°C with 20ul of anti-PE microbeads (Cat # 120-000-294, Miltenyi), 
before a further wash and re-suspension in 500ul of MACS buffer. The cells were then 
passed over a magnetic field in a MS column (Miltenyi Cat # 130-042-201).  
 
For isolation of cells expressing AdipoR1 and AdipoR2 surface receptors,107 PBMC in 
100ul MACS buffer were incubated with 10ug (at 1ug/ul) of receptor antibody for 30 
minutes at 4°C in the dark. After washing, 20ul of anti-rabbit antibody microbeads 
(Miltenyi, Cat # 120-000-292) were added to cells in 80ul of MACS buffer and 
incubated for a further 15 minutes at 4°C. After a 10 minute 400G wash in MACS 
buffer, the beads and cells mixture in 500ul of MACS buffer, was passed through the 
MS column once. The pre-passage mixture was labelled as “pre-sort”. The flow through 
was labelled as the “receptor negative” fraction. The fraction retained in the column 
was subsequently flushed out by a sterile plunger and labelled as “receptor positive”. 
We did not find that a second passage of the “receptor positive” fraction through the 
MS column, as recommended by the manufacturer, improved purity when AdipoR 
staining was checked on flow cytometry. CD14 microbeads (Miltenyi, Cat # 120-000-
305) were used to extract monocytes for DC generation. CD4+CD25- effector cells 
were obtained from whole PBMC by initial negative selection of CD4+ cells (Human 
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CD4+ T cell enrichment kit, Cat # 19052, Stemcell Technologies SARL, Grenoble, 
France). This was followed by CD25+ depletion using anti-CD25 microbeads (Miltenyi 
Cat # 130-092-983) and LD columns (Miltenyi Cat # 130-042-901). Sort purity was 
assessed by flow cytometry. 
   
3.6 Flow cytometry 
 
Between 5  105 to 106 cells were suspended in 100ul PBS in a 5ml polypropylene 
tube. They were incubated with antibodies of choice (see Table 3.2) for 30 minutes on 
ice and in the dark, then washed in 4ml of PBS and pelleted at 400G for 6 mins. The 
cells were re-suspended in a final volume of at least 400ul PBS. Isotype control 
antibodies matched in species, isotype, flurochrome and protein quantity to the staining 
antibody were used for negative control. Gain adjustments and compensation settings 
of the flow cytometer were made using unstained cells, cells stained in single colour 
CD4 FitC, PE, PerCP and APC.  With the exception of cells stained for intracellular 
antigens, PI at 3 ul (0.5ug/ml working solution) was added after the final wash to 
exclude dead cells. The manufactuer‟s protocol for the FoxP3 staining buffer kit (Cat 
No: 130-093-042, Miltenyi) was followed for intracellular FoxP3 labelling.  
 
The FACSCalibur 4-colour flow cytometer was used, with Cellquest Pro version 4.0 
(BD Biosciences) as the acquisition software. On average, 20000 events were 
recorded in the gate for viable cells, defined by forward/side scatter and negative PI 
staining. Analysis was performed using Flowjo version 8.8.6 (Treestar, Ashland, OR, 
USA). 
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3.6.1 AdipoR1 and AdipoR2 staining 
 
We prepared 7 tubes for each clinical sample as follows.  
 
Tube Primary antibodies Phenotyping antibodies 
1 Pre-immune Rabbit serum APC mouse IgG1 isotype 
2 AdipoR1 CD11c APC, CD14 PE 
3 AdipoR1 CD3 APC, CD19PE 
4 AdipoR1 CD4 APC, CD56 PE 
5 AdipoR2 CD11c APC, CD14 PE 
6 AdipoR2 CD3 APC, CD19PE 
7 AdipoR2 CD4 APC, CD56 PE 
Table 3.3 Tubes set for quantification of AdipoR1 & AdipoR2 expression by flow cytometry 
 
Tube 1 served as the internal negative control for each subject. It was the standard for 
background fluorescence from which net MFI values for AdipoR1 and AdipoR2 staining 
were calculated. For the exercise and cross-sectional clinical studies, we ensured that 
the batches of adiponectin receptor antibodies shared the same lot number (Lot no: 
02301 & 04005 respectively). As a means of internally controlling for variations in 
experiments done on different days in the cross-sectional study, at least two each of 
healthy controls and diabetic subjects were analysed on the same run. This however, 
was not possible for the exercise studies done in collaboration with the University of 
Bath, where samples arrived singularly. Cells (106 in 100ul PBS) were pre-incubated 
with 3ul of FcR blocker for 10 minutes on ice. They were then exposed to 
AdipoR1/AdipoR2 antibodies at 1ug in 100ul of PBS for 30 minutes on ice and in the 
dark. After washing in PBS the cells were blocked with 5ul of goat serum for 15 
minutes on ice and then incubated with secondary goat anti-rabbit antibody conjugated 
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to AF488 (100ul of a 1:250 dilution) for a further 30 minutes. The negative control (tube 
1) was treated with isotype APC-conjugated mouse IgG1 antibodies (control for CD11c 
APC), goat and rabbit sera (5ul each), followed by secondary antibody.  
    
Gates set for all viable PBMC, lymphocytes, monocytes (by scatter and CD14 labelling) 
and positive AdipoR1/AdipoR2 cells were set using the negative control tube (tube 1). 
They were then applied to the tubes 2-7 from the same donor. The net percentage of 
positive cells and the net MFI (geometric mean fluorescence of all cells in the FL-1 
channel) for AdipoR1 (tubes 2-4) and AdipoR2 (tubes 5-7) was obtained by deducting 
the background staining of tube 1 (negative control).  
 
3.7 Cell culture 
 
All cultures were performed under aseptic conditions with sterile filtering of all media. 
The incubation conditions were controlled at 37 C and 5% humidified CO2. In studies of 
AdipoR1 and AdipoR2 expression on PBMC, unsorted PBMC were grown in RPMI-
1640 complete media on 24-well plates for 72 hours, at 106 cells ml-1. Culture grade 
human insulin (Cat # I9278) and dextrose 10% solutions (Cat # G8644) were from 
Sigma and added at the beginning of culture. 
 
For antigen and mitogen stimulation, 2  105 CFSE-labelled whole PBMC in 100ul of 
complete Cellgro SCGM media were cultured on 96-well round bottom plates for 5-8 
days. Tetanus toxoid at 3ug ml-1 or PHA at 5ug ml-1 was added at the start of culture.  
The cells were fed a further 50ul of complete media on day 4.   
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3.7.1  DC generation 
 
Monocytes were positively selected using CD14+ microbeads from PBMC extracted 
from venous blood of healthy and T1D subjects. They were of 85-93% purity on flow 
cytometry. Two million CD14+ monocytes were suspended in 2ml of Cellgro DC and 
seeded onto 6-well plates. They were stimulated with GM-CSF and IL-4 (both at 1ug 
ml-1). The cells were re-fed GM-CSF and IL-4 (final concentration 1ug ml-1) in complete 
media on day 3.  
 
The cells were harvested on day 6 by cooling the culture plate on ice and using a cell 
scapper. After confirming surface phenotype on flow cytometry, the immature DCs 
were co-cultured, at ratio of 1:10, with 2  105 CFSE-labelled CD4+ CD25- responder 
cells in a total volume of 200ul of complete Cellgro SCGM on 96-well round bottomed 
plates for up to 7 days. Responder cells were retrieved on the day of the co-culture. 
Autogeneic T cells were used when tetanus toxoid (3 ug ml-1) was the stimulus, and 
allogeneic T cells in co-cultures with OKT3 (0.5 ug ml-1). Both stimuli were diluted in the 
suspension of the effector cells and then immediately added to the DC. Negative 
controls of responder cells without DC and stimuli were set up in parallel. To minimise 
variation, samples from at least three donors were processed in each run.  
 
To attain mature DC, LPS at 1ug ml-1 was added to immature DC on day 6 and 
harvested after 24 hours. 
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3.8  Measurement of cell proliferation by CFSE 
 
CFSE (carboxyfluorescein succinimidyl ester) dilution is a technique for measuring 
lymphocyte proliferation in vitro. The non-fluorescent and freely permeable precursor 
CFDA-SE (carboxyfluorescein diacetate succinimidyl ester) is cleaved by intracellular 
esterases to form the active moiety. This is then retained within cells and stablised by 
covalent linkage with protein thiols. Upon cell division, the dye is shared equally 
between the two daughter cells, such that successive generations of proliferating cells 
can be tracked by the exponential decrease in fluorescence. Advantages over the 
traditional radioactive labeling methodology are the increased sensitivity and capability 
of immuno-phenotyping responding cells.   
 
Recognised parameters for quantifying proliferation are the division index (DI), and the 
stimulation index (SI) (Fulcher, Wong 1999, Mannering, Morris et al. 2003). When the 
majority of cells proliferate with stimulation, DI is believed to be the more representative 
measure and conceptually this is the average number of cell divisions undergone by 
the responding cell. It is calculated from curve fitting of data assuming CFSE dilutional 
kinetics. For rare proliferating events, such as the response of unsorted PBMC to 
antigen stimulation, SI is more sensitive. SI is calculated by the formula: 
 
SI = % CFSE low antigen / % CFSE low no antigen 
 
CFSE low cells were defined as viable cells (scatter and PI negative) that have lower 
fluorescence in relation to the parent cells. This was determined from wells in the plate 
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containing unstimulated CFSE labelled cells, on the day of reading. The gating for this 
population was drawn based on the unstimulated control (figs 7.2 & 7.4).   
 
Significant proliferation above background is taken when SI is  2. 
 
Method 
 
Cells to be labeled are washed in PBS to remove traces of protein and resuspended at 
2  107 cells ml -1 of PBS.  CFDA-SE (cat # 1157, Invitrogen) was diluted with DMSO to 
give a stock solution at 10mM and stored at -20 C. The working solution was prepared 
by dissolving a 2ul aliquot in 8ml of PBS. An equal volume of the working solution was 
added to the cell suspension and mixed by pulse vortex. After incubation for 10 
minutes at room temperature, under agitation and light protection, FCS at half total 
volume was added to quench the reaction. After one minute of standing, the cells were 
washed for three times in complete media, counted and resuspended at 2  106 cells 
ml-1 for stimulation. I found the final concentration of CFDA-SE at 1.25 uM adequately 
labeled daughter generations above autofluorescence without inhibiting blastogenesis.  
   
3.9  Reverse transcriptional polymerase chain reaction (rt-PCR) 
 
Total RNA was extracted from a maximum of 107 cells using the RNeasy Mini Kit (Cat 
#: 74404, Qiagen, Hilden, Germany) as per manufacturer‟s instructions, using 350ul of 
RLT lysis buffer and the 30ul of nuclease free water for the final elution. Precautions for 
RNAse free conditions were the use of vinyl gloves, nuclease free tips and collection 
tubes, as well as the use of RNaseZap Decontamination solution (Cat # AM 9780, 
Applied Biosystems, Warrington, UK) on the work bench and pipettes. Purity and 
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concentration of the sample was assessed by the Nanodrop spectrophotometer (Model 
ND-1000, Thermo Scientific, Wilmington DL USA). All samples had 260/280 >1.8. 
One microgram of total RNA was reverse transcribed into cDNA by first annealing to 
1.5ul of random primers at 500ug/ul (Cat # C118A, Promega, Southampton, UK) in a 
total volume of 16.5ul, at 95 C for 5 minutes. After cooling to room temperature and 
centrifuging at 8000G for 10s centrifuge, a mastermix was added. This contained 1ul of 
SuperScript II reverse transcriptase (Invitrogen), 1.5ul of RNAout RNAase inhibitor 
(Invitrogen), 6ul of 5  first strand buffer, 3ul of 10mM dNTP and 2ul nuclease free 
water. Using a thermal cycler (Tetrad PTC-225, MJ Research, Waltham, 
Massachusetts, USA), the total mix was incubated at 37 C for 1 hour and the reaction 
terminated by boiling at 95 C for 5 minutes. A reverse transcriptase negative control 
was made using 1ug of RNA diluted to the same total volume of 30ul with nuclease 
free water. It was subjected to the same heating conditions.   
 
NTERA cells, a human cell line with phenotype similar to committed neuronal cells 
(Pleasure, Lee 1993), were used as a negative control for adiponectin rt-PCR 
(Spranger, Verma et al. 2006). These were donated by Dr S Chan, University of 
Birmingham. RNA from differentiated ChubS7 cells, which have characteristics similar 
to primary human adipocytes, was used as positive control (Gathercole, Bujalska et al. 
2007). These cells were a kind gift from Dr J Tomlinson, University of Birmingham. 
Human pancreatic RNA, cloned from autopsy specimen, was purchased from AMS 
Biotechnology (Europe), Abingdon, UK.  
 
For conventional PCR, 2ul of the cDNA sample and their negative control was 
amplified using BioTaq 0.2ul (Promega), 4mM of MgCl2, dNTP (0.4ul of 10mM stock) 
and 0.125 uM of sequence specific, intron-spanning primers in a 20ul reaction. 
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Sequences of the primers are listed in Table 3.4. Optimised PCR conditions are listed 
in Table 3.5. BLAST and GenBank were used to check the primers were gene specific 
and intron spanning.  Standard PCR conditions were 95°C for 5 minutes, followed by 
30-35 cycles at 94°C for 1 minute, annealing for 1 minute and 72°C 1 minute and then 
a termination step of 72°C for 2 minutes. For amplification of the adiponectin gene, the 
conditions were modified to 96°C for 6 minutes, followed by 35 cycles of 94°C, 64 C 
and 72°C at 45s each.  Amplicons were resolved on a 3% agarose gel, stained with 
ethidium bromide.  
 
Real-time quantitative PCR of the samples was performed, in triplicate, on the 
Strategene thermocycler with Taqman 2  Universal PCR Mastermix (Cat #: 58003365-
1, Applied Biosystems) on nuclease free 96-well plates, sealed with optically 
translucent covers. The cycling conditions were 50°C for 2 minutes, then 95°C for 10 
minutes followed by 40 cycles of 95°C for 15s and 60°C for 1 minute. 
 
Relative quantification of adiponectin and AdipoR1/R2 gene expression (Table 3.6), 
was calculated by the comparative Ct method (Livak, Schmittgen 2001). 18S was 
the internal control. The relative efficiencies of amplification in the duplex reaction was 
validated in a standard curve. Samples were repeated if the Ct SD of the triplicate is > 
0.5. Samples with a target gene Ct value of >37 were excluded because it laid outside 
the dynamic range of our calibrator standard curve. Significant genomic DNA 
contamination was assessed by target gene amplification in the rt-ve control. cDNA 
samples were excluded if the Ct of their rt-ve control was <5.5, as this implied >2% of 
the PCR products in log phase originated from a genomic DNA template.  
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Table 3.4: Primers used in conventional PCR 
 Forward (5’-3’) Reverse (5’-3’) Predicted 
bp 
-actin GCTCCGGCATGTGCAA 
 
AGGATCTTCATGAGGTAGT 541  
Adiponectin 
(ADIPOQ) 
AGGGTGAGAAAGGAGATCCA
G 
GGGCATGTTGGGGATAGTAA 194  
Adiponectin 
receptor 1 
(AdipoR1) 
TGCCCTCCTTTCGGGCTTGC GCCTTGACAAAGCCCTCAGCGATAG 526  
Adiponectin 
receptor 2 
(AdipoR2) 
GGAGCCATTCTCTGCCTTTC  ACCAGATGTCACATTTGCCA  467 
 
 
Table 3.5: Conditions for conventional PCR 
Primers Magnesium 
Volume of 50mM stock in 
a 20ul reaction (ul) 
Annealing 
temperature 
°C 
-actin 1.6 58 
Adiponectin 
(ADIPOQ) 
1.4 64 
Adiponectin receptor 
1 (AdipoR1) 
1.8 58 
Adiponectin receptor 
2 (AdipoR2) 
1.8 60 
 
Table 3.6: Taqman probes and primers used in real time qPCR 
 Forward Reverse Probe 
AdipoR1 TTCTTCCTCATGGCT
GTGATGT 
AAGAAGCGCTCAGGAA
TTCG 
TCACTGGAGCTGGCCTT
TATGCTGC 
 
AdipoR2 ATAGGGCAGATAGG
CTGGTTGA 
 
GGATCCGGGCAGCATA
CA 
CTGATGGCCAGCCTCTA
CATCACAGGA 
 
ADIPOQ CTATGATGGCTCCAC
TGGTA 
GAGCATAGCCTTGTCC
TTCT 
CTGTACTACTTTGCCTAC
CACATCACAGTCT 
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3.10  Immunoblotting and immunoprecipitation 
 
Up to 2  107 PBMC were lysed in 500ul ice cold RIPA lysis buffer containing 1  
protease inhibitor cocktail (Sigma, Cat# P2714) for 15 minutes. The mixture was 
subjected to maximum speed centrifuge for 10 minutes at 4°C. Protein content of the 
supernatant was quantified using Bradford reagent (Sigma, Cat# B6916). Briefly, 5ul of 
the supernatant was incubated with 250ul of Bradford reagent for 30 minutes and 
absorbance shift from 460nm to 595nm was measured by photometer. These values 
were referenced against a standard curve constructed from serial dilutions of 1ug ml-1 
of BSA. Twenty micrograms of protein was added to Novex Tris-Glycine sample buffer 
(Invitrogen Cat# LC2676) and Nupage Sample Reducing Agent (Invitrogen Cat# 
NP0009), as per manufacturer‟s instructions. The samples were then heated to 70°C 
for 10 minutes before loading onto wells on the 12% SDS Bis-Tris gel, alongside 
SeeBlue Plus 2 pre-stained standard ladder (7ul, Cat# LC5925, Invitrogen). Human 
serum, precleared with protein A-Sepharose beads, and diluted at 1 in 20 with PBS 
was used as the positive control in immunoblots for adiponectin. The gel was resolved 
with the Xcell Surelock Electrophoresis Cell (Invitrogen) at 160°C and the proteins 
transferred onto nitrocellulose using the iBlot system (Invitrogen), for 7 minutes. The 
membranes were blocked with 5% Marvel in PBS Tween at room temperature for 1 
hour, before incubation overnight with anti-adiponectin antibody (Abcam Cat# 
ab22554), diluted at 1:1000 with blocking solution, at 4°C under agitation. After three 
washes with PBS Tween for 10 minutes on an orbital shaker, the membranes were 
exposed to secondary anti-mouse antibody conjugated to HRP (Dako Cat# P0161) for 
1 hour at RT on a rocker. The secondary antibody was diluted 1:2500 in blocking 
solution. 
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The membranes were washed three times before chemiflurorescent detection with ECL 
Plus and autoradiography with Amersham Hyperfilm ECL (GE Healthcare Cat# 
RN2132 & 28906832, respectively). With ECL Plus, 2ml of solution A was mixed with 
50ul of solution B (40:1). The mix was applied drop-wise to a membrane of 2cm2 and 
left to stand for 3 minutes. To confirm specificity of the bands, immunoblotting was 
performed on a duplicate membrane with a) secondary antibody alone b) primary 
antibody blocked overnight with recombinant adiponectin, at a ratio of 1:4 by mass, 
before application to the transfer membrane.  
 
For immunoprecipitation, rabbit polyclonal antibodies to adiponectin (Abcam, Cat# 
ab18851) were used as the capture antibody, and protein A sepharose beads (GE 
Healthcare Cat# 17-0780-01) were used to isolate the immune complexes. The 
lyophilised beads were prepared by swelling in MilliQ water (0.4g in 8ml) for 30 minutes 
and collected by centrifugation (2000 RPM 7 minutes at 4C). They were then 
equilibrated in successive 12ml of Tris-HCl buffers at concentrations 1M, 0.1M and 
0.05M (all pH 8) for 30 minutes before storage in an equal volume of 0.01M Tris pH 7.5 
to form a 50% slurry.  
 
Lysates were pre-cleared by incubating with pre-immune rabbit serum for 2 hours and 
then adding protein A (50ul 50% slurry to 500ul of lysate). The mixture was left to stand 
for another hour at 4°C. The lysates were quantified by Bradford reagent, and at least 
500ug of total protein was incubated with the capture antibody, at 10ug ml-1, overnight 
at 4 C under gentle agitation. Protein A slurry (50ul 50% slurry to 500ul) was then 
added and the mix was incubated for a further 2 hours on a rotary mixer. The beads 
were then collected by centrifuge (10000g for 30s), washed in RIPA twice and proteins 
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were eluted by addition of 50ul SDS sample buffer 2  and boiling at 95C for 5 minutes. 
The supernatant from a 16000g 5 minute spin was then loaded onto resolving gel. 
 
3.10.1 Covalent coupling of antibody to protein A Sepharose 
 
Fifty micrograms of the IP capture antibody was incubated with 500ul of 50% protein A 
sepharose slurry for 1 hour with gentle mixing at room temperature. The beads were 
washed 3 times with 0.1M sodium borate pH9.0, and collected after a 30 second 
10000g spin. Re-suspended in 1ml of sodium borate, 5.184mg of dimethylpimelimidate 
(Mr 259.2, final concentration 20mM) was added to the mixture and incubated for a 
further 40 minutes at room temperature. The beads were then washed twice with 0.2M 
ethanolamine pH 8.0 and left to stand overnight in this solution at 4 C. For storage at 
4 C, the beads were washed twice with PBS and sodium azide added at 0.02%.   
 
3.10.2 Coomassie staining and in gel digestion 
 
The SDS-polyacrylamide gel containing resolved proteins was rinsed with MilliQ water 
before immersion in 50ml of SimplyBlue Safestain (Cat# LC6060, Invitrogen), a 
Coomassie G250 based stain, for 1 hour. The gel was destained overnight in MilliQ 
water.   
 
Steps for in gel digestion were carried out in a negative pressure hood to avoid keratin 
contamination. The band corresponding to molecular weight of 30-36 kDa was excised 
with a sterile scalpel and cut into smaller pieces. It was then washed twice in 100ul of 
50% acetonitrile in 50mM ammonium bicarbonate for 45 minutes at 37 C. After drying 
the band in a dessicator, the sample was incubated in 50ul of 50mM dithiothreitol, 
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made up in 10% acetonitrile/50mM ammonium bicarbonate at 56 C for 1 hour. After 
spinning, the pellet was then incubated with 50ul of 100mM lodoacetamide (in 10% 
acetonitrile/50mM ammonium bicarbonate) at room temperature in the dark for 30 
minutes. Again the sample was spun and supernatant discarded, followed by 3 washes 
in 10% acetonitrile in 50mM ammonium bicarbonate for 15 minutes under agitation. 
After drying for 1 hour, the sample was rehydrated in 20ul of 12.5ug ml-1 sequence 
grade modified trypsin (Cat# V5111, Promega) in 10% acetonitrile/ 50mM ammonium 
nitrate, for 1 hour at room temperature. Twenty microlitres of 10% acetonitrile/50mM 
ammonium nitrate was added and the mixture was incubated at 37 C overnight.   
 
On the next day the sample was spun. This supernatant was pooled with that obtained 
from two further washes with 30ul 3% formic acid in water, each lasting 1 hour. The 
final sample containing trypsinised peptides, of volume 70-90ul, was submitted for 
mass spectrometry. The resultant spectra was searched against the National Center 
for Biotechnology non-redundant database (released April 2004) using the 
TurboSequest (3.1) search algorithm (ThermoFinnigan).  
 
3.11 Serum adiponectin measurement by ELISA 
 
Serum adiponectin levels were measured using the Quantikine Human Total 
Adiponectin Immunoassay (Cat # DRP300, R & D, Abingdon, UK). Standard curves 
and pre-dilution of serum samples were done according to manufacturer‟s protocol 
(appendix 7). Maximum CV for total adiponectin is reported at 6.9% and detection limit 
is 0.246 ng ml-1. Absorbance was measured at 492nm for 0.1s by the Wallac Victor 4 
plate reader.  
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3.12 Statistics 
  
Statistical analysis and graphical composition were carried out using Excel 2003 
(Microsoft), SPSS 15.0 (SPSS Inc, Chicago, USA) and Graphpad Prism 5.0 for 
Windows (GraphPad Software, San Diego, USA). Continuous variables were 
expressed as mean +/- SD and categorical data as percentage of cases. The 
Kolmogorov–Smirnov test was used to test for normal distribution of raw data. 
Residuals plots were used to see if logarithmic transformation yielded a Gaussian 
population.  
  
Log transformed gene expression values, net percentage positive cells and 
proliferation indices from flow cytometry were compared using the two tailed student t-
test or ANOVA with Bonferroni post-test when there are more than two groups. When 
distribution of test data did not conform to normal distribution, the non-parametric 
Wilcoxon signed rank test was used to test significance when there were two groups, 
and the Kruskal-Wallis statistic with Dunn's correction for multiple testing was applied 
for comparisons between three groups. The Fisher exact test was used for categorical 
data. p values of less than 0.05 were considered significant.  
 
Two-tailed Pearson correlation analysis and scatterplots were used to determine 
relationships between serum adiponectin, AdipoR1 and AdipoR2 expression, as well as 
clinical parameters. The significant variables were entered into a forward stepwise 
linear regression model to assess their independent influence on AdipoR1 & AdipoR2 
expression.  
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4. EXPRESSION ANALYSIS OF ADIPONECTIN 
RECEPTORS AND ADIPONECTIN ON PERIPHERAL 
BLOOD MONONUCLEAR CELLS  
 
4.1 Introduction 
 
The adiponectin receptors, AdipoR1 & AdipoR2, modulate at least in part, the insulin 
sensitising and anti-inflammatory functions of adiponectin (Kadowaki, Yamauchi 2005). 
The isoforms share 66.7% primary sequence homology and are differentiated by their 
affinities to adiponectin multimers. AdipoR1 has preferential avidity for globular 
adiponectin, whereas AdipoR2 is promiscuous for all multimers (Yamauchi, Kamon et 
al. 2003). Recent studies suggest that there are also differences in signal transduction 
following agonist binding ( Xu, Wang et al. 2009. Charlton, Webster et al. 2010).    
 
Evidence for AdipoR1 & AdipoR2 expression on cell types known to mediate tolerance 
in T1D would support our hypothesis. Their gene expression has been described on 
PBMC (Weigert, Neumeier et al. 2008, Palmer, Hampartzoumian et al. 2008, Sohn, 
Kwak et al. 2010, Shen, Charlesworth et al. 2007, Alberti, Gilardini et al. 2007, Tan, 
Wang et al. 2009). In this series of studies, we aimed to extend this current knowledge 
by first demonstrating their expression at the protein level by flow cytometry. We then 
used this method to characterise their relative expression on PBMC subsets. Lastly, we 
investigated whether PBMC themselves express adiponectin, as the secretion of other 
adipokines by PBMC can have important autocrine/paracrine immunoregulatory effects 
(De Rosa, Procaccini et al. 2007).   
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4.2 Expression of adiponectin receptor mRNA on PBMC 
 
We first confirmed the presence of AdipoR1 & AdipoR2 mRNA (fig 4.1) on PBMC by 
conventional PCR, using intron-spanning primers. Amplicon size was consistent with 
the predicted base pair length on electrophoresis. Next, we validated our rt-qPCR 
assay for relative quantification of AdipoR1 & AdipoR2 mRNA by the Ct method 
(Livak, Schmittgen 2001) (fig 4.2). We derived standard curves of serial template 
dilutions against Ct (Ct target gene – Ct endogenous control) in duplex reactions. The 
reliability of 18S as a normalising control is demonstrated by the standard curve 
gradients of <0.1 (Applied Biosystems 2004)  
Figure 4.1: AdipoR1 & AdipoR2 mRNA on PBMC . Lanes A-D: AdipoR1 32 cycles. Lanes E-G 
AdipoR2 35 cycles. Predicted amplicon size AdipoR1 526bp; AdipoR2 467bp. 
A & E- Whole human pancreas RNA; B & F- rt-ve pancreas 
C & G- PBMC; D & H- rt-ve PBMC.
500
400
300
A      B      C     D      E       F     G    H
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Figure 4.2: Validation of Taqman duplex rt-qPCR . Ct values and Ct values (Ct target 
gene – Ct 18S) are shown following serial template dilutions for AdipoR1 (A&B) & AdipoR2 
(C&D). Best fit lines based on the linear regression model y=mx+C are shown. Error bars 
indicate SD.
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4.3 Characterising the surface expression of adiponectin receptor on PBMC by 
flow cytometry 
 
Having optimised the concentration of primary and secondary antibodies (fig 4.3), we 
checked for the specificity of AdipoR1 & AdipoR2 labelling on PBMC. The staining for 
both AdipoR1 & AdipoR2 was inhibited when the primary antibody, raised from a rabbit 
host, was pre-incubated with the specific immunising peptides (fig 4.4). Because of the 
primary sequence homology between the two receptors, we then asked whether the 
antibody labelling was specific to the receptor isotype. The blocking peptide of AdipoR1 
did not have significant inhibitory effect of labelling by the AdipoR2 antibody, and vice 
versa (fig 4.5). In addition, we looked for differences in gene expression levels in 
PBMC sorted according to their AdipoR1 & AdipoR2 labelling. Using anti-rabbit 
microbeads, the yield of positive cells was increased by 2.5 fold (fig 4.6). Second 
passage over the column reduced the yield without significantly improving purity. By rt-
qPCR, AdipoR1 & AdipoR2 gene expression was significantly higher in the respective 
positive fractions, relative to pre-sorted PBMC (Fold change AdipoR1+: 4.02 95%CI 
2.39 – 6.76; AdipoR2+: 2.08, 95% CI 1.44 - 7.23) (fig 4.7). Gene expression in the 
negative fraction was similar to pre-sort. Conversely, AdipoR1 expression in the 
AdipoR2+ fraction was not significantly increased compared to the pre-sort (fold 
change = 1.64, 95% CI 0.97-2.75), as was AdipoR2 expression in AdipoR1+ fraction 
(fold change = 2.08, 95% CI 0.93 – 4.67). Thus, although limited by possible receptor 
co-expression and sort purity, these gene expression findings nonetheless support our 
antibody labelling as being relatively isotype specific. 
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Figure 4.3: Optimisation of antibodies for the labelling of AdipoR1 & AdipoR2 (A) 
Secondary antibody only. The smaller peak on the right of the histogram is due to higher auto-
fluorescence of CD14+ monocytes (B). The primary antibody was suspended in 0.01ug ml-1
PBS. Differences in fluorescent labelling following addition of the primary antibody to AdipoR1 
(C) & AdipoR2 (D) at 0, 20, 50 & 100ul. The amount of secondary antibody was fixed at 100ul 
of a 0.008ug ml-1 suspension. (E) Titrating secondary (2y) antibody. Primary AdipoR1 antibody 
was fixed at 100ul.
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Figure 4.5: Inhibition of staining is receptor subtype specific. Numbers in legend denote 
MFI. AdipoR1 immunising peptide (AdipoR1p) inhibited AdipoR1 staining (a) but not AdipoR2 
(b). The vice versa was seen with AdipoR2p. 50ul of the primary antibody at 0.01 ugml-1 was 
used. 
AdipoR1
0
20
40
60
80
100
 ¤
C
e
lls
AdipoR1 Ig + AdipoR2 p2.57
AdipoR1 Ig + AdipoR1p 1.97
AdipoR1 Ig 2.83
rabbit serum + 2y 1.8
a)
AdipoR2
0
20
40
60
80
100
¤
C
e
lls
AdipoR2 Ig+ AdipoR2p 2.23
AdipoR2 Ig + AdipoR1p 2.75
AdipoR2 Ig 2.69
b)
ADIPOR1
%
 o
f 
M
a
x
primary antibody + block
Primary antibody
ADIPOR2
%
 o
f 
M
a
x
primary antibody + block
primary antibody
ADIPOR1
C
D
1
4
3.42 12.9
1271.7
ADIPOR1
C
D
1
9 3.41 6.97
10.579.1
ADIPOR1
C
D
5
6
7.6 4.22
17.670.6
A) B)
C) D) E)
Figure 4.4: Effect on AdipoR1 (A) & AdipoR2 (B) labelling when the primary antibody is 
co-incubated with its immunising peptide, at a ratio of 1:5. 
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Figure 4.6: Sorting PBMC according to AdipoR1 & AdipoR2 expression. Gates are set 
against isotype. Numbers denote percentage frequency of positive cells among all viable 
PBMC. Presort expression levels of AdipoR1 (a) & AdipoR2 (c) are shown. Note that the 
majority of monocytes (higher forward scatter) stain positive for AdipoR1 & AdipoR2. b & d-
staining of cells positively selected for AdipoR1 & AdipoR2.
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A
B
Figure 4.7: Gene expression of cells sorted according to AdipoR
expression. Each sort was performed twice and the mean Ct values were 
calculated from the 2 triplicates. Error bars denote SD. 
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4.4 Quantification of AdipoR1 & AdipoR2 expression on FACS and determining 
intra-subject variability 
 
The geometric mean fluorescence intensity (MFI) and the percentage of positively 
labelled cells (%pos), relative to isotype, are two conventional measures for quantifying 
surface receptor expression by FACS. The gating strategy for determining AdipoR1 & 
AdipoR2 is outlined in figure 4.8. Briefly, viable PBMC were defined according to 
scatter and propidium iodide staining. We found that monocytes have consistently 
higher auto-fluorescence compared to lymphocytes, hence 2 sets of gates for each cell 
type, accounting for 99% of events, were drawn to delineate negative staining in the 
isotype control. 
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Figure 4.8: Example gating for the determination of AdipoR expression on PBMC 
subsets. Viable lymphocytes were defined by their scatter characteristics (A) and 
propidium iodide staining (B). Quadrant gates were determined against isotype (C), such 
that at least 99% of cells are in the lower left quadrant. In this example, the percentage of 
CD3+ T cells expressing AdipoR1 (D) is 5.5% (4.01/(69.3+4.01)). 
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Next, we qualified the intra-subject variability of our assay. We calculated the CV based 
on independently stained replicates from 3 healthy subjects (Table 4.1 & 4.2). 
Lymphocytes and monocytes were defined according to scatter. The maximum CV for 
the assay was 13.2%. 
 
Table 4.1: Intra-assay variability for AdipoR1 expression measurement  
 Lymphocytes Monocytes 
Subject 1 2 3 1 2 3 
 MFI %pos MFI %pos MFI %pos MFI %pos MFI %pos MFI %pos 
N 
 
6 6 4 4 3 3 6 6 4 4 3 3 
Mean 
 
5.30 38.2 3.45 15.95 6.19 22.44 129.8 90.8 84.45 85.8 98.2 78.8 
SD 
 
0.51 2.22 0.46 0.58 0.68 0.85 12.2 3.64 8.69 8.28 7.40 4.62 
CV (%) 
 
9.71 7.87 13.23 3.64 10.99 3.79 9.40 4.02 10.2 9.65 7.54 5.86 
 
 
Table 4.2: Coefficient of variation for AdipoR2 expression measurement of PBMC 
by FACS 
 Lymphocytes Monocytes 
Subject 1 2 3 1 2 3 
 MFI %pos MFI %pos MFI %pos MFI %pos MFI %pos MFI %pos 
N 
 
6 6 4 4 3 3 6 6 4 4 3 3 
Mean 
 
5.82 19.45 3.54 
 
12.3 6.24 18.32 148.8 53.8 87.4 79.4 98.6 65.5 
SD 
 
0.43 1.88 0.38 1.19 0.56 0.67 16.22 6.29 10.44 9.69 7.10 4.21 
CV (%) 
 
7.48 9.7 10.68 9.7 8.97 3.7 10.90 11.7 11.96 12.2 7.20 6.4 
 
4.5 Distribution of adiponectin receptor expression on PBMC subsets 
 
As the first step in elucidating the immunoregulatory potential of adiponectin, we 
examined the relative expression of its specific receptors on PBMC subsets, at both the 
protein and mRNA level. PBMC were classified as monocytes, T cells, B cells and NK 
lymphocytes, using the phenotypic markers, CD14, CD3, CD19 and CD56 respectively. 
We also labelled PBMC for AdipoR1 or AdipoR2 (fig 4.9), and derived our estimates for 
relative protein expression of the receptors from the frequency of the “double positive” 
population. Over 10 independent experiments (fig 4.10), the percentage of cells 
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staining positive (%pos) for AdipoR1 are as follow (mean ± SD): CD3+: 4.7 ± 0.9; 
CD14+: 84.6± 2.0; CD19+: 55.6 ± 5.4; CD56+: 34.7 ± 3.4.  For AdipoR2, %pos values 
were: CD3+: 6.2 ± 1.4; CD14+: 80.2 ± 3.4; CD19+: 48.6 ± 8.6; CD56+: 36.8 ± 
4.2.
Figure 4.9: Distribution of AdipoR1 & AdipoR2 surface expression on 
PBMC. Representative example. Numbers denote percentage frequencies of 
gates. A & E) All PBMC analysed. Higher autofluorescence accounts for the 
difference in thresholds set for positive receptor staining in CD14 positive cells. 
For B-D, F-H, analyses are confined to lymphocytes only. In this example, the 
percentage of CD14+ cells expressing AdipoR1 is 77% (7.57/9.74) (A) and 67% 
(6.67/10) for AdipoR2(E).For CD3+ cells, AdipoR1: 10.3% (B), AdipoR2: 6.1% 
(F). For CD19+ cells, AdipoR1: 71%; AdipoR2: 45%. For CD56+, AdipoR1: 
48%; AdipoR2: 35%.
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Figure 4.10: Distribution of AdipoR1 & AdipoR2 expression on PBMC by flow cytometry.
(n=8) Error bars indicate SD.
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For the characterisation of AdipoR1 & AdipoR2 gene expression, we extracted RNA 
from positively selected CD3+, CD14+, CD19+ and CD56+ cells. The MACS sorts 
(n=4) were performed simultaneously from the same donor buffy coat, and had purities 
approaching 90% or over (figure 4.11). On conventional rt-PCR, AdipoR1 & AdipoR2 
gene expression was confirmed on all 4 subsets. By densitometry of the amplicon 
bands, expression of both receptors appeared to be highest on monocytes (figure 
4.12). We then proceeded to accurately quantify relative gene expressions by rt-qPCR. 
Relative to autologous CD3+ T cells (figure 4.13), AdipoR1 expression on CD14+ 
monocytes was 9.1 (95% CI: 8.0-10.2) times higher. The ratio for CD19+ was 6.9 (6.0-
7.9) and for CD56+, 5.8 (5.0-6.8). AdipoR2 gene expression was also the highest on 
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monocytes (fold change: 4.5, 95% CI: 4.5-5.6) and CD19+ B cells (fold change: 4.6 
95% CI: 3.8-5.4). This pattern of predominant expression on CD14+ monocytes and 
CD19+ B cells was in agreement with protein expression data from flow cytometry.  
Figure 4.11: Purity of PBMC subset sorts. Numbers denote gate frequencies (%). A) Presort
B) Following positive selection for CD3 C) Presort. D) Positive selection for CD14. E) Presort F) 
CD19 sort G) Presort H) CD56 sort.
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Figure 4.12: AdipoR1 & 
AdipoR2 mRNA 
expression on PBMC 
subsets.
(top) AdipoR1 (predicted 
amplicon size 526bp) 
L- ladder 
A-human pancreas RNA. B&C: 
CD3+ cells & rt-ve control. 
D&E: CD14+ & rt-ve. 
F&G: CD19+ & rt-ve. 
H&I: CD56+ & rt-ve. 
(middle) AdipoR2 (predicted 
size 467): A: water blank. 
A-D: CD3+, CD14+ CD19+ & 
CD56+. 
F-I: respective rt-ve control. 
(bottom) beta-actin
(predicted bp: 541bp). L-
ladder. 
A, C, E, H- CD3+, CD14+, CD19+ 
and CD56+ cells with rt-ve controls 
in lanes to the righ (B, D, F, I). 
L   A  B   C   D   E  F   G   H   I
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Figure 4.13: Relative gene expression of AdipoR1 & AdipoR2 in sorted PBMC, by rt-qPCR.
n =4. Expression levels in CD3 cells from each sort was used as reference in the calculation of 
relative gene expression level of the sorted population. Error bars indicate SD.
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4.6 Expression of adiponectin receptors on Tregs and non-monocytic CD11c+ 
cells 
 
Myeloid dendritic cells and Tregs are important in conferring tolerance in animal 
models of  cell autoimmunity (Bluestone, Tang et al. 2008, Saxena, Ondr et al. 2007). 
In particular CD11c+ antigen presenting cells are dominant in infiltrates of early insulitis 
(Uno, Imagawa et al. 2007, Shinomiya, Nadano et al. 2000). To address whether 
adiponectin signalling could influence function of these cells, we sought evidence of 
AdipoR1 & AdipoR2 expression, again at both mRNA and protein levels.  
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We identified naturally occurring Tregs in circulation using CD4+CD25highFoxP3+ 
phenotype (Fontenot, Gavin et al. 2003, Hori, Nomura et al. 2003). Recent studies 
have demonstrated that low IL-7 receptor expression (CD127) could be used as a 
discriminator for Tregs (Seddiki, Santner-Nanan et al. 2006, Liu, Putnam et al. 2006, 
Hartigan-O'Connor, Poon et al. 2007). This has the advantage of allowing live sorting 
(Hartigan-O'Connor, Poon et al. 2007). Using both these criteria on flow cytometry, we 
found 5-10% of Tregs express AdipoR1 & AdipoR2 (figure 4.14 & 4.15). This is of 
similar magnitude with expression levels on all resting CD3+ cells. Following the 
CD4+CD25+CD127low sort, we attained a Treg fraction of at least 80% purity (fig 4.16). 
AdipoR1 & AdipoR2 gene expression was demonstrated in these cells, and on rt-
qPCR, their levels were similar to whole PBMC (fig 4.16E).  
  
CD1a bears homology to MHC and is involved in the regulation of T cell responses to 
glycolipid antigens (Banchereau, Briere et al. 2000). It is expressed on myeloid DC (Ito, 
Inaba et al. 1999), and also on monocytes of healthy individuals (Gregory, Zilber et al. 
2000). We used CD1a and high forward scatter to enumerate circulating DC, with 
CD14 as the exclusion marker. Using these criteria, we found that peripheral blood DC 
amount to 0.5% of PBMC (fig 4.17) and that 50% of these cells express AdipoR1 & 
AdipoR2. DC can also be generated by differentiating peripheral blood monocytes 
using GM-CSF and IL-4 (fig 4.18). These monocyte derived DC (mDC) have increased 
costimulatory molecules (CD80, CD86, CD1a, DC SIGN) but have lost CD14 
expression. They express both AdipoR1 & AdipoR2, at both the protein (fig 4.19) and 
mRNA level (fig 4.16E), but both methods of quantification point to a reduced level of 
expression in comparison to peripheral blood monocytes.   
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Figure 4.14: Expression of AdipoR on FoxP3+ T cells. Representative example. 
CD4+CD25high cells (A) express high levels of Fox P3 (B) relative to CD4 CD25- cells (C). 
AdipoR1 (D) and AdipoR2 (E) is expressed on 6% of CD4+FoxP3+ cells. Expression of AdipoR1& 
AdipoR2 on CD4+FoxP3- cells is 7.4% and 8.4% respectively. The low numbers of co-expressers 
for AdipoR and FoxP3 is in keeping with the overall sparse expression of AdipoR on resting T cells, 
at both the protein (fig 4.10), and mRNA level (fig 4.13).
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Figure 4.15: AdipoR on CD4+CD25highCD127low Tregs. A & B. Representative gating of 
CD4+CD25highCD127low cells. C & D. Numbers denote percentage of cells exhibiting positive 
staining for the receptor, against isotype.
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Fig 4.16: Gene expression of AdipoR on CD4+CD25highCD127low Tregs. (A-C). Purity of 
positively selected fraction. 85% of cells were positive for CD4 & CD25, of which >90% were 
also CD127 low. Overall purity was 80%. In cells expressing the highest level CD25,(A) there 
was markedly reduced expression of CD127(C) . 
D. Conventional rt-PCR of RNA from CD4+CD25highCD127low cells and monocyte derived 
dendritic cells. 
1&6-PBMC; 2&3, 7&9 - CD4+CD25highCD127low and rt-ve; 4&5, 8&10- mDC & rt-ve. 
E. Quantification by rt-qPCR. Fold change relative to pre-sorted PBMC. Error bars indicate SD.
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Figure 4.17: AdipoR on peripheral blood dendritic cells (PBDC). Representative 
example. Viable PBDC were identified by (A) lack of propidium iodide staining, (B) 
high forward scatter, as well as positive CD1a and negative CD14 labelling. We used 
CD1a expressing monocytes as an internal comparison for AdipoR1 & AdipoR2 
staining (D&E). Numbers denote gate frequencies. (D&E). Cell counts for each 
subpopulation are appended in the legends.
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Figure 4.18: Phenotype of 
monocyte derived 
dendritic cells (mDC). The 
method of their generation is 
decribed in 3.7.1. CD14+ 
precurosrs were negative in 
their expression of CD80 (A), 
CD1a (C) and DC-SIGN (E). 
Following ex vivo expansion, 
mDC had increased 
expression of these markers 
(B, C, F). They had an 
immature phenotype (CD83-
ve) and had lost CD14 
expression (B).
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Figure 4.19: AdipoR on mDC. Surface staining for AdipoR1 & AdipoR2  was quantified on mDC
gated on high CD1a (A) as well as double positive staining for DC-SIGN and CD86.
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4.7 Expression of adiponectin receptors on activated T cells 
 
We then asked whether the relatively low expression of AdipoR1 & AdipoR2 on T cells 
could be altered by activation. Positively selected CD3+ cells (>97% purity) were 
activated using CD3+CD28+ Dynabeads or PHA, for 48-72 hours. Both means of 
activation resulted in a trend for AdipoR1 & AdipoR2 surface expression to decrease 
(fig 4.20 & 4.21). In particular, the fall in AdipoR2 expression following PHA was 
significant (fig 4.22). This change was also observed at the gene expression level (fig 
4,22D). In addition, we found that the upregulation of CD25 on PHA activation strongly 
and significantly correlated with the reduction in both AdipoR1 & AdipoR2 expression 
(fig 4.22C) (AdipoR1 r = -0.92 p<0.01, AdipoR2 r=-0.76 p<0.05).   
 
 102  
Figure 4.20:AdipoR on T cells activated by PHA. MACS sorted CD3+ cells were treated with PHA. 
After 72 hours, harvested cells were costained with CD25 and AdipoR1 or AdipoR2. Representative 
example. Numbers denote quadrant frequencies. Gates were set based on isotype, such that 99% of 
cells were bracketed in the left lower double negative quadrant. Differences in isotype gate setting 
between resting and activated T cells were due to autofluorescence (appendix 1).
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Figure 4.21: AdipoR on T cells activated by CD3+CD28+ Dynabeads. A & 
C: negative controls. B & D: treated. Expression of AdipoR1 (B) and AdipoR2 
(D) were quantified alongside CD25 staining. Numbers denote gate
frequencies. E & F. Comparison of AdipoR1 & AdipoR2 expression between 
Dynabeads treated T cells and control (n=4).
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Figure 4.22: Effect of T cell activation on AdipoR expression. (A & B) 
Changes in AdipoR1 & AdipoR2 MFI with PHA stimulation for up to 72 
hours. The paired experiments were from the same donor. (C) T cells from a 
single subject was exposed to increasing doses of PHA (0,1,2,5,10,20, 25 
ug/ml). A significant inverse correlation is demonstrated for both AdipoR1 & 
AdipoR2 against the activation marker CD25 (IL-2 receptor). (D) Gene 
expression of T cells for AdipoR1 & AdipoR2 following activation
0.1
1
10
100
untreated PHA
A
M
F
I
A
d
ip
o
R
1
0.1
1
10
100
Untreated  PHA
B
            p < < 0.0001
M
F
I
A
d
ip
o
R
2
0 20 40 60
0
2
4
6
8
10 AdipoR2
AdipoR1
r = -0.92  p < 0.01
r = -0.76  p < 0.05
CD25 MFI
%
 c
e
ll
s
 p
o
s
it
iv
e
fo
r 
re
c
e
p
to
r
C
0
0.2
0.4
0.6
0.8
1
1.2
1.4
re
st
in
g
un
tre
at
ed
P
H
A 
5u
g/
m
l
D
yn
ab
ea
ds
F
o
ld
 C
h
a
n
g
e
 v
s
 r
e
s
ti
n
g
 T
 c
e
ll
s
AdipoR1 AdipoR2
D
 
 105  
4.8 Expression of adiponectin by PBMC 
 
Next, we asked whether PBMC express adiponectin, as its secretion has been 
documented in non-adipose tissue (Katsiougiannis, Kapsogeorgou et al. 2006, Chen, 
Tan et al. 2006, Ding, Qin et al. 2007), as well as in primary osteocytes which share a 
common ontogeny with myeloid cells (Berner, Lyngstadaas et al. 2004, Shinoda, 
Yamaguchi et al. 2006). We discovered that PBMC do express adiponectin mRNA (fig 
4.23A), albeit at low levels when compared to mature adipocytes (figure 4.23B). Its 
gene expression was comparatively higher in CD19+ and CD56+ lymphocytes (fig 
4.23C) among the PBMC subpopulations.  
 
We then sought evidence of adiponectin protein expression on immunoblotting of 
PBMC lysates (Methods section 3.10), from buffy coats of healthy blood donors (fig 
4.24). Following immunoprecipitation (IP) with a rabbit anti-adiponectin antibody, 
immunoblotting revealed a band corresponding to the reported molecular weight of 
adiponectin (28kDa). This was also present in our human serum positive control and in 
the pre-IP PBMC lysate. However, its situation also approximated to the molecular 
mass of the IgG light chain, cleaved from the whole antibody during the final elution 
steps. Indeed, a fainter but similar sized band was seen in the supernatant sample 
following IP with pre-immune rabbit serum. We addressed the possibility of a tandem 
band by covalently coupling the IP antibody (Methods section 3.10.1), as well as the 
irrelevant antibody control. Indeed, the contaminating light chain signal was now lost in 
the negative control (lane 7), whilst the band of interest was preserved (lane 8). A 
further complication in the interpretation of blots was the consistent appearance of 
bands at 34-36kDa. We confirmed its non-specificity by demonstrating its persistence 
when the membrane was only exposed to the secondary HRP-conjugated antibody. 
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The band at 28kDa was absent in the secondary antibody only blots (figure 4.25), and 
its luminescence abrogated when the probing primary antibody was pre-incubated with 
recombinant adiponectin (fig 4.26). 
 
We attempted to isolate this band on Coomassie staining for further qualification on 
mass spectrometry (Methods section 3.10.2). However, only one band was visible in 
the 22-36 kDa range and this was excised and subjected to in-gel trypsinisation. The 
resultant spectra were a match for the IgG light chain.  
 
We had also cultured whole PBMC in complete media, supplemented by 10% FCS. By 
ELISA, the level of adiponectin in supernatants after 3 days of culture was below the 
detection limit.   
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Figure 4.23: gene expression of adiponectin on PBMC. A. conventional rt-PCR (37 cycles). a. 
whole pancreas RNA b. Ntera cells c & d. differentiated Chub S7 adipocytes and rt-ve control e & f. 
PBMC RNA & rt-ve control. B. rt qPCR of adiponectin mRNA in whole PBMC, from 3 independent 
samples for each cell type/tissue tested. C. MACS-sorted subpopulations of PBMC. Standard 
curve for the adiponectin/18S duplex rt-qPCR is shown in appendix 2. 
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1. Recombinant adiponectin (FLAG tag)
2. Human serum
3. Rabbit serum
4. PBMC lysate
5-8 supernatant post IP of PBMC lysate
5. anti-adiponectin Ig
6. Rabbit serum
7. Covalent coupled rabbit anti-AdipoR2 Ig
8. Covalent coupled rabbit anti-adiponectin Ig
1    2   3     4    5   6         7    8
Figure 4.24 Immunoblot for human adiponectin (28kDa) in PBMC lysates.
Recombinant adiponectin (with FLAG tag) and human serum were used as positive 
controls (lanes 1 & 2). A band at 28kDa can be seen in pre-IP PBMC lysate (lane 4) 
and is intensified following IP using anti-adiponectin antibodies (lane 5). However, 
this band is also seen in the negative IP control where rabbit serum was used (lane 
6). We postulated this was due to antibody light chain contamination (~25kDa). The 
28kDa band of interest persists after covalent coupling of the anti-adiponectin IP 
antibody (lane 8), but is absent in the control, where an irrelevant antibody was 
covalently coupled to Sepharose beads. The non-specificity of the larger 35 kDa
band in lanes 3-8 is investigated in figure 4.25.
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36
22
1  2   – 3   4   – 5   6  ¦ 3   5
Probing antibodies:
Primary & secondary                ¦ secondary only
1. human serum
2. Recombinant adiponectin (FLAG tag)
3-6 supernatants following IP of PBMC 
lysates
3. Protein G covalently coupled rabbit 
anti-adiponectin IgG antibody [run 1]
4. Protein G covalently coupled rabbit 
anti-AdipoR2 IgG antibody
5. Protein G covalently coupled rabbit 
anti-adiponectin IgG antibody [run 2]
6. Protein G covalent coupled to rabbit 
pre-immune serum
Figure 4.25 Non-specificity of the 35kDa band on immunoblots for adiponectin.
Shown on the left of the blot (lanes 1-6) are two more replicate experiments for 
adiponectin following IP with covalently coupled antibodies. Again, human serum and 
recombinant adiponectin were positive controls (lanes 1 & 2). Bands at ~30kDa, 
corresponding to the Mr of adiponectin, are seen in supernatants from PBMC lysates
following IP (lanes 3 & 5). These are absent in the negative controls (4 & 6). The 
bands at 35kDa are seen when the membrane is exposed only to the secondary 
antibody (to the right), whilst the intensity of bands at 30kDa are visibly reduced.
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A – recombinant adiponectin (FLAG tag)
B- human serum
C & E- supernatant post-IP using anti-adiponectin Ig
D- supernatant post IP using rabbit serum
Figure 4.26 Specificity of the 30kDa band in PBMC lysates following IP for 
adiponectin. The intensity of the band, following IP for adiponectin of PBMC lysates
(lane C), is attenuated when the primary probing antibody is pre-adsorbed with 
recombinant adiponectin (lane E). Here, the primary probing antibody (1ug) was 
incubated with 5ug of recombinant human adiponectin (Cat # ALX-522-063-C050, 
Alexis) overnight at 4 C before application to the membrane. Again, the 30kDa band 
is just barely visible with the negative control IP of the PBMC lysate (lane D).
A      B       C       D                E
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4.9 Discussion 
 
Previous studies have shown AdipoR1 & AdipoR2 gene expression on PBMC (Weigert, 
Neumeier et al. 2008, Palmer, Hampartzoumian et al. 2008, Sohn, Kwak et al. 2010, 
Shen, Charlesworth et al. 2007, Alberti, Gilardini et al. 2007, Tan, Wang et al. 2009). In 
a novel finding, we identified AdipoR1 & AdipoR2 expression on PBMC at the protein 
level by flow cytometry. We have taken precautions in our methodology to avoid non-
specific labelling, including the use of blocking serums, FcR blockade, as well as the 
optimisation of primary and secondary antibody concentrations. We have validated the 
specificity of receptor labelling by demonstrating its inhibition with a specific antibody 
blocking peptide. In addition, the increased gene expression for AdipoR1 & AdipoR2 in 
the positive sort using the labelling antibody was in proportion to increased purity of the 
fraction. Also in later experiments, there was general concordance in the level of gene 
and protein expression by the independent techniques. Furthermore, FACS labelling of 
AdipoR1 & AdipoR2 appeared to be exclusive, as the blocking peptide for one receptor 
isotype had negligible inhibition on the other. In support, the positively sorted cells for 
one isotype did not have increased gene expression for the other. This was an 
important question to address, given the structural homology of the receptors and their 
similar distributions on PBMC subsets.  
 
The advantage of our flow cytometric technique is the ability for quantification of 
receptor expression at both the protein and cellular levels. For quality control we have 
developed an explicit experimental protocol, as well as a preset method of data 
analysis. Over 3 subjects, our assays have a CV ranging from 3-13%. This compares 
favourably to other methods of quantification based on FACS (Gratama, D'hautcourt et 
al. 1998, Faint, Pilling et al. 1999), despite the inherent variability that comes from the 
use of polyclonal antibodies. At the time of writing, no monoclonal antibodies to 
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AdipoR1 or AdipoR2 were available commercially. We recognised that a further 
contributor to the variability is our analogue flow cytometer, as its optical and 
compensation settings have to be calibrated manually before each run. Whilst this is 
not a factor in single day experiments, this variability could significantly undermine 
validity in longitudinal studies. To control for this, we would standardise MFI values by 
subtracting against that in the isotype sample. In addition, we would seek corroborative 
evidence at the mRNA level in all future experiments.   
 
AdipoR1 & AdipoR2 was expressed in all PBMC, but there were significant differences 
in their distribution among subsets. We found the highest expression on monocytes, 
followed by B cells and then NK cells, with sparse expression seen on T cells. There 
was agreement of relative expression data acquired on FACS and rt-qPCR. In an 
earlier publication, we had found the high receptor expression on monocytes measured 
on FACS was not replicated at the gene expression level (Pang, Narendran 2008b). 
This could be reconciled by the increased purity of the monocyte sorts. For the 
presented set of experiments, we switched to using anti-CD14 microbeads, as opposed 
to the sequential application of PE-conjugated CD14 and anti-PE microbeads. The 
resultant purity of the positive fractions was consistently at 90%, as opposed to the 
85% previously.  
 
AdipoR1 & AdipoR2 mRNA in monocytes had been described by other groups 
(Chinetti, Zawadski et al. 2004, Weigert, Neumeier et al. 2008). We have extended this 
knowledge by demonstrating their expression at the protein level. We found reduced 
receptor expression on DC compared to their monocyte precursors, through direct 
comparison in peripheral blood and by the ex-vivo differentiation of primary monocytes. 
This is consistent with findings from Chinetti et al (Chinetti, Zawadski et al. 2004), who 
described reduced AdipoR1 & AdipoR2 in monocyte derived macrophages that 
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represent terminal differentiation of a myeloid antigen presenting cell. The time course 
for this decrease had occurred as early as the third day of culture, when cells are 
expected to acquire a DC phenotype.  
 
A shortcoming of our characterisation work on DC is that we have used relatively crude 
markers (high FSC, CD1a+CD14-) for their definition in peripheral blood. Older studies 
had used a more extensive panel of costimulatory molecules (Zacher, Knerr et al. 
2002, Vuckovic, Withers et al. 2007). More recent studies focused on the BDCA group 
of markers for delineating DC subtypes in circulation (Dzionek, Fuchs et al. 2000). Our 
approach had the benefit of co-identifying CD14+ monocytes, that served as an 
internal positive control for adiponectin receptor quantification on DC. However, not all 
human DC with antigen presenting capacity express CD1a (Chang, Wright et al. 2000, 
Gogolak, Rethi et al. 2007). Furthermore, we could not comment on the distribution of 
AdipoR1 & AdipoR2 on DC subsets. This may be relevant in context of in the early 
stages of islet autoimmunity, where a relatively expanded population of BDCA 2+ 
(CD303) plasmacytoid DC may have a pathogenic role (Allen, Pang et al. 2009).    
 
The expression of AdipoR1 & AdipoR2 on T cells has been reported by others (Palmer, 
Hampartzoumian et al. 2008). Our quantitative experiments found this to be at 
relatively low levels, with no preferential expression on Tregs. This suggests that for 
adiponectin to modulate T cell responses, accessory cells with high adiponectin 
receptor expression such as monocytes, B cells and NK cells are required. This is 
supported by an in vitro model of hepatitis C immunity, where the abrogation of 
interferon-  by T cells by adiponectin is dependent on the presence of NK cells 
(Palmer, Hampartzoumian et al. 2008). Our postulation does not contradict recent 
findings of adiponectin downregulation T cell responses to anti-CD3 antibodies, as 
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whole mice splenocytes were used in the initial stimulation (Okamoto, Christen et al. 
2009).     
 
We found that T cells upon activation had reduced AdipoR1 & AdipoR2 expression. 
The functional significance of this is limited by the relatively low expression at the 
outset. Notwithstanding, this observation is in agreement with findings of reduced 
adiponectin receptor expression on cells exposed to inflammatory stimuli (Rahman, 
Qadri et al. 2009, Ajuwon, Banz et al. 2009), and the increased expression with anti-
inflammatory treatments (Chinetti, Zawadski et al. 2004, Ding, Qin et al. 2007, Sun, 
Han et al. 2006). However, we recognised that this is an area of controversy, with 
reports of reduced adiponectin receptors with inflammation in some primary human 
tissues (Kaser, Moschen et al. 2005, Nannipieri, Bonotti et al. 2007), but not seen at 
other sites (Miller, Cho et al. 2009, Shen, Charlesworth et al. 2007, Tan, Wang et al. 
2009).  
 
We accept two major limitations to this series of studies. Our data regarding the 
expression of adiponectin on PBMC requires validation. We had aimed to confirm our 
rt-qPCR and immunoblotting data via qualitative analysis by mass spectrometry. Our 
failure was due to inadequate yield of the purified protein following immunoblotting. A 
future strategy could involve immunomagnetic pooling of CD19+ and CD56+ cells 
before lysis, as these cells had higher adiponectin gene expression. Another switch 
would be the use of protein G affinity interaction chromatography columns that allow a 
more efficient scale-up. Other groups have used alternative means of demonstrating 
the non-adipose expression of adiponectin, by immunohistology (Katsiougiannis, 
Kapsogeorgou et al. 2006, Miller, Cho et al. 2009, Tan, Wang et al. 2009) and by 
ELISA of culture supernatants from tissue explants (Chen, Tan et al. 2006). 
Nevertheless, as the relative gene expression of adiponectin was low and the secretion 
 115  
of adiponectin by PBMC was undetectable, we concluded any autocrine/paracrine 
effects in an in vitro system would be negligible.  
 
Secondly, our investigation into the immune repertoire of adiponectin assumes 
AdipoR1 & AdipoR2 are the major mediators of its immune function. This may not be 
the case, as at least some of these effects are attributed to alternative pathways 
(Masaie, Oritani et al. 2007, Takemura, Ouchi et al. 2007, Peake, Shen et al. 2006). 
Furthermore, a third receptor of adiponectin, T-cadherin, has been described and is 
thought to have biological activity despite the lack of an intracellular domain (Hug, 
Wang et al. 2004, Takeuchi, Adachi et al. 2007).  
 
4.10 Summary of findings 
 
We have optimised and validated a novel method for the flow cytometric quantification 
of AdipoR1 & AdipoR2 surface expression on PBMC. We found on rt-qPCR and flow 
cytometry, that cells which have antigen presenting function for T cell priming and 
activation, such as DC, monocytes and B cells, have the highest expression of 
AdipoR1 & AdipoR2. The levels of expression on T cells, both resting and activated, 
are low in comparison. Adiponectin mRNA can be found in PBMC, however, its 
significance needs to be confirmed at the protein level.   
  
 
 
 
5. THE EFFECT OF T1D ON CIRCULATING 
ADIPONECTIN AND ITS RECEPTOR EXPRESSION ON 
PBMC 
 
5.1 Introduction 
 
We proceeded to assess the effect of T1D on circulating adiponectin and its receptor 
(AdipoR) expression of PBMC. This is an important question to address in the testing 
of our hypothesis. For adiponectin to contribute to mediating in the relationship 
between insulin resistance and  cell autoimmunity, we would expect adiponectin 
signalling to immune cells to correlate with insulin sensitivity. The association between 
insulin sensitivity and serum adiponectin is seen in pre-T1D and in adolescents with 
early disease (Truyen, De Grijse et al. 2007, Diabetes Research in Children Network 
(DirecNet) Study Group 2008) , However, with age and progression, other factors 
including glycaemic control, renal function and presence of complications are more 
important determinants of serum adiponectin (Maahs, Ogden et al. 2007, Pfleger, 
Mortensen et al. 2008, Saraheimo, Forsblom et al. 2008, Frystyk, Tarnow et al. 2005, 
Barnes, Curran-Everett et al. 2008). There is evidence to support the association of 
reduced AdipoR1 & AdipoR2 expression on immune cells with obesity (Weigert, 
Neumeier et al. 2008, Sohn, Kwak et al. 2010, Alberti, Gilardini et al. 2007), but 
whether this extrapolates to T1D, where insulin resistance is also a feature (Pang, 
Narendran 2008), is not known.  
 
In this chapter, we report on the results of a cross-sectional study looking at PBMC 
adiponectin receptor expression in T1D, with healthy and T2D subjects serving as 
controls. 
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5.2 Assessing variability of AdipoR1 & AdipoR2 expression with circadian clock 
and feeding state 
 
Gene expression for AdipoR1 & AdipoR2 on visceral fat follows a diurnal variation with 
a nocturnal trough, and is increased with fasting (Tsuchida, Yamauchi et al. 2004, 
Gomez-Abellan, Gomez-Santos et al. 2010, Blüher, Fasshauer et al. 2005)Therefore, 
we asked whether feeding state and the time of venepuncture would alter adiponectin 
receptor expression on PBMC. Our approach was to measure AdipoR1 & AdipoR2 
expression by rt-qPCR, using fasting blood samples at 0900 hours, and at 1530 (2 
hours postprandial). These times would also approximate with the sampling times for 
subjects recruited from outpatient clinics. The samples were processed within an hour 
of venepuncture. There were no significant differences in AdipoR1 & AdipoR2 gene 
expression in PBMC from the 2 sampling times (figure 5.1) (n=6). We conclude that 
differences in sampling times between morning and afternoon subject catchments 
would not confound our study. 
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Figure 5.1: Effect of fasting and sampling time on AdipoR gene expression. 6 
healthy volunteers were studied. By 2-way ANOVA and Bonferroni post-tests, there 
were no significant differences in normalised gene expression of AdipoR1 (top 
panel) and AdipoR2 (bottom) between the 2 sampling times: 0900 hours (fasting), 
1530 ( 2hours post meal).
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5.3 Clinical characteristics of our study group 
 
Seventy six subjects were recruited. Only male Caucasian volunteers were enrolled to 
control for the possible effects of sex and ethnicity on adiponectin receptor expression 
(Barnes, Curran-Everett et al. 2008, Mente, Razak et al.). Their clinical parameters are 
described in Table 5.1. There were no significant differences in age, BMI and WHR 
between healthy (HC) and T1D subjects. We recruited a second comparator cohort 
with insulin treated T2D. Although they were older and more obese relative to subjects 
with T1D, they had similar HbA1C and duration of diabetes. Statin and ACE 
inhibitor/ARB use was higher in the T2D group.    
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  Healthy Control 
n = 22 
T1D 
n = 29 
T2D 
N = 25 
Age (yrs) 32.6 ± 5.7 35.2 ± 10.7 54.8 ± 11.5*** 
BMI (kg m-2) 25.2 ± 2.8 25.1 ± 4.1 35.3 ± 7.3*** 
WHR 0.90 ± 0.06 0.91 ± 0.09 1.00 ± 0.08** 
Systolic BP (mmHg) 112 ± 11 137 ± 17 141 ± 15 
Diastolic BP 75 ± 12 85 ± 10 85 ± 9 
Duration of Diabetes (yrs) n/a 15 ± 10 10 ± 7 
HbA1C (%) n/a 9.0 ± 1.4 8.8 ± 1.9 
Total cholesterol (mmol) n/a 4.4 ± 0.7 4.1 ± 0.9 
Triglycerides 
(mmol) 
n/a 1.6 ± 1.0 2.3 ± 1.4 
Insulin dose  
(total daily units/ kg) 
n/a 0.85 ± 0.24 1.08 ± 0.15 
Statin Use (%) n/a 31 100* 
ACE inhibitor or ARB use 
(%) 
n/a 52 80* 
Fibrate use (%) n/a 0 4 
Vascular complications 
(%) 
n/a 52 50 
 
Table 5.1: Clinical characteristics of study group. Mean ± SD values are 
represented for continuous variables. By t-test, there were no significant differences in 
age, BMI and WHR between T1D and HC groups. HbA1C, duration of diabetes, lipids 
and rates of vascular complications were similar between T1D and T2D groups. The  
T2D subjects were older and had greater BMI and WHR compared to both HC and 
T1D subjects (*** p <0.0001, ** p<0.01). By chi-square test, ACEI/ARB and statin use 
was significantly higher (p < 0.05*) in the T2D group, compared to T1D subjects. 
 
 
 121  
5.4 Serum adiponectin levels in T1D 
 
Serum total adiponectin between T1D subjects and matched HC was not significantly 
different (T1D: 9.6 ± 6.3 ug ml-1; HC: 7.6 ± 2.3 ug ml-1 p = 0.17) (figure 5.2) . In 
contrast, levels in T2D were significantly reduced (T2D: 4.2 ± 2.8 ug ml-1, p = 0.0003). 
Across all subjects, there were expected correlations between serum adiponectin and 
age (r = -0.333 p = 0.005), BMI (r = -0.461, p = 0.0005) and WHR (r =-0.273, p =0.026). 
In T1D, the inverse association with BMI was preserved ( r = -0.397 p = 0.033 ), and in 
addition, HbA1C was a significant correlate ( r = 0.442, p =0.016). There were no 
significant correlations were observed between WHR or eGDR with serum adiponectin. 
Levels in those with vascular complications compared to those without were not 
different (appendix 6).  
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Figure 5.2: Serum total adiponectin. All sample values are depicted by aligned dot plots. 
Mean values are represented by bar. 
*** p < 0.001; * p<0.05 by Bonferroni post test
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5.5  Measurement of AdipoR expression by FACS and qPCR 
 
We used MFI as a measure of AdipoR1 & AdipoR2 surface expression on PBMC (fig 
5.3). We then confirmed normal distribution of our qPCR and FACS data, as well as 
serum adiponectin measurements, using the one-sample Kolmogorov-Smirnov test 
(appendix 3). As further validation for our FACS and qPCR AdipoR expression assays, 
we found that MFI for both AdipoR1 (r = -0.84 p<0.0001) and AdipoR2 (r = -0.79 
p<0.0001) significantly and closely correlated with Ct (fig 5.4).In addition, the 
Figure 5.3: Gating analysis of FACS data from clinical study. Viable cells were identified 
based on propidium iodide staining (A) and scatter characteristics (B). PBMC were then 
further classified into lymphocytes and monocytes (C), which were co-stained with CD14 (D). 
Geometric mean fluroescence intensity (MFI) was calculated by subtraction against negative 
control (E). In this example (F), AdipoR1 MFI for monocytes is 107.8 (143-35.2). Numbers 
denote percentage frequencies of gates.
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expression of both receptor isotypes significantly correlated with each other (r = 0.86 
p<0.0001). Variations in monocyte count did not significantly affect MFI of both 
receptors in all PBMC or the CD14+ fraction (appendix 4).  
 
5.6 Correlation of AdipoR expression with indices of insulin resistance  
 
We then investigated whether insulin resistance is related to AdipoR expression in the 
three groups by correlation analysis (Tables 5.2-5.4). We used BMI and WHR as 
clinical surrogates of insulin resistance. For subjects with T1D, we also employed 
eGDR, a validated measure of insulin sensitivity calculated using HbA1C, blood 
pressure and WHR (Williams, Erbey et al. 2000).  
 
In healthy subjects we found that AdipoR1 expression on all cells correlated inversely 
with BMI (r = -0.70 p<0.01) and WHR (r = -0.53 p<0.01) (figs 5.5A & 5.5B). There were 
no significant clinical correlates to AdipoR2 expression (figs 5.5C & 5.5D). BMI also 
followed a significant inverse correlation with both AdipoR1 and AdipoR2 expression on 
monocytes in T2D, but this relationship was not present for „all cells‟ (AdipoR1: r = -
0.38; AdipoR2: r=-0.38 p<0.05).  
 
In T1D, eGDR significantly correlated with monocytic AdipoR expression (AdipoR1: r = 
0.42 p<0.05; AdipoR2: r = 0.49 p<0.01) (figs 5.5E & 5.5F). However, the clinical 
parameters used to derive eGDR, namely HbA1C, BP and WHR, did not share 
significant correlation with AdipoR expression. 
 124  
 
Figure 5.4: Surface expression of AdipoR1 & AdipoR2 is closely correlated with gene 
expression. We investigated this relationship by Pearson correlation analysis. MFI of AdipoR
on all cells were analysed against normalised Ct values of AdipoR from qPCR. A. AdipoR1 B. 
AdipoR2. C. The level of AdipoR1 & AdipoR2 expression were also closely correlated with each 
other.
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Table 5.2: Pearson correlation coefficients of AdipoR expression with surrogate 
measures of insulin resistance in healthy subjects 
Healthy controls Age BMI WHR 
AdipoR1 Total 
P 
-.565 
.103 
-.702** 
.003 
-.526* 
.005 
Lymphocytes 
P 
-.251 
.226 
-.270 
.192 
-.114 
.586 
Monocytes 
P 
.021 
.922 
.088 
.675 
.015 
.942 
AdipoR2 Total 
P 
-.356 
.081 
-.059 
.779 
.171 
.413 
Lymphocytes 
P 
-.284 
.169 
.135 
.520 
.376 
.064 
Monocytes 
P 
-.149 
.477 
-.245 
.238 
-.258 
.212 
 
 
Table 5.3: Pearson correlation coefficients of AdipoR expression with surrogate 
measures of insulin resistance in T1D subjects 
T1D Age BMI WHR eGDR 
AdipoR1 Total 
P 
.402 
.102 
-.177 
.240 
.096 
.472 
.250 
.068 
Lymphocytes 
P 
.417 
.201 
-.104 
.493 
.114 
.394 
.207 
.132 
Monocytes 
P 
.247 
.161 
-.149 
.322 
.111 
.409 
.418* 
.024 
AdipoR2 Total 
P 
.387 
.203 
-.145 
.337 
.041 
.759 
.388** 
.004 
Lymphocytes 
P 
.403 
.102 
-.090 
.554 
.078 
.563 
.293* 
.031 
Monocytes 
P 
.175 
.189 
-.125 
.407 
.033 
.806 
.494** 
.006 
 
 
Table 5.4: Pearson correlation coefficients of AdipoR expression with surrogate 
measures of insulin resistance in subjects with T2D 
T2D Age BMI WHR 
AdipoR1 Total 
P 
-.052 
.804 
.061 
.773 
-.187 
.371 
Lymphocytes 
P 
-.007 
.974 
.074 
.724 
-.179 
.392 
Monocytes 
P 
.050 
.812 
-.375* 
.045 
-.309 
.133 
AdipoR2 Total 
P 
-.060 
.777 
.068 
.747 
-.166 
.427 
Lymphocytes 
P 
-.019 
.930 
.086 
.684 
-.176 
.400 
Monocytes 
P 
.236 
.257 
-.373* 
.019 
-.173 
.409 
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Figure 5.5: Correlation of AdipoR1 & AdipoR2 expression with indices of insulin 
resistance in health and T1D. In healthy individuals, BMI (A) and WHR (B) inversely 
correlated with AdipoR1 expression, but not AdipoR2 (C & D) on all PBMC. In T1D, AdipoR1 & 
AdipoR2 expression of monocytes significantly correlated with eGDR (E &F).
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5.7 Effect of T1D on AdipoR expression  
 
The most striking finding is the lower protein expression of both AdipoR1 & AdipoR2 in 
T1D (fig 5.6), by approximately 40% when compared to matched healthy controls (fig 
5.7). This reduction is observed on both lymphocytes (MFI AdipoR1, HC= 3.42 ± 1.40; 
T1D=1.80 ± 1.70 p <0.01; AdipoR2, HC=3.04 ± 1.47; T1D= 1.34 ± 1.30 p<0.01) and 
monocytes (MFI AdipoR1, HC= 34.58 ± 18.47, T1D 19.46 ± 11.16 p<0.01; AdipoR2, 
HC= 23.14 ± 10.63, T1D= 11.12 ± 9.36 p<0.01). These changes at a protein level were 
confirmed at an RNA level through rt-qPCR (AdipoR1 relative gene expression =0.27, 
p <0.01; AdipoR2 = 0.55, p<0.05) (fig 5.8).  
 
Subgroup analysis showed the reduction in AdipoR expression in T1D was not biased 
towards those with longer duration of diabetes (appendix 5) or vascular complications 
(appendix 6) as has previously been reported (Soccio, Zhang et al. 2006). In addition, 
neither insulin dose per weight in kg nor HbA1C correlated with AdipoR expression 
(appendix 5). 
 
To explain the apparent reduction in AdipoR expression in T1D, we identified 
unadjusted parameters which have been reported to be associated with their 
expression. These include: hyperglycaemia (Fang, Palanivel et al. 2005, Guo, Xia et al. 
2007), exogenous insulin (Tsuchida, Yamauchi et al. 2004), statins (Saito, Fujioka et al. 
2007), lipids (Nannipieri, Bonotti et al. 2007, Staiger, Kaltenbach et al. 2004), serum 
adiponectin (Alberti, Gilardini et al. 2007, Civitarese, Jenkinson et al. 2004, Bauche, Ait 
El Mkadem et al. 2006) and vasculopathy (Soccio, Zhang et al. 2006). In addition, ACE 
inhibitors and ARB may directly modify AdipoR expression (Zhang, Li et al. 2009), or 
indirectly via the modulation of adiponectin signalling (Makita, Abiko et al. 2008, 
Clasen, Schupp et al. 2005, Pscherer, Heemann et al. 2010).  Our cohort of subjects 
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with insulin treated T2D were controlled for some of these factors (Table 5.1), although 
significant differences were observed with age, BMI, serum adiponectin, statin and 
ACEI use. Notwithstanding, AdipoR expression in T1D was also lower compared to 
T2D, at both protein and mRNA levels (figs 5.7 & 5.8). Post-hoc analysis showed the 
level of AdipoR expression in T2D for each PBMC subpopulation to be similar to HC. 
As discussed previously, serum adiponectin in T2D was significantly lower, compared 
to both T1D and HC (fig 5.2). Incorporating all subjects, we found a modest but 
significant inverse relationship between serum adiponectin and AdipoR1 (r = -0.29 
p<0.05), as well as AdipoR2 expression on all PBMC (r=-0.34 p<0.01) (fig 5.9). This 
association however did not hold within the three subgroups. 
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Figure 5.8: Gene expression of AdipoR1 (top) & AdipoR2 (bottom) of the three 
study groups. ANOVA testing was done on Ct values, before transformation to give 
fold change values. * p<0.05, *** p<0.001 by Bonferroni post test.
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Figure 5.9: Inverse correlation of serum adiponectin with total PBMC expression 
of AdipoR1 (top panel) and AdipoR2 (bottom). All subjects were included for this 
analysis.
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We employed multivariate linear regression to adjust for confounding between our 
diabetic subjects. AdipoR MFI on all PBMC, lymphocytes and monocytes were the 
dependent variables. We entered the following independent variables in a stepwise 
forward manner: age, BMI, WHR, HbA1C, total cholesterol, triglycerides, adiponectin, 
percentage of monocytes. The binary parameters were: presence of T1D, vascular 
complications, use of ACEI and statins. Variables with a p value of > 10% were 
removed from the model. Table 5.5 summarises results of the computation. We found 
that for AdipoR1 expression on all PBMC, presence of T1D and ACEI use were 
independent predictors. Age and presence of vascular complications were 
independently correlated with AdipoR1 expression for monocytes. For other measures 
of AdipoR expression, the presence of T1D was the only independent variable. Thus 
insofar as this analysis, the reduced expression of AdipoR in T1D appears to be 
disease specific, although the younger age, prevalence of vascular complications and 
absence of ACEI use in the group are also accountable. 
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Table 5.5: Linear regression modelling for AdipoR expression in diabetic 
subjects (T1D + T2D). R squared measures the proportion of variability of 
the dependent variable accounted by the model. For example, our model for 
AdipoR1 MFI on all PBMC accounts for 26% of the observed variation. 
Standardised coefficients measure the relative importance of the independent 
variable in predicting the dependent outcome. 
 
Dependent variable R 
square 
Independent 
variable 
Standardised 
coefficients 
P 
1. AdipoR1 
(all PBMC) 
 
0.255 T1D -0.329 0.024 
  ACEI 0.304 0.036 
 
2. AdipoR1 
(lymphocytes) 
 
0.215 T1D -0.463 0.002 
3. AdipoR1 
(monocytes) 
 
0.253 Age 0.447 0.003 
  Vasculopathy - 0.397 0.008 
 
4. AdipoR2 
(all PBMC) 
 
0.355 T1D -0.596 0.000 
5. AdipoR2 
(lymphocytes) 
 
0.337 T1D -0.580 0.000 
6. AdipoR2 
(monocytes) 
0.325 T1D -0.570 0.000 
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5.8 In vitro effects of glucose and insulin on PBMC AdipoR expression 
 
To further evaluate the effect of glucose and insulin on AdipoR expression, and to 
determine if this may contribute to the lower expression seen in T1D, we exposed 
whole PBMC to a gradient of glucose and insulin concentrations. These experiments 
were conducted in serum free media, and AdipoR expression was measured at 48-72 
hours by FACS because our preliminary experiments had shown readouts at later time 
points were affected by monocyte loss. For the glucose experiments, we recruited 6 
healthy subjects at different times. In each subject, AdipoR MFI was expressed as a 
ratio against untreated control for standardisation (fig 5.10). PBMC from 3 healthy 
subjects were used for the insulin dose-response experiments (fig 5.11), which were 
conducted simultaneously, and so unadjusted MFI values were used for comparison. 
Pearson correlation analyses of AdipoR1 & AdipoR2 MFI for both lymphocytes and 
monocytes, against logarithm of insulin and glucose did not uncover significant 
relationships.       
 
5.9 In vitro effects of adiponectin on PBMC AdipoR expression 
 
We then asked whether adponectin can modulate its receptor expression on PBMC, 
because of the significant albeit modest association between them in our clinical study. 
To test this, we performed dose response curves (n = 8) by adding back recombinant 
adiponectin to serum free media at concentrations of 0, 1, 2, 5 and 10 ug ml-1.  We did 
not find significant changes in AdipoR expression on monocytes or lymphocytes after 
48 hours of culture (fig 5.12).   
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Figure 5.10: The effect of glucose in vitro. MFI are measured on day 2 following 
addition of glucose on day 0, with starting concentrations 5.6, 11.2 and 27.8 mmol/L 
(A). These values are then standardised as a ratio against the measures on cells 
incubated in media only (untreated). By Pearson correlation(n=6), MFI of AdipoR1 
and AdipoR2 on lymphocytes (B) and monocytes (C) were not significantly different 
following exposure to increasing glucose. 
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Figure 5.11: The effect of insulin in vitro (Above) Representative example. PBMC were 
incubated in media containing increasing amount of recombinant human insulin and expression 
levels were measured by FACS after 48 hours (coloured histogram). Grey histograms indicate 
fluorescence of negative control. Numbers in legend depict MFI values. (Below) By Pearson 
correlation, expression levels of both receptors on monocytes and lymphocytes were not 
significantly related to insulin concentration.
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Figure 5.12: Effect of adiponectin on AdipoR expression on PBMC (n=8).
(Above) Whole PBMC were incubated for 48 hours in serum free media with 
adiponectin added back at 0, 1, 2, 5 and 10ug/ml. There were no significant
correlations between adiponectin and AdipoR1 (A & C) and AdipoR2 (B & D) 
expression on lymphocytes (A&B) and monocytes (C&D). 
(Below): Overlaid histograms of AdipoR1 (A) & AdipoR2 (B) staining on 
lymphocytes at the different concentrations, from one subject.
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5.10 Discussion 
 
To our knowledge, this is the first study to assess AdipoR protein expression on PBMC 
in T1D and T2D. Our sample size (n= 76) is comparable to that of previous studies 
(range 33-82) that investigated AdipoR gene expression of PBMC in insulin resistant 
states (Weigert, Neumeier et al. 2008, Sohn, Kwak et al. 2010, Shen, Charlesworth et 
al. 2007, Alberti, Gilardini et al. 2007). We achieved the desired matching of the pre-
determined parameters in the two control groups. These were age, BMI and WHR for 
HC; HbA1C, duration of diabetes, insulin treatment, lipid profile and prevalence of 
vascular complications. A further strength is the significant intra-subject agreement of 
AdipoR protein and gene expression levels. This allowed the independent validation of 
group trends seen from the FACS measures against data acquired from qPCR. In 
agreement with other studies of AdipoR expression in primary tissues (Weigert, 
Neumeier et al. 2008, Sohn, Kwak et al. 2010, Shen, Charlesworth et al. 2007, 
Nannipieri, Bonotti et al. 2007, Alberti, Gilardini et al. 2007, Civitarese, Jenkinson et al. 
2004, Bluher, Williams et al. 2007), we found that a strong interrelationship between 
the levels of expression of the two receptor isotypes.     
 
Our first important finding is evidence for an inverse relationship between AdipoR 
expression on PBMC and insulin resistance in health, T1D and T2D (fig 5.5). The 
strongest evidence for this appears to be on the monocyte subpopulation (tables 5.3 & 
5.4), cells which express the highest level of adiponectin receptors. BMI is a simple 
clinical surrogate of insulin sensitivity for the general population (MacKay, Haffner et al. 
2009, Vazquez, Duval et al. 2007, Stern, Williams et al. 2005), as well as T2D 
(Inchiostro 2005). eGDR has been validated against the euglycaemic clamp in T1D 
(Williams, Erbey et al. 2000), and has been widely used in epidemiological studies as a 
measure of insulin sensitivity (Chillaron, Goday et al. 2009, Kilpatrick, Rigby et al. 
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2007, Pambianco, Costacou et al. 2007, Orchard, Olson et al. 2003). Other groups 
have reported on the negative correlation of BMI or HOMA-IR with AdipoR1 & AdipoR2 
gene expression on PBMC (Weigert, Neumeier et al. 2008, Sohn, Kwak et al. 2010, 
Alberti, Gilardini et al. 2007), skeletal muscle (Civitarese, Jenkinson et al. 2004) and 
adipose tissue (Nannipieri, Bonotti et al. 2007, Bluher, Williams et al. 2007, 
Rasmussen, Lihn et al. 2006) of mostly non-diabetic individuals. Our data extends this 
literature by demonstrating the correlation at the level of protein expression, and also in 
diabetes. In the respective papers by Weigert and Alberti (Weigert, Neumeier et al. 
2008, Alberti, Gilardini et al. 2007), only 11 (33%) and 12 (15%) of the study subjects 
had T2D. We attribute our finding of a significant correlation between monocytic 
expression of AdipoR1 & AdipoR2 to eGDR in T1D and BMI in T2D as the 
consequence of a larger sample size. We did not detect significant correlations 
between lymphocytic expression of AdipoR with indices of IR. Lymphocytes are low 
expressors of AdipoR1 and AdipoR2 (figures 4.10 & 4.13). Against the CV of the assay 
(3-9%, Tables 4.1 & 4.2), our study was underpowered to detect differences against 
the small range of IR in our subjects at the 5% significance level. In healthy subjects, 
we did not find AdipoR2 expression to correlate with BMI or WHR (Table 5.2). This has 
been described previously (Staiger, Kaltenbach et al 2004, Zhang, Holt et al. 2005,) 
and reflects the existence of factors other than IR,  such as  cell function, lipids and 
truncal fat as independent modulators of expression.           
 
Is the reduction of AdipoR expression on PBMC a cause or effect of insulin resistance? 
In the landmark paper by Yamauchi et al (Yamauchi, Kamon et al. 2003), the silencing 
of AdipoR1 & AdipoR2 gene expression suppressed insulin-stimulated glucose uptake 
on C2C12 myocytes. The same group has recently extended their findings to in vivo, 
using skeletal muscle specific AdipoR1 knockout mice (Iwabu, Yamauchi et al. 2010). 
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The corollary is the finding of reduced AdipoR expression in animals of insulin 
resistance, such as the ob/ob strain and the insulin receptor knockout mouse 
(Tsuchida, Yamauchi et al. 2004, Lin, Kim et al. 2007). Further support for the 
counterargument is the increased AdipoR expression in human peripheral tissues that 
follows the amelioration of insulin resistance (Bluher, Williams et al. 2007, Vu, Riddell 
et al. 2007). It is therefore possible for expression of AdipoR to be regulated in a 
bidirectional feedback manner according to the prevalent level of insulin sensitivity. 
Such a mechanism has been proposed for the modulation of adiponectin production 
(Cook, Semple 2010). 
 
Our other significant and novel finding is the reduced expression of AdipoR by PBMC 
in T1D (fig 5.7). Indirect evidence to support this comes from Abke et al (Abke, 
Neumeier et al. 2006), who showed adiponectin stimulated release of cytokines on 
monocytes is impaired in T1D. We excluded feeding state and diurnal rhythm as 
confounders by demonstrating the absence of gene expression changes between 
morning fasting and afternoon postprandial sampling times (fig 5.1). Insulinisation had 
been shown to reduce AdipoR expression in the liver and skeletal muscle (Tsuchida, 
Yamauchi et al. 2004). However this was an unlikely explanation for our observations 
for a number or reasons. Firstly, there was no clinical evidence for over-insulinisation in 
our T1D cohort. They were not hypoglycaemic at the time of blood sampling, and the 
group‟s HbA1C (mean 9.0%, SD 1.4) was well above the level (<7.0%) where frequent 
hypoglycaemia would be suspected with intensive insulin therapy (The Diabetes 
Control and Complications Trial Research Group, 1993). As further support, insulin 
dose per unit weight did not correlate with AdipoR1 or AdipoR2 expression in T1D 
subgroup analysis (appendix 5). The observed reduction persisted when contrasting 
against our T2D cohort, where hyperglycaemia, duration of disease and exogenous 
insulin use were controlled. Lastly, our in vitro data showed changes in insulin did not 
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alter AdipoR expression on PBMC (fig 5.10) , and this is consistent with findings from 
skeletal muscle explants (Staiger, Kaltenbach et al. 2004). Using the same triple 
assessment (T1D subgroup correlation analysis, comparison with T2D and in vitro 
testing), we concluded that hyperglycaemia did not play a critical role in the modulation 
of AdipoR expression on human PBMC. We believe that species differences in 
receptor distribution (Kadowaki, Yamauchi 2005) and variations in expression 
regulation between tissues (Blüher, Fasshauer et al. 2005) 
 to account for the apparent contradiction against a previous report (Fang, Palanivel et 
al. 2005), which studied rat muscle cells where AdipoR1 is the predominant isotype.    
 
Our regression analysis showed the reduction in AdipoR expression in T1D is disease 
specific (Table 5.5), although the relatively modest R2 values of the models suggest a 
large proportion of the variability remains unaccounted for. The independent predictive 
value of serum adiponectin, suggested by its inverse association on univariate 
analysis, was lost. In any case, it was not sufficient to explain the reduced AdipoR 
expression in T1D, given the similar levels with HC group. We further confirmed its 
neutral effects in vitro. We recognise the results are at odds with reports from 
transgenic models where adiponectin negatively regulates expression of AdipoR2 on 
adipose tissue (Bauche, Ait El Mkadem et al. 2006). However, their findings did not 
apply to AdipoR1 expression. 
 
Nonetheless, our regression modeling identified vascular complications as an 
independent predictor of reduced AdipoR1 expression on monocytes. This has 
previously been described (Soccio, Zhang et al. 2006).  Although not significant, T1D 
subjects with vascular complications tended to have lower expression of AdipoR1 & 
AdipoR2 on monocytes. Vasculopathy in T1D is associated with subclinical 
inflammation (Schram, Chaturvedi et al. 2005, Lin, Glynn et al. 2008, Devaraj, Cheung 
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et al. 2007, van Hecke, Dekker et al. 2005). We propose therefore that the reduced 
AdipoR expression in T1D reflects the broad activation of innate immunity associated 
with this disease (Schaumberg, Glynn et al. 2005). Such a state of adiponectin 
resistance has been described in experimental models of diabetes, and in the setting of 
systemic inflammation that stems from chronic heart failure (Guo, Xia et al. 2007, Van 
Berendoncks, Garnier et al. 2010). Further measurements of serum inflammatory 
markers, such as IL-6, hsCRP and TNF , can address this issue. 
 
There were two unexpected findings from the clinical study. Firstly, older obese T2D 
subjects had similar AdipoR1 & AdipoR2 expression levels compared to young lean 
healthy controls (fig 5.7). This is however in agreement with two previous studies 
(Weigert, Neumeier et al. 2008, Debard, Laville et al. 2004). In contrast to its title, 
Weigert et al showed AdipoR gene expression levels on monocytes were not 
significantly different between T2D subjects and their obese non-diabetic controls. 
From our regression analysis, the older age and blockade of the renin-angiotensin 
system in T2D subjects may offset the reduced AdipoR expression associated with 
greater insulin resistance.  
 
Secondly, we did not find the increased serum adiponectin widely reported for T1D (fig 
5.2), when compared against age and BMI matched non-diabetic controls (Leth, 
Andersen et al. 2008, Maahs, Ogden et al. 2007, Barnes, Curran-Everett et al. 2008, 
Celi, Bini et al. 2006, Imagawa, Funahashi et al. 2002). These studies had employed a 
commericial radioimmunoassay for adiponectin measurement, but the ELISA method 
used is a validated alternative (Suominen 2004). In agreement with these studies, we 
found an inverse correlation of serum adiponectin with BMI and a positive association 
with HbA1C in T1D (Diabetes Research in Children Network (DirecNet) Study Group 
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2008, Barnes, Curran-Everett et al. 2008, Celi, Bini et al. 2006). Thus, we believe our 
study was underpowered to detect the difference between HC and T1D (posthoc power 
calculation 33.3%). Furthermore, the lower than expected absolute difference between 
the groups may be accounted for by the majority of T1D subjects having normal 
albumin excretion rate, normal renal function and a favourable lipid profile (Maahs, 
Ogden et al. 2007, Schalkwijk, Chaturvedi et al. 2006). 
 
The higher adiponectin associated with poor glycaemic control in T1D may represent 
metabolic adaptation, given that adiponectin levels fall after the initiation of insulin 
treatment at diagnosis (Martos-Moreno, Barrios et al. 2006). We, and others, did not 
find total serum adiponectin levels in T1D to be associated with eGDR (Costacou, 
Zgibor et al. 2005), or IR as determined by the euglycaemic clamp (Perseghin, 
Lattuada et al. 2003). Nevertheless, HMW adiponectin may be more reflective for 
changes in insulin sensitivity (Pajvani, Hawkins et al. 2004). There had been one study 
reporting its increased levels in T1D (Leth, Andersen et al. 2008). We had attempted to 
measure HMW adiponectin in our subjects using a validated ELISA (Aso, Yamamoto et 
al. 2006), but in our hands, the intra-subject CV was unacceptably high. We had 
identified the initial protease digestion of the LMW adiponectin to be the source of the 
poor reproduciblity between duplicates. 
 
We accept the following limitations. The case for insulin sensitivity correlating with 
AdipoR expression across health and diabetes would be strengthened if a universal 
laboratory measure of insulin sensitivity was applied in all 3 groups. HOMA-IR requires 
endogenous insulin secretion, and so is not applicable for subjects with established 
T1D. We believe our strategy of outpatient recruitment would have a low subject 
consent rate if the insulin tolerance test or the euglycaemic clamp were adopted. 
Secondly, both insulin and glucose are obligate ingredients of culture media. Further 
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addition of glucose and insulin could conceivably have only a marginal effect on 
AdipoR expression, if the control experiment was conducted at near the plateau of the 
dose-response range. In our defence, we applied wide ranging concentrations of 
insulin and glucose to PBMC from different subjects, and the results were consistent 
across replicates.  
 
In conclusion, AdipoR expression on PBMC is reduced in T1D, with the lowest 
expression seen in the most insulin resistant. This data supports our working 
hypothesis that reduced adiponectin signaling to immune cells is a mechanism by 
which insulin resistance could drive islet autoimmunity. 
 
5.11 Summary of findings 
 
This is the first study to demonstrate differences in adiponectin receptor expression at 
the protein level in a pathophysiological state. AdipoR1 & AdipoR2 expression on 
PBMC significantly correlated with indices of insulin sensitivity in health, T1D and T2D. 
In addition, we found a global reduction of AdipoR expression on PBMC from T1D 
subjects, relative to matched controls, and this was most marked in the CD14+ 
monocyte population. We explored reasons for this by studying the effects of 
glycaemia, insulin and serum adiponectin, in vitro and by comparison with a cohort of 
HbA1C-matched subjects with insulin-treated T2D. However, these established 
regulators of AdipoR expression did not appear to play a critical role.  
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6. EFFECT OF LIFESTYLE INTERVENTION ON 
ADIPONECTIN RECEPTOR EXPRESSION BY PBMC 
 
6.1 Introduction 
 
In the previous chapter, we demonstrated the correlation of AdipoR expression on 
PBMC with insulin sensitivity in an observational study. To establish causality, we 
assessed the relationship between these variables in interventional trials. Lifestyle 
interventions, which include structured exercise and dietary counselling, are safe and 
have proven efficacy in ameliorating insulin resistance (Diabetes Prevention Program 
Research 2002, Tuomilehto, Lindstrom et al. 2001, Pan, Li et al. 1997). In the following, 
we assessed the effect of lifestyle interventions on the expression of AdipoR on PBMC 
in three independent, investigator-blinded, randomised controlled studies.  
 
6.2  The Early ACTID 
 
The Early ACTID study is a 12 month study based at the University of Bristol (principal 
investigator - Dr Rob Andrews) which examined the effects of diet and exercise in 
patients newly diagnosed with T2D. 
 
6.2.1 Clinical parameters at baseline and at 6 months 
 
In a collaborative sub-study with Dr Andrews, we tested whether the delivery of an 
educational lifestyle package would increase AdipoR expression over and above that of 
conventional T2D care. Subjects with newly diagnosed T2D were randomised to 
conventional care or intensive lifestyle interventions for 6 months. At the time of the 
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study, 349 subjects had been enrolled. We studied samples from 66 consecutively 
recruited subjects from the Early ACTID, as well as the 12 subjects who were positive 
for anti-GAD antibody (titres > 14 units/ml, WHO 97.5 centile) (Bingley, Christie et al. 
1994). The total sample size of 78 subjects had previously been shown to be sufficient 
in demonstrating a significant increase of at least 50% in AdipoR expression of skeletal 
muscle (Bluher, Williams et al. 2007, Christiansen, Paulsen et al. 2010). All subjects 
were within 6 months of their diagnosis with T2D. Before unblinding of clinical data, we 
had excluded 21 subjects for further analysis, because at least 1 of 2 paired samples 
contained significant genomic DNA contamination. After unblinding, a further 4 subjects 
were excluded because of thiazolidinedione use, whose PPAR  agonistic activity 
independently increases AdipoR expression on monocytes (Chinetti, Zawadski et al. 
2004). The final number of subjects included in the analysis was 53, with 19 in the 
conventional care arm (CON) and 34 in the diet and exercise interventional arm (INT). 
Baseline and 6 month data are shown in Table 1. 
 
At baseline, subjects from both arms were matched for age, sex, BMI, WHR, VO2 max, 
MABP, glycaemia and fasting insulin. In the setting of a new diagnosis of non-insulin 
dependent diabetes over age of 35, anti-GAD antibodies (GADA) identifies patients 
with latent autoimmune diabetes of adulthood (Tuomi, Groop et al. 1993). The 
proportion of subjects positive for GADA was similar in both arms (CON: 16%, INT 
18%). 
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Table 6.1: Baseline and 6 month results of Early ACTID. Conventional (CON) and intensive 
(INT) arms are shown. Data expressed as mean ± SEM. Two-tailed unpaired t-test was applied 
for continuous data between the arms at baseline and 6 months, paired t-test for intra-group 
comparsions, and Fisher‟s exact test for categorical data.  
** p <0.01 intragroup  * p <0.05 intragroup 
 
 CON (n=19)  INT (n=34)  
 Baseline 6 months Baseline 6 months 
Age  57.1 ± 3.5  60.8 ± 1.7  
Male sex (n) 13 (68%)  20 (59%)  
BMI (kg m-2) 32.6 ± 1.2  31.1 ± 0.9  
WHR 0.95 ± 0.01  0.95 ± 0.01  
Weight (kg) 89.2 ± 3.4 89.5 ± 3.4 87.8 ± 2.4 87.4 ± 2.5 
WC (cm) 104.3 ± 2.4 103.4 ± 2.1 105.3 ± 2.2 104.7 ± 1.6 
VO2 max (L min
-1) 26.5 ± 2.6 27.2 ± 2.5 25.1 ± 1.8 27.3 ± 1.7* 
HbA1C (%) 6.67 ± 0.18 6.95 ± 0.20 6.61 ± 0.20 6.60 ± 0.14 
MABP (mmHg) 101.6 ± 2.0 90.9 ± 2.9* 97.7 ± 1.6 92.9 ± 1.7** 
Fasting glucose 
(mmol-1) 
7.9 ± 0.3  7.2 ± 0.3*  7.9 ± 0.3 7.2 ± 0.2* 
Fasting insulin 
(mU L-1) 
15.6 ± 1.9 18.1 ± 3.0 15.8 ± 2.0 17.8 ± 2.8 
HOMA-B (%) 72.1 ± 8.1 98.6 ± 15.6 74.0 ± 9.3 100.1 ± 15.7 
HOMA IR 5.66 ± 0.81 4.95 ± 1.16 5.69 ± 0.85 4.93 ± 1.07 
Medications at  
6 months (n, %) 
Metformin  15 (79%)  21 (62%) 
ACEi/ARB  7 (37%)  13 (38%) 
Statin  11 (58%)  18 (53%) 
GADA + (n) 3  6  
 
 
Use of metformin, drugs which block renin-angiotensin system and statins were not 
different between the arms at 6 months. On paired t-testing, no significant weight loss 
was detected with either treatments. However in both arms, MABP fell at 6 months, but 
the difference in MABP decrease between the arms were similar. There was also a 
small but significant intra-group increase in VO2 max in the INT arm (baseline: 25.1 ± 
1.8, 6 months: 27.3 ± 1.7 paired t-test = 0.011). In both arms, there was a significant 
fall of the 6-month fasting glucose from baseline (CON: baseline 7.9 ± 0.3, 6 month 7.2 
± 0.3 p = 0.050; INT: baseline 7.9 ± 0.3, 6 month 7.2 ± 0.2, p = 0.048), but the 
difference in values between groups was similar. There was a non-significant trend for 
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subjects assigned to conventional care to have a higher HbA1C at 6 months (CON: 
6.95 ± 0.20; INT: 6.60 ± 0.14; p = 0.14). Otherwise, no other differences in the 
metabolic parameters at 6 months, within and between arms were detected.  
 
6.2.2 Changes in adiponectin receptor gene expression on PBMC  
 
Consistent with our cross-sectional study, we found baseline AdipoR1 & AdipoR2 gene 
expression to be significantly inter-correlated (r = 0.687 p<0.001) and with HOMA-IR 
respectively (AdipoR1: r = -0.308 p = 0.025; AdipoR2: r = -0.363 p = 0.008) (fig 6.1). In 
addition, AdipoR2 gene expression was inversely related to fasting insulin levels          
(r = -0.322 p = 0.019). There were no significant correlations with other clinical 
parameters. 
 
At 6 months, subjects randomised to the INT arm had a significant increase of AdipoR1 
& AdipoR2 expression, compared to those in CON (fig 6.2). Expressed as fold change 
relative to baseline values, the average increase in the INT arm was 1.73 ± 0.42 for 
AdipoR1, and 5.57 ± 2.77 for AdipoR2. In subjects assigned to conventional care, 
AdipoR1 expression decreased, whereas AdipoR2 levels did not alter from baseline 
(AdipoR1: 0.64 ± 0.17; AdipoR2: 1.04 ± 0.37). We excluded the possibility of mRNA 
degradation during storage as a confounder by demonstrating the absence of a 
significant correlation between the normalised gene expression values against the date 
of sample collection (fig 6.3).  
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Figure 6.1: Correlation 
analysis of AdipoR1 & 
AdipoR2 gene 
expression at baseline. 
AdipoR expression was 
normalised against r18S 
by the Ct method, such 
that a low numerical value 
reflects high expression.  
(Top) AdipoR1 & AdipoR2 
gene expression levels 
significantly inter-
correlated and with 
HOMA-IR (middle and 
bottom panels). The 
correlations of AdipoR1 & 
AdipoR2 with HOMA-IR 
retained significance 
despite removal of the 
three outliers ( ) to the 
right.
*p < 0.05
**p < 0.01
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Figure 6.2: Gene expression changes of AdipoR1 and AdipoR2 on PBMC in the 
Early ACTID. Relative change at 6 months to baseline was calculated for each
subject using the - Ct method. t-testing between the arms was done following 
logarithmic transformation.
The apparent reduction in HOMA-IR between 6 months and baseline for both groups 
did not reach statistical significance. Thus given that in both arms an appreciable 
proportion of subjects experienced improved insulin sensitivity, we performed a 
posthoc correlation analysis accounting all subjects, to investigate the association of 
HOMA-IR with AdipoR expression. We found the change in AdipoR1 & AdipoR2 
expression, transformed to logarithm and normality, correlated inversely with absolute 
changes in HOMA-IR and weight (Table 6.2 & fig 6.4). Also, changes in AdipoR1 and 
AdipoR2 expression were inter-correlated (r = 0.707, p <0.0001).       
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Figure 6.4: correlation of AdipoR1 & AdipoR2 gene expression change with insulin 
resistance across whole cohort (n = 53). Absolute HOMA-IR change was derived by 
subtracting HOMA IR at 6 months to baseline value. Gene expression change at 6 
months relative to baseline for each subject was calculated by the Ct method. 
Logarithmic transformation was done so to allow for Pearson correlation analysis 
between the variables. The significance of the correlations persists despite removal of 
the outlier ( ) from the analysis. 
* p < 0.05, **p<0.01 
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Table 6.2: Pearson correlation of AdipoR1 & AdipoR2 gene expression changes at 6 
month with absolute changes in weight and HOMA-IR (n=53). For this analysis,  AdipoR1 
was the logarithm of fold change in gene expression at 6 months, compared to baseline. The 
transformed distribution approximates to normal, by KS testing. 
 
  AdipoR1   AdipoR2 
Weight                    r 
                                p 
-0.114 
0.416 
-0.345 
0.011 
 
HOMA-IR                r 
                                p 
-0.328 
0.016 
-0.356 
0.009 
  
 
6.2.3 Subjects with latent autoimmune diabetes of adulthood (LADA) 
 
We were interested in whether the changes in AdipoR expression with exercise, weight 
loss or improved insulin sensitivity in T2D could extend to autoimmune diabetes. LADA 
is a slowly progressive form of autoimmune diabetes (Fourlanos, Dotta et al. 2005). It is 
distinguished from T1D by the absence of insulin dependence at initial presentation. In 
the 9 subjects with LADA, there were significant decreases in weight, fasting glucose, 
together with a rise in VO2 max at 6 months (Table 6.3). As demonstrated for patients 
with T2D, these metabolic changes were accompanied by a significant upregulation in 
AdipoR1 gene expression (2.63 fold, p = 0.017), with borderline increase in AdipoR2 
expression (1.50, p = 0.07). 
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Table 6.3: Changes at 6 months for subjects positive for GADA. 
Data presented as mean ± SEM. Fold change at months for AdipoR1 (  
AdipoR1) & AdipoR2 (  AdipoR2) expressed as 95%CI.  
 Baseline 6 months 
Age (yrs) 60.3 ± 3.0  
Male sex (n) 7  
Weight (kg) 81.5 ± 3.9 78.3 ± 3.7** 
WC (cm) 99.1 ± 3.2 99.4 ± 3.4 
VO2 max (L min
-1) 30.2 ± 2.7 32.1 ± 2.4* 
MABP (mmHg) 96.1 ± 2.5 96.2 ± 3.2 
HbA1C (%) 6.3 ± 0.3 7.2 ± 0.7 
Fasting glucose 
(mmol-1) 
7.5 ± 0.6 7.3 ± 0.5* 
Fasting insulin 
(mU L-1) 
10.6 ± 2.1 10.3 ± 1.8 
HOMA-B (%) 61.0 ± 17.3 62.4 ± 16.3 
HOMA-IR  3.70 ± 0.78 3.22 ± 0.62 
 AdipoR1  1.0 2.63  (1.00 – 6.89) 
 AdipoR2 1.0 1.50  (0.84 – 2.70) 
       ** p <0.01  *p <0.05 paired t-test        
         p <0.05 single two-tailed t-test against inferential value of 0 (no  
 change), following  logarithmic transformation 
         p =0.07  
 
 
6.3 The relative importance of exercise as a component of lifestyle interventions 
 
As lifestyle change consists of both exercise and diet, we then asked whether the 
component of exercise alone is sufficient in modulating changes in AdipoR expression. 
The Exercise and Over-eating Study from the University of Bath is a study of one week 
duration and included 11 healthy non-diabetic subjects (Principal Investigator: Dr Dylan 
Thompson). In this collaborative sub-study, we compared the effect of intensive 
exercise (EXE) (45 minutes of supervised exercise at 70% of maximum heart rate) 
versus activity restriction (SED) (<4000 steps/d). In both arms, subjects followed a 
hypercaloric diet, with energy intake increased by 50%. With the acquisition of live 
PBMC, we were able to quantify expression at both the mRNA and protein levels.  
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Table 6.4 Clinical data from the Exercise and Over-eating Study. Mean ± SD 
values shown. 
 SED  EXE  
 Day 0 Day 7 Day 0 Day 7 
n 4  7  
Age (yrs) 25.5 ± 5.4  27.9 ± 7.7   
BMI (kg m-2) 22.9 ± 1.7  24.7 ± 2.9  
Weight (kg) 77.1 ± 2.9 79.5 ± 3.7* 77.8 ± 11.4 79.2 ± 12.1* 
Fasting glucose (mmol-1) 4.80 ± 0.28 4.81 ± 0.33 5.03 ± 0.33 4.95 ± 0.18 
Fasting insulin (mU l-1) 4.03 ± 3.09 6.13 ± 3.68* 4.83 ± 2.97 6.37 ± 4.09 
HOMA-IR  0.87 ± 0.70 1.29 ± 0.74* 1.09 ± 0.68 1.41 ± 0.92 
Serum adiponectin (ug ml-1) 5.5 ± 1.6 7.5 ± 2.3* 7.0 ± 4.7 8.2 ± 4.9 
 
* p < 0.05 paired t-test (within group d7 vs d0) 
  
 
The metabolic changes of the subjects are described in Table 6.4.  There were no 
significant differences between the groups at baseline or on day 7. In the SED arm, 
there were significant intra-subject increases in weight (1.9% p = 0.017), fasting insulin 
(52% p = 0.037) and HOMA-IR (48% p = 0.024) at the end of the study. Unexpectedly, 
serum adiponectin also increased (p = 0.034). In the EXE arm, there was significant 
weight gain (p=0.018). Interestingly, two of the seven subjects did not follow the 
increase in insulin resistance from weight gain seen in the rest of the group (fig  6.5).   
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Figure 6.5. Changes in HOMA-IR in the Exercise & Over-
eating Study.
* P < 0.05 paired t-test
 
Monocyte numbers, as a percentage of total PBMC count, were similar between 
groups, at baseline and at the end of study. AdipoR1 mRNA levels in the SED group 
were significantly reduced from baseline (fold change: 0.6, p = 0.03), but not in the 
EXE group. There were no significant changes for AdipoR2 mRNA in either group on 
completion of the trial. Change in protein expression was standardised using the ratio 
of MFI on day 7 relative to day 0. The transformed measure passed the KS normality 
test. In both arms, there was heterogeneity in response between subjects, such that 
the confidence of the group mean estimates was wide. Consequently, a consistent 
change, in the direction of reduction, was observed only for AdipoR1 expression in both 
lymphocytes and monocytes for SED (95% CI, lymphocytes: 0.02-0.74; monocytes: 
0.02-0.88). This is in keeping with the uniform reduction in gene expression for all 
subjects in SED. Of interest is the significant inter-group difference in monocytic 
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expression for AdipoR1 (fig 6.6), but not for lymphocytes (fig 6.7). Our data here 
suggests overeating alone can significantly suppress AdipoR1 expression across all 
PBMC in just 1 week. However, concurrent intensive exercise can negate part of this 
reduction, especially on monocytes. No significant changes in AdipoR2 expression in 
both arms were detected at entry or exit of the trial.  
 
Table 6.5: Changes in AdipoR expression between the exercise (EXE) 
and sedentary (SED) arms of the trial. All subjects were on a hypercaloric 
diet (150% of normal intake) for 7 days.  
 SED  EXE  
 Day 0 Day 7 Day 0 Day 7 
Monocyte (%) 2.0 ± 0.8 3.4 ± 0.9 3.1 ± 1.4 3.2 ± 0.9 
mRNA   
 AdipoR1 
  
0.6 ± 0.1  
  
1.2 ± 0.6 
 AdipoR2  0.7 ± 0.3  1.6 ± 0.5 
Protein 
MFI   
AdipoR1(D7 :D0)  
lymphocytes 
Monocytes 
  
 
 
0.4 ± 0.1  
0.4 ± 0.1 * 
 
 
 
 
 
0.9 ± 0.4 
1.0 ± 0.2* 
MFI  
AdipoR2(D7:D0) 
lymphocytes 
Monocytes 
  
 
0.7 ± 0.5 
0.6 ± 0.2 
  
 
1.1 ± 0.6 
1.6 ± 0.6 
 - p < 0.01   - p <0.05 by one sample t-test against inferential value of 1.0  (no 
change) 
* - p < 0.05 by t-test between groups 
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Figure 6.6: (top) AdipoR1 expression on monocytes in a 1 week study where subjects were 
randomised either to intensive exercise (INT: n=6) or sedentary activity (CON; n=5) against a 
hypercaloric diet. AdipoR1 MFI on CD14+ monocytes were measured at 1 week and 
standardised against values obtained at entry. (bottom) Representative calculation from dot 
plots. For subject 22 (CON), MFI AdipoR1 is 62.8/94.5 = 0.66; for subject 25 (EXE), this is 1.0.
Gates shown define positive cells and numbers denote percentage frequencies * p = 0.016, 2 
tailed t-test. 
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Figure 6.7: No significant 
difference in the mean 
change of AdipoR1 on 
lymphocytes between 
intensive exercise (INT) 
and sedentary activity 
(SED). (top) p = 0.33 
between groups. (bottom) 
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from 2 matched subjects 
where there were 
significant differences in 
monocytic expression of 
AdipoR1 (fig 6.6).
Quadrant gates were 
drawn based on isotype
control and numbers 
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6.4 The effect of moderate vs vigorous exercise on receptor expression 
 
Next, we asked whether exercise intensity has differential effects on AdipoR 
expression. The Exercise Intensity Study is a three week study conducted at the 
University of Bath with Dr Dylan Thompson as the principal investigator. In this trial with 
a total of 13 healthy non-diabetic but overweight subjects, we compared the effects of 
vigorous (SV) against moderate (SM) exercise. In the SV group, subjects exercised on 
a treadmill at 70% VO2 max, as opposed to 50% VO2 max in the SM group. The total 
energy expenditure (600kCal), the frequency of exercise (5 times a week for 3 weeks), 
and dietary intake (714 kCal) were controlled. 
 
Table 6.6: Clinical parameters at entry and on completion of the Exercise 
Intensity Study.   
 SM (n=6) SV (n=7) 
 Baseline 3 weeks Baseline 3 weeks 
Age (yrs) 49.7 ± 1.3  54.7 ± 2.1  
Male sex (n) 4  4  
BMI kg m-2 29.0 ± 1.0  32.3 ± 0.9*  
Weight (kg) 89.0 ± 6.1 86.8 ± 6.1* 94.9 ± 4.8 92.3 ± 4.7** 
WC (cm) 100.7 ± 4.0  97.4 ± 2.6* 105.0 ± 2.6 103.0 ± 3.0 
Fasting glucose 
(mmol-1) 
6.0 ± 0.8 5.7 ± 0.1 5.9 ± 0.6 5.98 ± 0.3 
Fasting insulin 
(mU L-1) 
9.7 ± 2.9 7.2 ± 1.4* 8.1 ± 2.3 6.5 ± 1.3 
HOMA-IR 3.1 ± 1.5 2.1 ± 0.4 2.1 ± 1.0 1.6 ± 0.4 
Adiponectin  
g ml-1 
9.6 ± 2.5 9.0 ± 1.7 9.4 ± 2.6 8.6 ± 1.7 
        
  ** p <0.01          *  p <0.05  
 
 
At baseline, age, sex, fasting glucose and insulin were equally distributed between the 
groups. Subjects from the SV arm had a significantly higher BMI, but starting weight 
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and WC were similar. At 3 weeks, subjects in both groups achieved significant weight 
loss (95% CI: SM: 0.7-3.6kg; SV: 1.3-3.9kg) but final weight was not different. In the 
SM arm there was also a significant decline in WC and fasting insulin. No significant 
changes in serum adiponectin or HOMA-IR were observed in either interventional 
arms.   
 
At the mRNA level there was no significant change with AdipoR1 & AdipoR2 from 
baseline for either group (fig 6.8). At the protein level (fig 6.9), there was marked 
heterogeneity in response within each group and  AdipoR1 &  AdipoR2 values did 
not conform to normality. Using the non-parametric Wilcoxon signed rank test, there 
was significant change from unity for AdipoR1 & 2 expression on monocytes for 
subjects in the SM arm (median: AdipoR1 2.2; AdipoR2 2.3) and AdipoR2 on 
lymphocytes in the SV arm (median AdipoR2 1.9). The application of Kruskal-Wallis 
test with Dunn‟s correction for multiple testing showed significant change in AdipoR1 
protein expression with monocytes only (median AdipoR1 SM 2.2, SV 0.7). 
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Figure 6.8: Changes in mRNA levels of AdipoR1 & AdipoR2 at completion of 
the trial. Fold change was calculated by the Ct method using Ct at d21 - Ct 
at d0. Following logarithmic transmformation, no significant group changes were 
observed for the gene expression of both receptors, by two-tailed one sample t-
test against the inferential value of 0. 
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Figure 6.9: (top) representative 
examples of  AdipoR1 & AdipoR2 
protein expression changes n the 
exercise intensity study. For 
comparision, gates were drawn 
against isotype control. For subject 
SM17 at d0 (A), MFI of AdipoR1 for 
lymphocytes (CD14- cells) is 5.13 
and for monocytes (CD14+) 114. At 
day 21 (B), the correponding values 
are 6.27 and 195 respectively. 
Hence the ratio of AdipoR1 for 
lymphocytes is 1.22 and 1.71 for 
monocytes. For SV14, AdipoR1 for 
monocytes is 1.08 and 1.27 for 
monocytes. 
(bottom) Changes in AdipoR
expression in the exercise intensity 
study. Median and range plotted. 
p <0.05 by Wilcoxon signed rank 
test, against inferential median value 
of 1.0 (no change).
* p <0.05 by Dunns post test
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6.5 Discussion 
 
Three large multi-centred trials have demonstrated that lifestyle interventions reduce 
insulin resistance and can prevent T2D in high risk groups (Diabetes Prevention 
Program Research 2002, Tuomilehto, Lindstrom et al. 2001, Pan, Li et al. 1997). 
Impressively, despite the relatively short duration of intervention in these studies, the 
metabolic benefits are maintained for at least 10 years (Lindström, Ilanne-Parikka et al. 
2006, Diabetes Prevention Program Research Group 2009, Li, Zhang et al. 2008) 
The combination of exercise and diet is also effective in raising serum adiponectin 
levels in insulin resistant individuals (Mather, Funahashi et al. 2008, Cambuli, Musiu et 
al. 2008, Esposito, Pontillo et al. 2003, Monzillo, Hamdy et al. 2003). In other studies, 
this is also accompanied by increased adiponectin receptor gene expression on 
adipose tissue and skeletal muscle (Bluher, Williams et al. 2007, Christiansen, Paulsen 
et al. 2010, Kim, Maachi et al. 2006, O'Leary, Jorett et al. 2007). However, two 
systematic reviews of exercise studies have found an overall inconsistent effect on 
adiponectin signalling (Vu, Riddell et al. 2007, Simpson, Singh 2008). In addition, the 
authors noted that many studies in the area were observational only, and also the 
majority of interventional trials were uncontrolled. 
 
In this series of controlled studies, we showed the upregulation of AdipoR expression 
by exercise can be achieved on immune cells in normal weight, obese and diabetic 
subjects. In the Early ACTID, both AdipoR1 & AdipoR2 gene expression is increased in 
the intensive interventional arm in early T2D and LADA. In the second study of 
exercise vs sedentary activity in young healthy subjects, we found that intensive 
exercise can compensate for the fall in AdipoR1 expression on monocytes brought on 
by overeating. In the final study of exercise intensity in overweight individuals, we found 
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regular moderate exercise intensity to be effective in augmenting AdipoR1 expression 
of monocytes. We attribute the variations in the response of AdipoR expression to 
lifestyle measures in these trials to be the result of differences in study group, design 
and duration, as well as number of patients studied. Such discrepancies have 
previously been reported. Subjects who are glucose intolerant appear to be more 
responsive when given the same treatment, and increase in AdipoR on adipose tissue 
was independent of the reduction in body weight (Bluher, Williams et al. 2007, Kim, 
Maachi et al. 2006). Furthermore, short term exercise interventions (< 1 week) have not 
been successful in upregulating AdipoR (Zeng, Isobe et al. 2007, Punyadeera, Zorenc 
et al. 2005, Zeng, Fu et al. 2007). Lastly, differences in the amount of prescribed 
exercise can affect the degree of AdipoR1 change (Zeng, Isobe et al. 2007).   
 
Nevertheless, the three studies are unanimous in demonstrating the importance of 
exercise in the regulation of AdipoR on PBMC. In the Early ACTID, where the 
intervention was motivational only, the increased VO2 max in the INT arm was 
consistent with increased exercise objective for the group. The difference in AdipoR 
expression change between groups had occurred despite the absence of significant 
change in weight, HOMA-IR and similar falls in fasting glucose. We justified our 
posthoc analysis because of probable dilutional effect in the benefits of intensive 
exercise between the groups. Subjects in CON arm were aiming for the same 
metabolic targets and were not restricted in the pursuit of lifestyle changes. Here, the 
finding of weight loss as a significant independent predictor of AdipoR change is 
consistent with the upregulation on at least part of the PBMC subset in the exercise 
intensity study. It appears that reduction of central obesity, measured by the fall in WC 
in the SM arm, is a potent stimulus for AdipoR expression change on monocytes.   
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Our second study illustrates the profound effect of diet, that one week of hypercaloric 
intake can suppress AdipoR1 expression, at both the gene and protein expression 
levels. This is a novel finding, and is consistent with the converse evidence where the 
sole institution of a very low caloric diet for 3-8 weeks promotes AdipoR expression on 
adipose tissue and skeletal muscle (Christiansen, Paulsen et al. 2010, Kim, Maachi et 
al. 2006). However, the significance of the reduced expression may be diminished by 
the increase in serum adiponectin with overeating. This rise is paradoxical to the 
change in insulin resistance, but has been observed in binge eating disorders 
(Monteleone, Fabrazzo et al. 2003). Given its insulin sensitising action, the increased 
adiponectin here may represent compensation against hyperinsulinaemia from a 
hypercaloric meal (Taylor, Hubbard et al. 1999).  
 
One way of elucidating a mechanism for the exercise induced AdipoR upregulation is 
through correlation analysis with changes in other variables. Some studies have shown 
changes in serum adiponectin levels, AdipoR1 and AdipoR2 expression levels to 
coordinate (Bluher, Williams et al. 2007, Kim, Maachi et al. 2006, O'Leary, Jorett et al. 
2007, Punyadeera, Zorenc et al. 2005), but this is not a universal finding (Christiansen, 
Paulsen et al. 2010, Kim, Maachi et al. 2006, Punyadeera, Zorenc et al. 2005). More 
consistent across these studies is the link with changes in insulin sensitivity and we 
have demonstrated this using posthoc analysis of our Early ACTID data. Myokines, of 
which a prototypical example is IL-6, are cytokines released by contracting skeletal 
muscle fibres and thus increased with exercise (Petersen, Pedersen 2005). They have 
endocrine effects on fuel metabolism and inflammatory cytokine profile and thus offer a 
possible molecular explanation.    
 
The strengths of these studies are their controlled design and blinding during 
acquisition of AdipoR expression data. However there are a number of weakneses. 
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The differences in BMI between SM and SV arms in the exercise intensity study could 
be a source of bias in the interpretation of our results. Statistical adjustments could not 
be done because of the relatively small sample size. Secondly, a significant number of 
subjects were primarily excluded in the Early ACTID because of genomic DNA 
contamination of the samples. However the baseline characteristics of subjects from 
both groups remained similar. Also, serum adiponectin levels from the Early ACTID 
were unavailable for analysis at the time of writing. I will arrange an addendum analysis 
as soon as I am in receipt of these from our collaborators. Lastly, we did not perform an 
internal validation assay of 18S as a housekeeping gene on PBMC for exercise 
studies, nor did we use multiple internal controls for adjustment. Whilst ribosomal RNA 
is an accepted normalising gene for rt-qPCR of PBMC (Bas, Forsberg et al. 2004) and 
has been used in some exercise studies (Richardson, Wagner et al. 2000, Kim, Cross 
et al. 2005), its expression on skeletal muscle fibre following exercise can increase 
(Jemiolo, Trappe 2004), thereby introduce a bias toward elevation when used as 
loading control for AdipoR expression level. In defence, there was relative concordance 
in the fold change values between mRNA of whole PBMC and lymphocytic (accounting 
for >95% of PBMC) AdipoR expression by FACS from the second study. We recognise 
the reported changes for monocytes could be strengthened by confirmation at the 
mRNA level following CD14+ sorting. 
 
In conclusion, these studies confirm that exercise upregulates AdipoR expression on 
PBMC. The positive effects seen in patients with LADA suggest applicability to the 
setting of pre-T1D. Here, increased signalling may augment the putative anti-
inflammatory functions of adiponectin. Our working hypothesis is that this is beneficial 
in the containment of islet autoimmunity and prevention of disease. 
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6.6 Summary of findings 
 
We studied the effect of lifestyle intervention on AdipoR expression of PBMC via three 
independent, investigator-blinded controlled trials. In the Early ACTID, diabetic subjects 
in the intensive arm had a significant upregulation of both AdipoR1 & AdipoR2 gene 
expression, and these were accompanied by increases in VO2 max, fasting glucose, as 
well as improvements in insulin sensitivity. Both exercise and dietary restriction are 
likely to be important components in mediating this change. Overeating for just 1 week 
can significantly downregulate AdipoR1 expression at both gene expression and 
protein levels, whilst intensive aerobic exercise in parallel can offset, at least in part, 
the decreased expression on monocytes. In the final study, a structured program 
employing moderate intensity exercise was more effective in reducing central obesity 
and fasting insulin, and increasing AdipoR1 expression on monocytes. Taken together, 
these studies demonstrate an increase in AdipoR expression can be achieved through 
lifestyle intervention, although its impact varies according to treatment group, duration, 
exercise intensity and degree of weight loss. 
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7. EFFECT OF ADIPONECTIN ON PBMC 
PROLIFERATION AND DC FUNCTION 
 
 
7.1 Introduction 
 
As proof of concept that adiponectin can modulate autoimmune diabetes, in this 
chapter we present studies describing effects of adiponectin on the function of cells 
involved in T-cell mediated immunity.   
 
7.2 Optimisation of serum free (SF) conditions for testing effect of adiponectin 
on immune function 
 
We developed a serum free (SF) culture system for assessing T cell proliferation to 
mitogens and antigens, as well as the transformation of DC from monocytes. FCS 
contains biologically active adiponectin (Wang, Lu et al. 2004). Given its high 
concentration in serum, the standard practice of 10% supplementation would result in 
the presence of adiponectin at 1-2 ug ml-1 in the complete media of control 
experiments. In addition, its constituents are largely unknown and the presentation of 
bystander antigens in FCS during DC maturation may affect interpretation of their 
antigen-specific effects on T cells (Lutz, Rößner 2008). There can also be  
batch-to-batch differences in FCS contributing to significant interculture variations 
(Witte, Kincade et al. 1986). Our methodology therefore has benefits in standardising 
culture conditions, and allows testing of exogenous adiponectin at physiological doses. 
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After verifying that the SF media contain no significant adiponectin as per 
manufacturer‟s disclosure (fig 7.1), we compared its efficacy in supporting proliferation 
of PBMC with serum based complete media. To ensure specificity in the enumeration 
of proliferating T cells to tetanus toxoid (TTC), we gated for cells that were PI negative, 
CD3 positive, CFSE dim, and increasing in CD25 expression (IL-2 receptor) and 
forward scatter in successive generations (fig 7.2). Derived from ratio CFSE dim cells 
under stimulation against unstimulated control, the stimulation indices (SI) of PBMC 
cultured in the two media with PHA (fig 7.3), PPD and TTC (fig 7.4) were similar. We 
confirmed that the level of proliferation in SF media was optimal by demonstrating no 
further increase in SI upon addition of 1% FCS (fig 7.5).   
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A   B   C   D   E  F   G   H   I  J   K 
Immunblot for adiponectin in cellgro SCGM (predicted Mr = 
30kDa) in cellgro SCGM media. A: recombinant adiponectin at 
0.01ug. B to J, 1 in 2 serial dilutions of cellgro media. K: human 
serum (diluted 1 in 100 in PBS). 
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Figure 7.2: Example gating for enumerating proliferating T cells to TTC. This population is 
first gated according to scatter (A) and propidium iodide staining (B), followed by the 
simultaneous gain in forward scatter and loss in CFSE fluorescence (C). Proliferating T cells are 
then identified by CD3 and CD25 (IL-2 receptor) staining. Numbers denote percentage 
frequencies of gated cells.   
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Figure 7.3: comparison of cellgro SCGM (A) vs serum based system (B) (RPMI + 10% 
human AB- serum) in whole PBMC culture stimulated by PHA. Gate denotes percentage of 
proliferating cells.
Figure 7.4: comparison of cellgro SCGM (D,E,F) vs serum based media (A,B,C) in whole 
PBMC cultures stimulated by the antigens purified protein derivative (PPD) (B&E) and TTC 
(C&E). Quadrant gates were set against undivided cells and APC isotype control (A&D), such 
that cells in top left quadrant are proliferating T cells proliferating. SI of PBMC for PPD and TT 
in serum based media are 2.5 ((10.2 + 5.86)/6.46) and 1.9; corresponding values in SF media 
are 5.8 and 4.8.
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Figure 7.5: Effect of adding 1% FCS to cellgro SCGM in whole PBMC cultures. (A-C) 
cellgro media alone (D-F) addition of 1% FCS. (A,D) unstimulated (B,E) tetanus toxoid at 
3ug/ml (C&F) PHA at 3 ug/ml. SI in cellgro SCGM alone, TTC 2.32 ((4.7+7.68)/(1.85+3.47)), 
PHA 15.2; addition of 1% FCS, TTC 2.6, PHA 10.1.
Figure 7.6: Titrating PHA dose in for PBMC stimulation in cellgro SCGM. (A) 
3ug/ml (B) 5ug/ml (C) 10ug/ml. Gate denotes percentage of CD3+ cells that are 
CFSEdim after 3 days of culture. 
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Further optimisations were performed regarding the dose of mitogen stimulation and 
the duration of TTC culture. We found PHA at 3ug ml-1 to be the lowest dose producing 
consistent T cell proliferation at 3 days (fig 7.6). It had previously been reported that SI 
to TTC in a CFSE proliferation assay in serum based culture was maximal on day 10 
(Mannering, Morris et al. 2003). In our system we found that SI were comparable 
between days 7 & 10 (fig 7.7).  
 
Commercially available adiponectin had been reported to contain significant endotoxin 
contamination (Turner, Smolinska et al. 2009), in the order of 2-5%. This may be 
attributable to its binding avidity to LPS (Peake, Shen et al. 2006). We tested for this 
possibility with our batch of adiponectin by culturing with CFSE labelled PBMC (fig 7.8) 
and found no significant increase in SI compared to background. Spiking SF cultures 
with LPS at 0.1ug ml-1 (equivalent to a 1% contamination of 10ug adiponectin dose), 
produced marked proliferation of PBMC at 3 days and this response was ameliorated 
by the LPS antagonist polymyxin B.  
 
Lastly, we confirmed monocyte derived DC (mDC) could be effectively generated from 
CD14+ monocytes in SF media under the influence of GM-CSF and IL-4 (fig 7.9). The 
cells after 5 days of culture had an immature DC phenotype, with a modest increase in 
CD80 and CD86, and were positive for DC-SIGN but negative for the mature DC 
marker CD83. As will be demonstrated in a subsequent section, they are functionally 
effective in stimulating T cells in the presence of antigen (TTC) and anti-CD3 antibody 
(OKT3) (figs 7.21 & 7.22). Compared to DC generated in serum-based media, 
expression of the co-stimulatory ligands CD80, CD86, DC-SIGN and the antigen 
presenting molecule HLA-DR were similar (fig 7.10). However, the yield of CD1a 
positive DC in SF culture was lower (92 vs 65% n=3 p<0.05).  
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Figure 7.7: Changes in SI of 
whole PBMC to TTC with time. 
Gates represent percentage of 
CFSE -dim proliferating cells on 
day 7 (A) and day 10 (E). 
Respective background counts 
are shown in B & F. Stimulation 
index is the ratio of proliferating 
cells exposed by antigen relative 
to the unstimulated control. On 
day 7 this is 8.7 (11.7/1.35) and 
on day 10 this is 6.0 (21.8/3.61). 
On day 7 (C), approximately 70% 
(16.1/(16.1+6.88)) of proliferating 
cells are CD3+ T cells. D is the 
no antigen control for C.  
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Figure 7.8 Testing for LPS contamination in the recombinant adiponectin used. A. To mimic 
1% contamination of recombinant adiponectin, LPS at 0.1 ug ml-1 was added to CFSE labelled 
whole PBMC. On day 7, 88% of cells had undergone division (CFSE low). In particular, up to 75% of 
CD4+ T cells had proliferated. B. CD4+ T cells did not proliferate in response to LPS if CD14+ 
monocytes were magnetically depleted (C) using anti-CD14 microbeads and MS columns. D. The 
positive fraction from the same sort after a single passage, showing purity of CD14+ cells to be at 
91.8%. E. The proliferation of CD4+ T cells to LPS was antagonised by the addition of polymyxin B 
(10 ug ml-1). F. Adiponectin at 10 ug ml-1 did not stimulate whole PBMC above background. 
Alternatives to a cell based system for LPS contamination include the in vitro Limulus amoebocyte
lysate (LAL) assay and the in vivo rabbit pyrogen test. The LAL test is based on the coagulation of 
blood cells from the horseshoe crab upon LPS contact. 
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Figure 7.9: Transformation of CD14+ monocytes to mDC in Cellgro DC media. Positively selected 
CD14+ cells (A) with low CD1a (C) and DC SIGN expression (E) were cultured in the presence of GM-
CSF and IL-4 for 5 days. The yield of mDC are deficient in CD14 expression (A). In keeping with their 
immature phenotype, they are also low in CD80 (A) and CD83 (F) expression, whilst acquiring DC-SIGN 
(F) and CD86 (D). About 60% of these are also CD1a positive.
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Figure 7.10.  Comparison of mDC (day 6) grown in  serum based media (A,C,E) 
(RPMI + 10% FCS) vs Cellgro DC (B,D,F).
Numbers denote percentage frequency of gated cells and quadrants defined against 
isotype control. mDC grown in cellgro DC are lower in their expression of CD80 and 
CD1a (A & B), whilst levels of DC SIGN, HLA-DR and CD86 are similar (C – F).  
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7.3 Adiponectin decreases T cell proliferation in healthy subjects 
 
We modelled T cell immunity using PBMC responses to PHA and tetanus toxoid (TTC). 
TTC is a recall antigen to most young adults because of the UK immunisation 
schedule. We tested the effect of adiponectin by comparing SI with and without its 
addition (figs 7.11a & 7.11b) from the same subject. Over 8 healthy subjects, we found 
a physiological dose of adiponectin of 10ug ml-1 has a modest but significant effect in 
dampening PHA-stimulated T cell proliferation (mean change in SI = -9.5%, p < 0.05). 
More impressive is the reduction in SI by adiponectin in the TTC assay (figs 7.12a & 
7.12b; mean suppression in SI = 46.9%, p < 0.01).  
 
We next investigated the cellular mechanism of this reduced T cell stimulation. 
Adiponectin has been described to cause growth inhibition by promoting apoptosis in 
human cell lines (Yokota, Oritani et al. 2000, Dieudonne, Bussiere et al. 2006, Cong, 
Gasser et al. 2007, Konturek, Burnat et al. 2008, Bråkenhielm, Veitonmäki et al. 2004) 
We found that the proportion of cells staining for annexin V, a marker for early 
apoptosis, was significantly increased with adiponectin replacement (figs 7.13 & 7.14) 
in TTC and PHA stimulated cultures.  
 
Our expression analysis of AdipoR had shown sparse distribution on resting and 
activated T cells. On this basis, we predicted the effect of adiponectin on dampening T 
cell immunity to be mediated via accessory cells. Tregs are potent suppressors of T 
cell proliferation. We found that the proportion of CD4+CD25high cells, which include the 
Treg subset, was increased with adiponectin replacement over 48 hours (fig 7.15), in a 
dose-dependent manner.  
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Figure 7.11b: Reduction in stimulation index of CD4+ T cells by adiponectin
when whole PBMC are stimulated by PHA (3ug/ml) (n=8). Mean reduction = 
9.5% p = 0.0476 by paired t-test.
Figure 7.11a: Representative experiment showing reduction in proliferation of 
CD4 T cells (A) by adiponectin when whole PBMC are stimulated by PHA (B).  
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Figure 7.12a: Representative experiment showing reduction in proliferation of CD3+ T 
cells (A) by adiponectin when whole PBMC are stimulated by tetanus toxoid (B). SI 
without adiponectin is 19.7/2.42 = 8.14; SI with adiponectin = 12/2.42 = 4.96. 
Figure 7.12b: Adiponectin suppresses proliferation of TTC stimulated CD3 T cells 
(n=8) in healthy controls . Mean suppression is 46.9% p = 0.0085, by two tailed paired 
t-test.
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Figure 7.13: Adiponectin promotes apoptosis of PBMC during culture with TTC 
and PHA. Bars represent percentage cells staining positive for annexin V, relative to 
isotype. Cells staining positive for propidium iodide were excluded. Representative 
samples. 
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Figure 7.14: Adiponectin is pro-apoptotic. Whole PBMC stimulated by TTC and PHA 
had a higher proportion of annexin V positive, PI-ve cells when adiponectin in present.
**  p <0.01 by Bonferroni's post-test correction for multiple testing.
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Figure 7.15: Adiponectin increases CD4+CD25high cells. Whole PBMC were cultured in 
serum free media with adiponectin added back at 0 (A), 1(B), 2(C), 5(D), and 10ug/ml(E). 
CD4+CD25+ counts as a percentage of lymphocytes were assessed on day 2. (below) 
summary of experiments (8) with PBMC from 3 donors showing a significant positive 
correlation. 
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7.4 Adiponectin decreases dendritic cell function  
 
Monocytes are also important in regulating the T cell responses studied. The induction 
of T cell proliferation by PHA in whole PBMC is monocyte-dependent. They also serve 
as APC for the antigen mediated T cell responses (Randolph, Jakubzick et al. 2008). 
Because monocytes express the highest level of AdipoR, we wanted to determine the 
effect of adiponectin on APC function. We chose the most potent monocyte derived 
APC, the DC.  
 
7.4.1 Adiponectin decreases expression of CD86 on mDC 
 
CD86 on APC is a ligand to CD28 on T cells and provides the critical secondary signal 
for T cell activation (Salomon, Bluestone 2001, Greenwald, Freeman et al. 2005).  
Adiponectin replacement at 10ug ml-1 to the SF generation of mDC resulted in a 
significant reduction of CD86 at both protein and mRNA levels by approximately 50-
70% (fig 7.16). On FACS, the reduction of CD86 occurred in both CD1a positive and 
CD1a negative DC. Expression of HLA-DR, CD80, and DC-SIGN was similar between 
adiponectin treated DC and their control (Table 7.1 and figs 7.17, 7.26). The proportion 
of CD1a positive DC was also unchanged. 
 Ratio MFI  
Adiponectin DC: control DC  
CD1a 1.02 ± 0.21 
CD86  0.40 ± 0.11** 
CD80 1.00 ± 0.20 
HLA-DR 1.09 ± 0.20 
Table 7.1: MFI of DC surface markers of adiponectin treated DC relative to control in 10 
normal weight healthy subjects. Ratio expressed as mean ± SD.  
** p < 0.0001 by one sample two-tailed t-test against inferential mean of 1.0 (no change)  
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Figure 7.16: Adiponectin suppresses the upregulation of CD86 during 
transformation of monocytes to DC. This is demonostrated at the protein level by 
FACS (above) and at the RNA level by qPCR (below). Significant reduction in CD86 RNA 
levels in adiponectin treated mDC (n=5). Error bars represent SD of fold change, which is 
calculated by Ct method. 
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Figure 7.17: Effect of adiponectin on costimulatory molecules of DC. (A) A significant 
reduction in CD86 is seen DC SIGN positive DC (red – adiponectin treated DC, blue – control; 
numbers in legend denote CD86 MFI. In comparison, the change in CD80 (B) and HLA-DR (C-
control; D- adiponectin-treated DC) is marginal. The reduction in CD86 expression is seen on 
both CD1a+ and CD1a- DC (E- control, F-adiponectin treated DC).
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We followed the kinetics of the CD86 downregulation by adiponectin in time course 
experiments (fig 7.18, n=5). The ratio of CD86 MFI on CD1a positive cells of 
adiponectin treated DC to its negative control was 0.45 ± 0.09 at 0 hours. This was not 
significantly different to 6 hours (0.69 ± 0.06). However, this difference was completely 
abolished when adiponectin was added at 18 and 24 hours.  
 
We discovered also that the inhibition of CD86 expression upon adiponectin 
replacement was dose-dependent and followed sigmoidal dose-response modelling (fig 
7.19). It was overcome by the addition of LPS to DC, following transformation to mature 
DC phenotype (fig 7.20)  
 
7.4.2  Adiponectin reduces mDC stimulated T cell proliferation    
 
We next asked whether the inhibition of CD86 on DC by adiponectin translated to 
changes in stimulatory capacity. The synapsing of CD86 to CD28 and CTLA-4 on 
CD4+CD25high Tregs is essential in the initiation maintenance of their immunoregulatory 
function (Salomon, Lenschow et al. 2000, Zheng, Manzotti et al. 2004). In our system 
however, this would complicate the interpretation of overall T cell proliferation as a 
measure of DC stimulation capacity. For this reason, we sorted responder cells 
according to the phenotype CD4+CD25-. We compared stimulatory capacity in two 
CFSE-based assays, using (1) autogeneic responder cells with TTC, and (2) allogeneic 
responder cells with OKT3 antibody. We found that adiponectin treatment of mDC 
reduced T cell proliferation by an average of 43.2% with TTC (three donors, see fig 
7.21), and 39.4% with OKT3 (5 donors, fig 7.22). 
 191  
0h 6h 18h 24h
0.0
0.5
1.0
time adiponectin 10ug added
C
D
8
6
 M
F
I 
re
la
ti
v
e
to
 u
n
tr
e
a
te
d
CD86 FitC
0
20
40
60
80
100
%
 o
f 
M
a
x
no adiponectin
0h
6h
18h
Figure 7.18: Time course of the CD86 suppression on DC by 
adiponectin. Adiponectin at 10ug/ml were added to cultures at 0, 6, 18 
and 24h. (top) Histograms of CD86 expression on CD1a+ DC at the 
different timepoints. (bottom) Summary of 5 experiments  demonstrating 
the effect of CD86 suppression occurred within 18h. CD86 MFI was
standardised against untreated DC from the the same subject.
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Figure 7.19: Reduction of CD86 expression on mDC by adiponectin is dose 
dependent. (top) Adiponectin at 0,1,2,5 & 10ug/ml was added at the beginning of 
culture. (bottom) Dose response curve derived from 3 independent experiments and 
fitted using standard log(inhibitor) vs response model*. IC50 (dose of adiponectin
eliciting 50% inhibition) is shown at 95% CI. 
*Y=Bottom + (Top-Bottom)/(1+10^((X-LogIC50))) .     
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Figure 7.20: LPS overcomes inhibition of CD86 expression on DC by adiponectin.
CD83 is a marker of mature DC. mDC harvested on day 5 have an immature phenotype 
(A). Q DC (C) have significantly lower CD86 expression compared to control DC (B). DC 
harvested one day after addition of LPS are high on CD83 expression (D). Both control 
DC (E) and Q DC (F) have increased and comparable expression of CD86. 
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Figure 7.21: Adiponectin treated DC (Q DC) have reduced stimulatory capacity 
compared to DC grown in its absence (control DC). Both Q DC and control DC were 
washed twice in cold PBS after harvest and then co-cultured with effector
CFSE+CD4CD25- T cells and tetanus toxoid (TTC). (top) representative example, gate 
represents frequency of CFSE dim, CD25+ cells. 
* p < 0.05 by Bonferroni's Multiple Comparison Test.
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7.5 Suppression of DC function by adiponectin is released in T1D 
 
We then asked whether the effects of adiponectin on PBMC responses and DC 
function would be altered in T1D because of the reduction in AdipoR expression. We 
show this to be the case in a number of ways.  
 
Firstly and most directly, there is a trend for reduced mDC stimulation of T cell 
proliferation in T1D (n=5), compared to non-diabetic controls (n=5) (figs 7.22 & 7.23) 
(HC = 39.4%, T1D = 9.6% p = 0.0556).  
 
Secondly the reduction of PBMC proliferation to TTC by adiponectin is significantly 
reduced in T1D (fig 7.24 ) compared to HC (mean reduction in SI, HC = 47 (n=8) vs 
T1D = 26% (n=4) p<0.05).  
 
Furthermore, the dose response curve of CD86 inhibition on mDC with adiponectin 
replacement in T1D is consistent with the effect of reduced AdipoR expression and not 
changes in agonist-receptor kinetics (fig 7.25). Maximal inhibition of CD86 was reduced 
(T1D: -61% HC: -71% p<0.05), whilst no significant change in IC50 was seen (95% CI: 
T1D = 0.6 - 2.1; HC =1.3-1.9).  
 
In attributing the release of adiponectin-mediated suppression of APC driven T cell 
proliferation in T1D as the result of reduced AdipoR, we compared the degree of CD86 
inhibition on mDC by adiponectin to the expression of AdipoR on precursor monocytes 
in healthy and T1D individuals. The same dose of adiponectin replacement at 10ug/ml 
was used at the start of culture. We justified not adding adiponectin in the re-feeding 
media on day 2 from findings in our time course experiment. We recruited T1D subjects 
(n=11) whose clinical features predicted low monocytic AdipoR expression. 
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Consequently, they had features of insulin resistance (mean HbA1C 8.5 ± 0.8, 
presence of hypertension and WHR 0.85 ± 0.08), presence of vascular complications 
(8 / 11), and were older than our healthy controls (HC – mean age: 28 ± 4; T1D: 35 ± 
7).  
 
Our T1D subjects had lower AdipoR1 expression approaching significance (MFI 
AdipoR1 T1D: 35.5 ± 5.3; HC 62.8 ± 13.0, p = 0.0579) but AdipoR2 expression levels 
were not significantly different (T1D = 33.4 ± 4.0, HC 51.7 ± 12.3 p = 0.190) (fig 7.26). 
Similar yields of CD1a positive DC were achieved at the end of culture in both groups, 
with or without adiponectin (HC 39.3 ± 5.0%, T1D 43.8 ± 5.5%). Importantly, we found 
that the degree of CD86 inhibition on mDC in T1D was significantly reduced (HC = -
60.0 ± 3.0%; T1D = -40.8 ± 5.8%, p = 0.011), whilst expression of HLA-DR and CD80 
was unchanged (figs 7.27a & 7.27b).  
 
Consistent with our hypothesis that AdipoR signalling mediates CD86 expression on 
mDC (fig 7.28), AdipoR1 expression on CD14+ precursors negatively correlated with 
the degree of CD86 inhibition with adiponectin replacement (r = -0.53, p = 0.013). The 
correlation between AdipoR2 expression with adiponectin-mediated CD86 inhibition 
was not significant (r=-0.411 p=0.064). Changes in HLA-DR and CD80 expression did 
not appear to be associated with AdipoR expression (figure 7.29). We had previously 
shown AdipoR1 & AdipoR2 expression was unaffected by adiponectin replacement in 
SF media, thus excluding its possible confounding influence on our results (fig 5.11). 
 197  
Event Count: 20868
CFSE
0
200
400
600
#
 C
e
lls
61.8
Event Count: 21276
CFSE
0
200
400
600
#
 C
e
lls
82.9
Event Count: 21298
CFSE
0
100
200
300
400
500
#
 C
e
lls
76.9
Event Count: 21173
CFSE
0
100
200
300
400
500
#
 C
e
lls
74.5
CD86 FitC
0
20
40
60
80
100
%
 o
f 
M
a
x
CD86 FitC
0
20
40
60
80
100
%
 o
f 
M
a
x
Event Count: 1304
AdipoR1
C
D
1
4
 P
E
Event Count: 956
AdipoR1
C
D
1
4
 P
E
A
HGFE
DCB
0
20
40
60
80
100
Subject 1
Subject 2
*
  -        +        -        +        +         -        +        +
  -        -        +        +        -         +        +        -
  -        -         -        -         +         -        -         +
OKT3
control DC
adiponectin DC
%
 C
F
S
E
 d
im
 c
e
ll
s
Figure 7.22: The reduced stimulatory capacity of Q DC is related to the degree of CD86 
suppression. Subject 1 (A) had higher AdipoR1 expression on CD14 precursor cells compared to 
subject 2 (E), who has T1D. The suppression of CD86 by the same 10ug ml-1 adiponectin is greater (Q 
DC –red histogram, control DC- blue) on subject 1 (C) compared to 2 (F). The stimulatory capacity of the 
DC were tested in co-cultures with CFSE+CD4+CD25- effector cells. Bar indicates % of divided cells, In 
HC, Q DC stimulated fewer cells to proliferate (D) compared to control DC (C). In contrast, the difference 
between Q DC (H) versus control DC (G) in the T1D subject is marginal. (Bottom) summary of replicates 
for these two subjects. The difference in stimulatory capacity between control DC and Q DC, as a 
percentage, is 29.8 for subject 1, and 3.8% for subject 2.
* p = 0.0105 by Bonferroni‟s post-test  
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Figure 7.23: Stimulatory capacity of Q DC in T1D (Above) The difference in number of 
CFSEdim cells stimulated by Q DC and their paired unntreated control  is expressed as 
percentage reduction. The non-parametric Mann Whitney U test was used for significance testing
(Below) Example CFSE dilution plots from 4 more subjects. Blue histogram denotes control DC, 
grey filled histogram denotes Q DC. Event counts shown
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Figure 7.24: Reduced 
suppression of TTC driven T cell 
proliferation by adiponectin in 
T1D. (A) Similar to HC, there is 
reduced SI when adiponectin is 
replaced in serum free media at 10 
ug/ml (Q10). (B) Th mean reduction 
in SI in T1D 26%, compared to 
47% in HC p = 0.0464. (C) Data 
from a T1D subject (depicted in the 
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Figure 7.25: dose response curve of CD86 suppression on mDC in T1D (n = 3) (above). Error bars 
denote SD. IC50 was not significantly different compared to HC, although the level maximum inhibition was 
less than that seen with HC. (below) representative example from one donor. CD14+ monocytes were 
incubated with 0 (A), 1(B), 2(C) and 10ug/ml (D). Numbers denote percentage frequencies of quadrant 
gates, defined by isotype. 
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Figure 7.26: AdipoR expression of CD14+ precursors from HC (n=10) and 
T1D subjects (n=11). Subjects with T1D were chosen based on the prediction 
that their monocytes would have reduced AdipoR expression (older age and 
presence of vascular complications). There was a non-significant trend of 
reduced AdipoR1 expression (p = 0.06), whilst expression of AdipoR2 was not 
significantly different (p = 0.19).  
 202  
0.0
0.5
1.0
1.5
 CD86  CD80  HLA-DR
  *
Healthy control
T1D
M
F
I 
a
d
ip
o
n
e
c
ti
n
: 
M
F
I 
c
o
n
tr
o
l
Figure 7.27a. Effect of adiponectin on the expression of co-
stimulatory and antigen presenting molecules on mDC in 
T1D. MFI of CD80, CD86 and HLA-DR on mDC following 
adiponectin treatment is expressed as a ratio of MFI on control 
mDC from the same subject. Error bars denote SEM.
* p = 0.011 
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Figure 7.27b. Example raw data. ATa11 (A & B) is a HC and DFr12 is a 
T1D subject (C & D). The ratio of CD86 expression on Q DC relative to its 
control is 8.58/42.2 = 0.20 in ATa11 and 0.83 in DFr12. 
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Figure 7.28: correlation of AdipoR1 expression with the reduction of 
CD86 expression of mDC following adiponectin treatment. All subjects 
(HC and T1D) were included for this analysis.
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Figure 7.29: Absence of significant correlation between AdipoR1 expression of CD14+ 
precursors and expression of HLA-DR (bottom) and CD80 (top) following adiponectin
treatment.
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 7.6 Discussion 
 
Adiponectin has previously been shown to modulate cytokine secretion of 
macrophages, T cells and their recruitment to inflammatory loci (Wolf, Wolf et al. 2004, 
Okamoto, Folco et al. 2008, Palmer, Hampartzoumian et al. 2008). In this chapter, we 
present novel data describing its dampening effects on APC-dependent T cell 
immunity. Adiponectin treated DC had reduced CD86 expression and stimulatory 
capacity on T cells. This function appears to be diminished in T1D, resulting in 
relatively preserved CD86 expression despite equivalent adiponectin replacement. 
Reduced AdipoR expression of precursor monocytes in T1D may explain the 
difference, given the significant negative correlation between AdipoR1 expression and 
the degree of CD86 suppression on mDC.   
Our in vitro tests were performed in SF conditions and with recombinant human 
adiponectin that can mimic physiological oligomeric distribution. We believe these 
factors explain the apparent disagreement between our findings and that of Wolf et al, 
who reported that despite treatment with adiponectin at 20ug/ml, no changes of 
monocyte derived DC phenotype or function were detected (Wolf, Wolf et al. 2004). In 
that paper, FCS was added at 10%, without prior removal of bovine adiponectin by 
affinity columns (Luo, Guo et al. 2005). As a result, we believed that the “negative 
control” experiments for mDC phenotype were conducted with active adiponectin levels 
close to the IC50 values of 1-2 ug/ml we had determined in SF conditions. Clearly, this 
would obscure any potential changes, whereas the improved sensitivity in our SF 
system allowed significant differences to be detected with physiological adiponectin 
replacement. Furthermore, the source of adiponectin used by Wolf et al was not 
disclosed in their paper. Variations in biological function of recombinant adiponectin 
have been reported because of differences in host species, ability to form high 
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molecular weight oligomers and LPS contamination (Richards, Stephens et al. 2006, 
Neumeier, Weigert et al. 2006, Turner, Smolinska et al. 2009). The adiponectin 
sourced (Alexis, Cat #: ALX-522-063) was derived from mammalian HEK cells and can 
form high molecular oligomers analogous to the circulating distribution (manufacturer‟s 
product information sheet). An independent group had reported that adiponectin can 
contain significant LPS contamination if used at ug ml-1, contrary to manufacturer‟s 
internal validations (Turner, Smolinska et al. 2009). However, we believe that this was 
not a factor in influencing our findings given that cultures spiked with LPS had opposing 
effects to that of adiponectin. 
We found the suppression of T cell proliferation by adiponectin in whole PBMC assays 
to be moderate with TTC ( 50%) and modest with PHA ( 10%). This is in keeping with 
the degree of monocyte participation in each reaction. We expected monocytes to be 
the main effector of adiponectin-mediated immunomodulation, given that they have 
highest receptor expression among all PBMC. Monocyte helper activity is critical for the 
initial activation of T cells by PHA stimulation (de Vries Caviles et al. 1979). Both cell 
contact and monocytic secretion of cytokines such as IL-1 and IL-6 are thought to be 
important in the induction of IL-2 and IL-2 receptor expression (Ceuppens, Baroja et al. 
1988, Wakasugi, Bertoglio et al. 1985, Williams, Ransil et al. 1984, Manger, Weiss et 
al. 1985). After which, propagation of activated T cells escapes monocytic modulation 
(Manger, Weiss et al. 1985) and here we had expected adiponectin to have only 
modest effect given their relative paucity of AdipoR expression. In TTC stimulation, 
monocytes function as APC.  
 
Our data indicate the effect of adiponectin on APC function, lymphocyte apoptosis and 
Treg induction may contribute to the overall dampening of antigen driven T cell 
immunity. Our finding that adiponectin increases lymphocyte apoptosis is consistent 
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with its effects on cell lines (Yokota, Oritani et al. 2000, Dieudonne, Bussiere et al. 
2006, Cong, Gasser et al. 2007, Konturek, Burnat et al. 2008, Bråkenhielm, Veitonmäki 
et al. 2004).  There is however lack of consensus in these studies regarding a common 
molecular mechanism. The demonstration of increased apoptosis of activated T cells 
with adiponectin in experiments of PHA stimulation suggests AdipoR signalling is not a 
requirement.  
 
In vitro and ex vivo expansion of the CD4+CD25high Treg has been proposed as means 
of immunotherapy (Tang, Henriksen et al. 2004, Peters, Hilbrands et al. 2008). We 
have shown adiponectin increases their proportion in whole PBMC culture in a dose 
dependent manner. This is consistent with recent studies demonstrating an in vivo role 
of adipose tissue in negatively regulating resident Treg numbers (Feuerer, Herrero et 
al. 2009, Winer, Chan et al. 2009). Furthermore, other adipokines, such as leptin, have 
also been shown to have similarly potent, albeit opposite effects (De Rosa, Procaccini 
et al. 2007).  
 
We studied the effect of adiponectin on APC function using the mDC. Impressively, 
relatively physiological doses of adiponectin replacement brought a significant 
reduction in CD86 expression. This effect was dose-dependent, occurred within 18 
hours of culture, reversible with LPS, and correlated with AdipoR1 expression on 
precursor monocytes. This data is consistent with a model of adiponectin, possibly via 
AdipoR1, in modulating CD86 expression. We believe the absence of significant 
change in other co-stimulatory markers excludes the effect on CD86 expression as a 
consequence of a global inhibition on DC maturation, in contrast to another example of 
a humoral factor, vitamin D (Griffin, Lutz et al. 2001, Penna, Adorini 2000). Indeed 
adiponectin treated mDC were able to antigen present TTC to stimulate responder 
cells, at a level well above that of the no antigen control. In the same co-culture 
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experiments we demonstrated lone CD86 suppression on DC resulted in reduced 
stimulatory capacity. This is in agreement with other in vitro studies (Lanier, O'Fallon et 
al. 1995, McLellan, Starling et al. 1995).  
 
In contrast, AdipoR2 expression on monocytes did not follow the inverse correlation 
AdipoR1 had with CD86 inhibition on mDC. Our previous data had shown the 
expression of the two receptor isotypes on PBMC to be interrelated and co-regulated 
by insulin sensitivity. However, AdipoR1 and AdipoR2 may have distinct functions. 
Consistent with this are the differences in downstream signalling pathways. For 
example in the liver, AdipoR1 activates AMP kinase whilst AdipoR2 activates PPAR  
(Yamauchi, Nio et al. 2007). In immune cells, signal transduction via AMP kinase and 
p38 MAP kinase is important in mediating function (Tang, Chiu et al. 2007, Wolf, Wolf 
et al. 2004, Crawford, Peake et al. 2010), and the triggering of these secondary 
messengers is attributable to AdipoR1, and not AdipoR2 (Tang, Chiu et al. 2007). The 
molecular basis for specificity lies in interaction between AdipoR1 with the endoplasmic 
reticular protein ERp46 (Charlton, Webster et al., 2010). Thus, it is biologically 
plausible that AdipoR1 is more important in suppressing CD86 expression on mDC and 
hence the stronger association.  
 
Following our clinical study, we wanted to define the functional significance of the 
reduced AdipoR expression in T1D. Accepting the borderline significant reduction in 
AdipoR1 expression for this new cohort, our data imply that in T1D, there is a partial 
release from the inhibitory effects of adiponectin. In other words, there is greater T cell 
proliferation than expected for the same dose of adiponectin compared to healthy 
individuals. Further studies are needed to define the pathologic importance of these in 
vitro effects in T1D.   
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Collectively, these studies demonstrate the potential for adiponectin to modulate T cell 
immunity. We recognised the case for causation and AdipoR mediation would be 
strengthened if the observed responses were abrogated by inhibitors of adiponectin 
signalling. We had attempted the adiponectin and mDC phenotype experiments using 
our existing stock of anti-adiponectin, and anti-AdipoR1/R2 antibodies, but saw no 
significant change. We believed further optimisations would be required regarding the 
choice of neutralising antibodies. The indicated use for our anti-adiponectin antibody 
was immunoblotting, as such it would be raised to recognise solubilised proteins. 
AdipoR1 & AdipoR2 receptors have recently been shown to undergo endocytic cycling 
between cell surface and endoplasmic reticulum by clathrin and Rab-5 dependent 
pathways (Ding, Wang et al. 2009). Blocking antibodies may thus only have short-lived 
effects during cell culture.  
 
Ideally, we would also test the function of mDC from T1D in a TTC assay to confirm the 
changes seen with OKT3. However, antigen based mDC tests would require 
autogeneic responder cells and our attempts to re-stimulate after 5 days in culture were 
not successful. In the OKT3 assay, fresh allogeneic responder cells were used. 
 
We accept also that as memory T cells were not depleted from our responders, some 
of their proliferation in the mDC stimulation assay with TTC would have occurred 
independently of APC. In defence, the percentage of divided cells from the responder 
cells and TTC only experiment was well below that of mDC and responder cells with no 
antigen. Hence we concluded that APC-independent activation was not a significant 
contributor to background proliferation levels used to derive SI.  
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7.7 Summary of results 
 
 
We demonstrate adiponectin dampened T cell proliferative response to mitogens and 
antigens in an optimised serum free CFSE-based assay. The expansion of the 
CD4+CD25high subset and the promotion of apoptosis upon adiponectin replacement 
may contribute. In addition, adiponectin can modulate the phenotype and stimulatory 
function of monocyte derived DC, by downregulating expression of CD86. This 
inhibitory effect on CD86 was dose dependent, occurred within 18 hours of culture and 
correlated with AdipoR1 expression on monocyte precursors. The expression of other 
costimulatory molecules (HLA-DR, DC SIGN, CD80 and CD1a) were unaffected. The 
reduced expression of AdipoR in T1D may be functionally relevant, given that immune 
cells were released from the inhibitory effects of adiponectin replacement.   
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8. DISCUSSION AND CONCLUSIONS 
 
8.1 Summary of key findings and a model for adiponectin in T1D 
 
I have shown that AdipoR1 and AdipoR2 are expressed by peripheral blood myeloid 
cells, and that the level of expression of these receptors modulates T cell proliferation 
through adiponectin mediated inhibition of CD86 expression. There is release of this 
suppression in T1D attributable to the reduced AdipoR expression. We found that  
receptor expression was inversely related to insulin resistance, and that intervention 
could upregulate expression.     
 
Figure 8.1 depicts these findings applied to our hypothesis. It defines a mechanism of 
how insulin sensitivity can modulate autoimmunity of T1D through adiponectin 
signalling in individuals with a predicted disease incidence of at least 20% in 10 years. 
Adiponectin synthesis by adipocytes is reduced by weight gain, and both these factors 
act in tandem to increase IR. The associated reduction of AdipoR on monocytes 
attenuates the inhibition of CD86 expression on DC exposed to adiponectin.The 
increased costimulation of CD4+ T cells favours the recruitment and maintenance of 
diabetogenic T cells. We speculate that this escape of T cell immunoregulation, in 
conjunction with other immune aberrations (Lesage, Hartley et al. 2002, Brusko, 
Wasserfall et al. 2005, Schneider, Rieck et al. 2008, Allen, Pang et al. 2009, Kukreja, 
Cost et al. 2002), predisposes the breakdown of peripheral tolerance in T1D and 
hastens the development of diabetes. CD86 expression on APC has a critical role in 
priming of diabetogenic CD4+ T cells and its knockout in the NOD mouse is effective in 
preventing diabetes (Yadav, Judkowski et al. 2004). However, the effect of CD86 , and 
hence that of adiponectin, is not antigen specific. Nevertheless, as LPS can override 
 213  
the inhibitory effects of adiponectin, I believe this system would not lead to a state of 
immunocompromise.  
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monocytes
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CD4 T cell (+)
(+) Autoreactive
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Acceleration of 
islet autoimmunity 
and development 
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Figure 8.1 Summary diagram for the putative role of adiponectin signalling in 
immune tolerance of T1D. See sections 8.1 & 8.3 for commentary. 
8.2 Critique of key findings 
 
There are several weaknesses to our studies. Firstly, the quantification of AdipoR 
expression on PBMC by flow cytometry had a high intra-assay CV (up to 14%). As 
such, it could be prone to type 2 (false negative) errors. Therefore the findings of 
neutral effect of glucose, insulin and adiponectin on AdipoR expression in vitro need 
further validation, particularly since conflicting animal model data exists (Tsuchida, 
Yamauchi et al. 2004, Bauche, Ait El Mkadem et al. 2006). Furthermore from our own 
clinical study, adiponectin had a significant but modest inverse correlation with 
AdipoR1 and AdipoR2 expression when examined across all subjects (T1D and 
controls). Secondly, the strongest evidence for insulin resistance as a modulator of 
AdipoR expression on PBMC came from data in the early ACTID. However, as 
monocytes have the highest expression of AdipoR among PBMC, a simple increase in 
relative monocyte count from lifestyle intervention could explain the apparent increase 
in AdipoR gene expression of whole PBMC in the interventional arm. Nevertheless, a 
specific effect on monocyte counts by lifestyle changes had not been reported 
(Timmerman, Flynn et al. 2008, Shephard, Shek 1994), nor observed in our two 
smaller exercise studies. Lastly, unequivocal evidence for the mediatory role of AdipoR 
on the inhibition of CD86 expression on APC is lacking. As previously outlined, 
adiponectin can exert its immune effects independently of AdipoR (Takeuchi, Adachi et 
al. 2007, Peake, Shen et al. 2006, Masaie, Oritani et al. 2007, Takemura, Ouchi et al. 
2007,). To clarify this issue, recent papers citing novel biological functions of 
adiponectin have included data describing the abrogation of effect through siRNA 
knockdown of AdipoR gene expression (Miller, Cho et al. 2009, Yamauchi, Kamon et 
al. 2003, Tang, Chiu et al. 2007, Iwabu, Yamauchi et al. 2010). In our case and as a 
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further project, similar AdipoR1 RNA interference can be achieved on CD34+ primary 
haemopoietic stem cells before their transformation to DC (Martino, di Girolamo et al. 
2009).  
 
Nevertheless, our data is consistent with what is already known about regulation of 
adiponectin receptor expression and the anti-inflammatory effects of adiponectin. We 
validated previous studies that reported mRNA of AdipoR on PBMC by showing 
expression at the protein level (Palmer, Hampartzoumian et al. 2008, Sohn, Kwak et al. 
2010, Shen, Charlesworth et al. 2007, Alberti, Gilardini et al. 2007). Similar to skeletal 
muscle and adipose tissue, the expression on PBMC is also correlated to insulin 
sensitivity and can be increased with exercise (Nannipieri, Bonotti et al. 2007, Bluher, 
Williams et al. 2007, Christiansen, Paulsen et al. 2010, O'Leary, Jorett et al. 2007). The 
reduced APC-dependent T cell proliferation fits with the reported anti-inflammatory 
effects of adiponectin in models of T cell driven hepatitis (Palmer, Hampartzoumian et 
al. 2008, Kaser, Moschen et al. 2005, Sennello, Fayad et al. 2005). As previously 
elaborated, we attributed the discrepancy between our study and that of Wolf et al 
regarding co-stimulatory molecules on APC by the differences in culture conditions 
(Wolf, Wolf et al. 2004).       
 
The functional significance of the high AdipoR expression on NK and B cells deserves 
investigation. Adiponectin may yet have further influence on disease pathogenesis, as 
these cells are known to have important accessory roles (Alba, Planas et al. 2008, 
Rodacki, Svoren et al. 2007, Brodie, Wallberg et al. 2008). In particular, B cell depletion 
by the anti-CD20 monoclonal antibody rituxamab preserves  cell function in patients 
with newly diagnosed T1D (Pescovitz, Greenbaum et al. 2009) 
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We have only studied a small number of functional readouts. The full immunoregulatory 
potential of adiponectin on APC function would be comprehensively documented using 
gene expression microarray approach. It would be intriguing to see if adiponectin 
activates the trancriptional repressor cyclic AMP response element modulator , which  
has been recently been shown to be an important and specific negative regulator of 
CD86 expression in APC (Ahlmann, Varga et al. 2009). Apart from proliferation, other 
effects of APC-CD4 interaction arising from adiponectin treatment, such as the 
development of effector phenotype and cytokine production, would also be of interest. 
The data showing an increase of CD4CD25+ proportion following adiponectin 
replacement is preliminary, and further Treg phenotype characterisation, using markers 
such as FoxP3 CTLA-4 and CD127 low which confer protection from autoimmune 
diabetes (Schmidt, Wang et al. 2009, Liu, Putnam et al. 2006, Lundsgaard, Holm et al. 
2005), should be performed. 
 
8.3 Further refinements to proposed model 
 
There are gaps in the model that require further elucidation. I have not accounted for 
how weight gain can inhibit AdipoR expression on PBMC. The level of control is likely 
to be at gene transcription, given the changes in AdipoR protein expression are also 
seen with mRNA. The AdipoR1 gene promoter region contains binding sites for ATF3 
(activating transcription factor 3) (Park, Kang et al. 2010), a negative transcriptional 
factor that is upregulated with obesity-associated ER stress. Using a mouse myotube 
model, Park et al have shown that ATF3 is a physiologically relevant regulator.   
 
The mechanism of how lifestyle interventions can modulate AdipoR expression is not 
clear. I have shown that achieving weight loss and improvements in IR are necessary 
 217  
for AdipoR expression to increase. The ATF3-AdipoR1 gene promoter interaction is 
potentially relevant as weight loss is associated with reduced ER stress and ATF3 
expression levels (Gregor, Yang et al 2009).  
 
Next, the cause for the reduced AdipoR expression in T1D, relative to HC and T2D, is 
not known. Genetic factors were unlikely to be responsible, as polymorphisms in both 
AdipoR1 and AdipoR2 genes were not found to be associated with increased incidence 
of T1D (Barrett, Clayton et al 2009). Neither was IR or hyperglycaemia, two known 
modulators of AdipoR expression matched for in the clinical study. Notwithstanding, IR 
accounted for some of the variation in AdipoR expression (figure 5.5). 
 
We propose two alternative explanations for the difference between the groups.  
The reduced AdipoR expression in T1D could be the result of inflammatory stress. We 
had found AdipoR expression to reduce with T cell activation and was inversely related 
to that of CD25 (figure 4.22). In testing this, investigating for possible correlations 
between AdipoR expression with serum levels of inflammatory cytokines, such as 
TNF , IL-6 and hsCRP, would be a useful first step.  
 
The differences in  cell function between the groups may be important. Skeletal 
muscle AdipoR1 mRNA, whose levels are correlated with those on PBMC (Shen, 
Charlesworth et al. 2007), is independently associated with first phase insulin secretion 
(Staiger, Kaltenbach et al. 2004). However, despite AdipoR expression on  cells 
(Kharroubi, Rasschaert et al. 2003), a direct facilitative role for adiponectin signalling 
on insulin secretion is controversial (Okamoto, Ohara-Imaizumi et al. 2008, Staiger, 
Stefan et al. 2005, Winzell, Nogueiras et al. 2004). Nevertheless, the corollary is that 
low AdipoR expression in our cohort of longstanding T1D would relate to the presumed 
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absence of residual endogenous insulin secretion, and vice versa in healthy controls. A 
similar inverse correlation has been described for serum adiponectin levels with fasting 
C-peptide across the spectrum of non-obese healthy controls, T2D and T1D (Furuta, 
Tamai et al. 2006, Behre, Brohall et al. 2006). Thus, to further examine the temporal 
relationship and control for genetic confounders, a study of AdipoR expression on 
stored PBMC from pre-diabetic subjects developing disease could be done. An 
analogous study from animal models of autoimmune diabetes would also be 
supportive.   
 
Whether lifestyle change, by increasing AdipoR expression, would ameliorate 
resistance to adiponectin inhibition on APC function is another area for study. CD86 
expression on mDC following adiponectin replacement would be a suitable primary 
readout. If proven, then there would a possibility that the immune sequelae of reduced 
AdipoR expression in T1D is subject to therapy. 
 
Importantly, we would need to confirm the tolerogenic effects of adiponectin at the level 
of islet autoimmunity. Our experiments of APC cocultured with effector CD4+ T cells 
could be repeated using clones reactive to  cell autoantigens (Mannering, Morris et al. 
2004). Another approach would be to look for adiponectin receptor expression by 
immunohistochemistry in pancreatic nodes of patients with T1D by 
immunohistochemistry, with non-pancreatic lymph nodes from the same subject as 
control. Suitable tissue sample could be attained from the Network for Pancreatic 
Organ Donors with diabetes (www.jdrfnpod.org), a project funded by JDRF where 
pancreatic tissue is harvested from cadaveric organ donors with T1D. 
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Although circulating adiponectin can bind to both AdipoR1 and AdipoR2, there are 
differences in signal transduction downstream to both receptors (Section 1.7.2). We 
have identified that AdipoR1 expression on precursor monocytes may be more 
important in determinng the attenuating effect on CD86 of DC (figure 7.2.8).  Thus a 
deficiency of AdipoR1 may not be simply compensated for by AdipoR2 on the same 
cell. Furthermore, we (figure 5.4) and others have found that the expression of both 
receptors appear to be under co-regulation (Staiger Kaltenbach et al 2004. Bluher, 
Williams et al. 2007. Shen, Charlesworth et al. 2007). Thus, it is unlikely under 
physiological conditions that a human subject would have reduced AdipoR1, but 
normal expression levels of AdipoR2.  
 
In summary, our data supports adiponectin to be a molecular mediator of the link 
between insulin resistance and immunity in T1D. Further investigation is merited given 
the potential application in disease prevention, preservation of  cell function in LADA, 
islet allografts and early T1D.  
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10. SUPPLEMENTARY DATA 
Appendix 1: Autofluorescence of activated T cells. Positively selected CD3+ cells 
were activated with (A) PHA or (B) CD3+CD28+ Dynabeads. After 48-72 hours, they 
were then stained using the secondary AF-488 conjugated goat antib-rabbit antibody 
only, read on the FL-1 channel. Activated cells are larger (by forward scatter) and are 
higher in expression for CD25 (C &D). They also have higher background fluroescence, 
before addition of the primary labelling adiponectin receptor antibody.
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Appendix 2: standard curve for Taqman ADIPOQ rt-qPCR assay.
Ct (Ct ADIPOQ – Ct 18S) is plotted for serial dilutions of whole 
pancreas RNA template. The plot shows that Ct for the sample is 
unaffected by dilution, thus validating the application of the Ct 
method in the calculation of relative gene expressions.
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Appendix 3: Testing normal distribution of data. We applied the one-sample Kolmogorov-
Smirnov test procedure to assess whether our FACS data, as well as serum adiponectin
values, conform to Gaussian distribution. In this test, a p value of <0.05 indicates the observed 
distribution does not follow normality. Our data, allR1 (MFI AdipoR1 on all cells), lymphR1 
(MFI AdipoR1 on lymphocytes), monoR1 (MFI AdipoR1 on monocytes), allR2, lymphR2, 
monoR2 and adiponectin (serum adiponectin by ELISA) passed this test, thus validating the 
subsequent application of ANOVA testing for group differences.
One-Sample Kolmogorov-Smirnov Test
76 76 76 76 76 76 76
3.4877 3.0402 28.6487 2.9791 2.7492 21.6690 7.1469
2.14489 2.08204 18.66972 2.27769 2.14650 18.37408 5.16318
.106 .105 .152 .111 .129 .149 .148
.106 .105 .152 .111 .129 .149 .148
-.086 -.080 -.084 -.100 -.101 -.143 -.111
.877 .876 1.266 .922 1.069 1.234 1.229
.425 .427 .081 .364 .203 .095 .098
N
Mean
Std. Deviation
Normal Parameters a,b
Absolute
Positive
Negative
Most Extreme
Dif ferences
Kolmogorov-Smirnov Z
Asymp. Sig. (2-tailed)
allR1 lymphR1 monoR1 allR2 lymphR2 monoR2 adiponectin
Test distribution is Normal.a. 
Calculated f rom data.b. 
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Appendix 4: Correlation matrix of FACS data and monocyte count. AllR1 (MFI AdipoR1 on 
all PBMC). LymphR1 (MFI of AdipoR1 on lymphocytes). MonoR1 (MFI of AdipoR1 staining on 
CD14+monocytes). “Monocytes” denotes the percentage of viable monocytes in the sample.
Correlations
1 .863** .224 .854** .787** .258* .201
.000 .065 .000 .000 .033 .098
.863** 1 .116 .796** .924** .314** .059
.000 .341 .000 .000 .009 .630
.224 .116 1 .140 .110 .638** .112
.065 .341 .252 .370 .000 .359
.854** .796** .140 1 .907** .436** .032
.000 .000 .252 .000 .000 .797
.787** .924** .110 .907** 1 .457** -.012
.000 .000 .370 .000 .000 .925
.258* .314** .638** .436** .457** 1 -.011
.033 .009 .000 .000 .000 .931
.201 .059 .112 .032 -.012 -.011 1
.098 .630 .359 .797 .925 .931
Pearson Correlation
Sig. (2-tailed)
Pearson Correlation
Sig. (2-tailed)
Pearson Correlation
Sig. (2-tailed)
Pearson Correlation
Sig. (2-tailed)
Pearson Correlation
Sig. (2-tailed)
Pearson Correlation
Sig. (2-tailed)
Pearson Correlation
Sig. (2-tailed)
allR1
lymphR1
monoR1
allR2
lymphR2
monoR2
monocyte
allR1 lymphR1 monoR1 allR2 lymphR2 monoR2 monocyte
Correlation is signif icant at the 0.01 level (2-tailed).**. 
Correlation is signif icant at the 0.05 level (2-tailed).*. 
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Appendix 5: correlation matrix of glycaemic parameters against AdipoR MFI values 
for subjects with T1D. Insulin dose (total daily dose), insulinperwgt (total daily dose per 
kg), HbA1C and duration of disease did not bear significant correlations with AdipoR MFI 
values on all PBMC, lymphocytes or monocytes. 
292929292929
N
0.2720.6740.0930.2090.4110.182
Sig. (2-
tailed)
0.2110.0820.3180.2400.1590.255
Pearson 
Correlation
HbA1C
292929292929
N
0.2340.3290.2990.9630.2860.410
Sig. (2-
tailed)
0.2580.2130.2260.0100.2320.180
Pearson 
Correlation
duration
292929292929
N
0.5030.7400.8610.2090.5760.204
Sig. (2-
tailed)
-0.1300.0640.034-0.241-0.108-0.243
Pearson 
Correlation
insulinperwgt
292929292929
N
0.8200.8100.7370.4130.3220.249
Sig. (2-
tailed)
-0.044-0.047-0.065-0.158-0.191-0.221
Pearson 
Correlation
insulindose
monoR2lymphR2allR2monoR1lymphR1allR1
Correlations
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Appendix 6: effect of diabetic complications on AdipoR expression in T1D. We found no 
significant differences in AdipoR MFI values of subjects with (1) and without micro- and 
macrovascular complications (0) by the paired t-test.
3.138499.138311
1.00
8.3281710.151018
0.00adiponectin
2.755917.572711
1.00
11.8289412.854918
0.00monoR2
1.414851.497711
1.00
1.334181.448218
0.00lymphR2
1.212941.325311
1.00
1.114951.486718
0.00allR2
11.1584416.070011
1.00
17.6822225.918018
0.00monoR1
1.638822.076811
1.00
1.883561.930118
0.00lymphR1
1.962872.212311
1.00
1.799712.438618
0.00allR1
Std. DeviationMeanNcomplications
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Appendix 7: Standard curve of ELISA for total serum adiponectin (Cat # DRP 300, 
R&D Systems, Abingdon, UK). We made serial dilutions of the adiponectin standard 
solution  (250ng ml-1). The lowest dilution was at 3.9 ng ml-1. Each concentration was 
assayed in duplicate wells. Absorbance values for each well was recorded at 450nm 
and then at 540nm. The reading at the 540nm wavelength corrects for optical 
imperfections in the plate. The linear regression plot between the logarthithms of 
adiponectin concentration and corrected absorbance values is shown.       
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11. PUBLICATIONS AND ABSTRACTS AT 
NATIONAL AND INTERNATIONAL MEETINGS 
 
Publications 
1) Diabet Med. 2008 Sep;25(9):1015-24. 
Addressing insulin resistance in Type 1 diabetes. 
Pang TT, Narendran P. 
Division of Medical Sciences, Medical School, University of Birmingham, Birmingham, 
UK. 
Abstract 
Type 1 diabetes is recognised to include an element of insulin resistance. 
Insulin resistance is an independent risk factor for the development of macro- 
and microvascular complications of Type 1 diabetes and may also contribute to 
the development of the disease. This understanding comes at a time when the 
incidence of Type 1 diabetes appears to be rising and the public health burden 
from its vascular complications is high. A variety of safe and efficacious 
manoeuvres are available to redress insulin resistance in Type 2 diabetes. So 
far however, clinical trials addressing insulin resistance in Type 1 diabetes have 
been small with only short periods of follow-up. Regardless, these trials have 
yielded promising results. This review examines the evidence for insulin 
resistance in the pathophysiology of Type 1 diabetes and its complications, the 
problems associated with its measurement, and summarizes the trials aimed at 
reducing insulin resistance in Type 1 diabetes. This includes a meta-analysis of 
controlled trials of adjuvant metformin in Type 1 diabetes. 
PMID: 19183305 [PubMed - indexed for MEDLINE] 
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2) Ann N Y Acad Sci. 2008 Dec;1150:143-5. 
The distribution of adiponectin receptors on human peripheral 
blood mononuclear cells. 
Pang TT, Narendran P. 
Division of Medical Sciences, Medical School, University of Birmingham, Birmingham, 
England, United Kingdom. t.t.pang@bham.ac.uk 
Abstract 
Adiponectin, an adipocytokine with anti-inflammatory and insulin-sensitizing 
properties, may provide a mechanism by which insulin resistance accelerates 
autoimmunity in type 1 diabetes (T1D). Its actions are mediated by two 
receptors, adiponectin receptors 1 (ADIPOR1) and 2 (ADIPOR2). In this study, 
we measured their distribution on human peripheral mononuclear cells by flow 
cytometry. ADIPOR1 is present approximately on 1% of T cells, 93% of 
monocytes, 47% of B cells, and 21% of NK cells (P < 0.01 for difference 
between subsets). The distribution of ADIPOR2 was found to be similar (r= 
0.992, P < 0.01), and staining could be blocked in an antigen-specific manner. 
We were also able to confirm our finding at an RNA level by PCR using 
sequence-specific primers. Our data are consistent with an immunoregulatory 
role for adiponectin in T1D. 
PMID: 19120283 [PubMed - indexed for MEDLINE] 
 273  
Presentation abstracts  
1) Diabetes UK 2008, British Society of Immunology 2008, FOCIS 2008, Endocrine 
Society 2008 
 
Adiponectin gene expression in peripheral blood mononuclear 
cells is modulated by activation, and by diet and exercise in 
patients with type 2 diabetes  
 
Pang TTL1, Boora U1, Gough SCL1, Andrews R2, Narendran P1. 
 
1 Division of Medical Sciences, Medical School, University of Birmingham 
2 Early ACTID office, Joint Clinical Research Unit, University of Bristol 
 
Background and aims: Circulating adiponectin and skeletal-tissue expression of its 
receptors is reduced in obesity and increases following lifestyle intervention.  We asked 
whether adiponectin and its receptors were also expressed by peripheral blood 
mononuclear cells (PBMC) and if so, whether expression was modulated by cell 
activation or lifestyle changes.  
 
Method: Adiponectin expression was studied by real-time PCR in freshly isolated 
PBMC from healthy volunteers, and following activation with phytohaemagglutinin or 
lipopolysaccharide.  Expression was also measured at baseline and following lifestyle 
intervention in 10 subjects from the Early ACTID trial, a randomised controlled study of 
exercise in newly-diagnosed type 2 diabetes. Adiponectin receptor 1 & 2 (ADIPOR1 & 
2) expression was measured by flow cytometry.  
 
Results:  The adiponectin gene was expressed by PBMC in all healthy and diabetic 
subjects, at a level comparable to the pancreas. Following in-vitro stimulation, it 
decreased by 90.9 - 92.7% (95% CI), whilst the surface expression of its receptor was 
upregulated (1.8-2.7× 95% CI). In Early ACTID, adiponectin expression was increased 
at 6 months in subjects achieving moderate weight loss (mean= -2% of baseline), 
compared to those who did not (+52% vs  -47%, p<0.05%). There was also a trend for 
increased receptor gene expression (ADIPOR1: +13% vs -16% p=, ADIPOR2 +15% vs 
-8% p=0.2) 
  
Conclusions: Adiponectin and adiponectin receptor expression by PBMCs may be 
influenced by obesity, analogous to that described for circulating and peripheral tissue 
receptor levels. This may be an important mechanism by which lifestyle intervention 
modulates the inflammatory response associated with insulin-insensitivity. 
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2) Diabetes UK 2009 
Lifestyle intervention increases adiponectin receptor 
expression by peripheral blood cells (PBC) in type-2-diabetes 
(T2D) 
 
Pang TTL1, Weaver K1, Norcross A2, Gough SCL1, Andrews R2, Narendran P1. 
 
1 Division of Medical Sciences, Medical School, University of Birmingham 
2 Early ACTID office, Joint Clinical Research Unit, University of Bristol 
 
Background: PBC express the adiponectin receptors AdipoR1 and AdipoR2. In T2D, 
low levels of receptor expression on PBC are associated with obesity, insulin 
resistance and coronary artery disease. We have previously shown that weight loss 
increases the PBC expression of AdipoR1 and AdipoR2 in a small cohort of patients 
with T2D. 
 
Aims: To assess the effect of lifestyle interventions, over and above that of weight loss, 
on the expression of adiponectin receptors by PBCs in T2D  
 
Method: 71 consecutive subjects were recruited from early-ACTID, a blinded 
randomised controlled trial of lifestyle interventions in newly diagnosed T2D. AdipoR1 
& AdipoR2 expression was measured by real-time quantitative PCR at baseline and at 
6 months following intervention. Insulin resistance was measured by HOMA-IR using 2 
pairs of fasting glucose and insulin.  
 
Results: At baseline, subjects had a mean BMI of 31.6+/-1.3kgm{sup}-2{/sup} and a 
HbA1C of 6.6+/-0.2%. By intention-to-treat analysis, AdipoR1 was significantly 
upregulated in the lifestyle intervention arm (fold change 2.02 vs 0.64 in the standard 
care arm, p=0.02). There was a trend for AdipoR2 to increase (fold change: 7.44 vs 
1.08 p=0.06). Post-hoc analysis including all subjects showed a fall in HOMA-IR 
(mean+/-SEM = -26+/-4% vs +32%+/-7%) was associated with a significant increase 
(p<0.05) in AdipoR1 and log(AdipoR2), as well as improvements in HbA1C (-0.3% vs  
+0.5% p<0.05). 
 
Conclusion: Lifestyle interventions and improved insulin sensitivity increase adiponectin 
receptor expression on PBC, and this could be a mechanism by which the glycaemic 
and cardiovascular benefits of diet and exercise are achieved. 
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3) EASD 2009 
 
Adiponectin receptor expression on peripheral blood 
mononuclear cells is reduced in autoimmune diabetes and can 
be upregulated with lifestyle intervention 
 
T.T.L. Pang1, E. Goble1, K. Weaver1, M. Chinem1, S.A. Eldershaw1, S.C. Gough1, R. 
Andrews2, P. Narendran1;  
1School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, 
United Kingdom, 2Joint Clinical Research Unit, University of Bristol, Bristol, United 
Kingdom. 
 
Background and aims: Studies of patients with genetic predisposition for T1D show 
that insulin resistance (IR) is an independent risk factor for T1D. We are interested in 
defining the mechanisms that link IR with progression to T1D, and in particular the 
potential role of adipocytokines such as adiponectin. Adiponectin is an anti-
inflammatory and insulin sensitising cytokine whose levels are inversely associated 
with IR. It signals through receptors AdipoR1 & AdipoR2, whose expression levels are 
increased by manoevres that reduce IR. These receptors have previously been found 
on peripheral blood mononuclear cells (PBMC) where stimulation reduces their 
proliferation and cytotoxicity, and increases their secretion of anti-inflammatory 
cytokines. We hypothesise that adiponectin has an anti-inflammatory effect on human 
islet autoimmunity. Our initial aim was to assess the expression of adiponectin 
receptors on PBMC in healthy and T1D subjects, and whether these expression levels 
could be modulated by exercise. 
Materials and methods: PBMC expression of AdipoR1 & AdipoR2 was quantified by 
flow cytometry and qPCR on 26 T1D subjects and 14 age and anthropometrically 
matched healthy male Caucasian volunteers. The proportion of cells expressing each 
receptor, and the mean fluorescence intensity (MFI) were calculated by subtracting 
from subject-specific isotype control staining. The estimated glucose disposal rate 
(eGDR) of T1D subjects was calculated using waist hip ratio, blood pressure and 
HbA1C as previously described. In addition, we measured the effect of 6 months of diet 
and exercise training on adiponectin receptor expression by PBMC using qPCR, in 9 
subjects with autoimmune diabetes. 
Results: AdipoR1 & AdipoR2 are expressed on monocytes and lymphocytes in both 
healthy and T1D subjects. On average, 47% of monocytes and 11% of lymphocytes 
expressed AdipoR1 and AdipoR2. AdipoR1 & AdipoR2 expression is decreased on 
monocytes (with a tendency to decrease in lymphocytes) in T1D compared to healthy 
subjects (figure). AdipoR1 & AdipoR2 expression by both monocytes and lymphcytes, 
measured by MFI, correlated significantly with eGDR in subjects with T1D (monocytes 
AdipoR1 r = 0.475, AdipoR2 r = 0.512; lymphocytes AdipoR1 r = 0.292, AdipoR2 r = 
0.420). Lifestyle intervention increases AdipoR1 & AdipoR2 gene expression at 6 
months (Fold change: AdipoR1 2.6 p = 0.02, AdipoR2 1.5, p = 0.07). 
Conclusion: Adiponectin receptor expression is decreased on PBMC from T1D 
subjects. These findings are consistent with adiponectin playing an anti-inflammatory 
role on islet autoimmunity, and may explain the association between insulin resistance 
and the development of T1D. Furthermore, therapies that reduce IR may also modulate 
the development of this disease.  
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4) American Diabetes Association 2010, EASD 2010 
 
T cell function is released from the anti-inflammatory effects of 
adiponectin (apM1) in type 1 diabetes (T1D): a potential link 
between insulin resistance (IR) and T1D. 
 
Pang TTL, Chimem M, Eldershaw SA, Gough SC, Narendran P 
 
School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, 
United Kingdom 
 
IR is independently associated with the development of T1D, though the mechanism 
for this is not clear. ApM1 is an insulin sensitizing and anti-inflammatory adipokine 
whose serum levels are reduced with IR. We hypothesized that changes in apM1 and 
its receptors may mediate the link between IR and T1D. We have previously shown 
that receptors for apM1, AdipoR1 & AdipoR2, are expressed by peripheral blood 
mononuclear cells (PBMC), and in particular by monocytes and CD14-, CD11c+ 
CD1a+ dendritic cells (DC). In a cross-sectional study (n=86), we also found that 
patients with T1D have reduced AdipoR1 & AdipoR2 expression on monocytes, 
compared to matched healthy controls as well as subjects with insulin treated type 2 
diabetes.  
 
DC are key regulators T cell immunity in T1D. To determine the effect of apM1 on DC 
function, we optimized the serum-free generation of DC from CD14+ monocytes. We 
found that the addition of apM1 decreased the expression of the co-stimulatory 
molecule CD86 on DC at both RNA and protein level by 39-64%. This inhibitory effect 
was dose dependent (IC50 = 1.3-1.9 ug/ml) and was maintained despite LPS 
stimulation. The expression of HLA-DR & CD80 did not alter. DC generated in the 
presence of apM1 showed reduced stimulatory capacity when tested on CD4CD25- 
effector T cells in CFSE proliferation assays. To determine the significance of the lower 
PBMC AdipoR expression in T1D, we compared the effect of addition of fixed doses of 
10ug/ml apM1 to monocytes from T1D and healthy subjects in the DC generation 
culture (n=12). ApM1 induced suppression of CD86 expression was significantly 
decreased in T1D by up to 31%, and the degree of inhibition significantly correlated 
with AdipoR1 protein expression of the monocyte precursors (r = -0.69 p <0.05). 
Moreover, the suppression of PBMC proliferation to the common antigen tetanus toxoid 
by the 10ug/ml apM1 dose was also significantly reduced in T1D. 
 
In conclusion, T cells are released from the anti-inflammatory effects of apM1 in 
patients with T1D. This mechanism may contribute to the association between IR and 
the development of T1D. 
 
